Steroidal studies in vascular disease by Duffy, Thomas
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
STEROIDAL STUDIES IN VASCULAR DISEASE
BY
THOMAS DUFEY, B.Sc.
Thesis submitted for the Degree of 
Doctor of Philosophy 
of the University of Glasgow, Scotland.
May, 1969.
ProQuest Number: 10647319
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this reproduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a co m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria l had to be rem oved,
a no te  will ind ica te  the de le tion .
uesL
ProQuest 10647319
Published by ProQuest LLO (2017). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C o de
M icroform  Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 4 81 06 - 1346
I, Acknowledgements -
I would like to thank Prof. J.N. Davidson for his interest 
in the work, I am very grateful to Dr. J.K, Grant for his
encouragement and valuable criticism, I am indebted to 
Prof. T.D.V, Lawrie for supplying laboratory facilities and for 
his continued interest in the work.
I would like to express my gratitude to Dr. R. Luke,
Dr. R. Fraser, Mr. M. Divers and, in particular, Dr. A.R.Lorimer 
for arranging the supply of biological material.
It is a pleasure to express my thanks to Mrs. C . Jolly for
her help in preparation of diagrams, to Mr. C. Giles for reading 
of proofs and Mr* I.G, 0*Muircheartaigh for advice on statistical 
matters.
To my wife Rend and Miss Irene Adams who typed the script,
I wish to express my hearty thanks for their remarkable patience
and the high standard of their work,
Pfizer Limited partly financed the work reported and I am 
grateful for their generosity.
LIST OF CONTENTS
11
I. Acknowledgements.
II. Abbreviations.
III. INTRODUCTION.
A, Hypertension.
1. Glucocorticoids.
2. Mineralocorticoids.
3. Adrenal "Androgens".
B . Salt Metabolism.
1. Salt retention.
2. Salt excretion,
G, Uric Acid, Lipids, Steroids and Vascular Disease.
1. Hyperuricaemia, gout and hypertension.
2. Urinary 17-oxosteroids in relation to gout and 
hyperuricaemia.
3. Vascular disease.
(a) The relationship between plasma, lipids and 
vascular disease.
(b) Steroids and lipid metabolism.
(i) Adrenocortical steroids,
(ii) Androgenic steroids.
D. Nature of the Present Investigation.
Page No 
i
xix 
1 
1 
11 
16 
21 
28 
28 
28 
48 
48
55
58
59 
62 
63 
65 
71
Ill
Page No.
EXPERIMENTAL PART 1. 73
A, Routine Biochemical Methods. 73
1, Urinary electrolytes. 73
(a) Sodium & potassium. 73
(b) Chloride. 73
2. Kidney function tests. 73
(a) Blood urea. 73
(b) Serum creatinine. 73
(c) Urinary creatinine. 74
3. Plasma lipids. 74
(a) Plasma cholesterol. 74
(b) Plasma phospholipids. 74
(c) Plasma glycerides. 74
4. Serum uric acid. 74
5. Blood and urine collection. 75
6. Group urinary steroid analysis. 75
(a) 17-oxosteroids (17-08). 75
(b) 17--Hydroxycorticosteroids (17-OHCS). 76
B. Incubation Techniques. 76
1, Source of tissue. 76
2. Preparation of tissue. 76
3. Method of incubation. 77
4. Extraction of steroids. 78
Page No,
B . Incubation Techniques (Continued).
5. Preparation of thin-layer chromatograms. 78
6. Detection and elution of steroids from
chromatograms, 78
7. Preparation of derivatives. 79
(a) Acétylation, 79
(b) Saponification, 79
(c) Reduction, 80
8. Quantitation of steroids. 80
9. Measurement of radioactivity in extracts. 80
C . Quantitation of Urinary ll-Deoxy-17-oxosteroid
(D.17-OS) sulphate and Glucuronides. 82
1. Introduction, 82
2, Materials and method, 86
(a) Reagents. 86
(b) Solvents. 88
(c) Choice of internal standard. 89
(d) SoVolysis of ll-Deoxy-17-oxosteroid
sulphates (D.17-OS.S), 89
(e) Hydrolysis of ll-Deoxy-17-oxosteroid 
glucuronides (D,17-OS,G). 90
(f) Alumina chromatography. 91
(g) Trimethylsilyl ether (TMSE) formation, 91
/
Page No
C . Quantitation of Urinar M - D eoxy-17-oxosteroid 
(D.17-OS) sulphate and Glucuronides (Continued).
(h) Gas liquid chromatography.
(i) Preparation of column packing.
(ii) Packing of column.
(iii) Gas chromatograph,
(i) Calculation of results.
(j) Measurement of radioactivity.
3. Results.
Evaluation of reliability of the method.
(a) Specificity.
(b) Sensitivity.
(c) Precision.
(d) Accuracy,
(i) Relative recovery.
(ii) Absolute recovery,
4. Discussion,
D . Statistical Procedures.
1, Tests of significance.
(a) Student's t-test.
(b) The Mann-Whitney U test.
2, Correlation and regression.
3, Multivariate analysis.
92
92
93
94
94
95 
95 
95 
99 
99
100
100
100
103
104 
114
. 114 
114 
114 
116 
119
page No,
V. EXPERIMENTAL PART 2, 122
A, Individual Urinary D,17-OS Sulphates and 
Glucuronides: Values in Normal Males
and Females. . 122
1. Subjects studied. 122
2. Analytical techniques. 122
3. Results. ' 123
(a) Sulphate conjugates. 123
(b) Glucuronide conjugates. 127
(c) Sulphate plus glucuronide conjugates. 127
(d) Correlations. 131
4. Discussion. 137
(a) Comparison of data with other investigators, 137
(b) Comparison of males and females, 144
B. Individual Urinary D,17-OS Sulphates and
Glucuronides: Values in Male and Female
Hypertensive Patients. 154
1. Patients studied. 154
2. Analytical techniques. 155
3. Results. 155
(a) Male hypertensive patients. 155
(i) Serum uric acid - urinary DHA relationship, 157
(ii) Sulphate conjugates. 159
(iii)Glucuronide conjugates. 161
(iv) Sulphate plus glucuronide conjugates, 161
Page No.
V.B.3. Results (Continued),
(b) Female hypertensive patients. 163
(i) Serum uric acid - urinary DHA
relationship, 168
(ii) Glucuronide conjugates. 168
(iii) Sulphate conjugates, 168
(iv) Sulphate plus glucuronide conjugates, 169
(c) Correlations. 169
(i) Males 169
(ii) Females 175
4. Discussion. 179
(a) Serum uric acid - urinary DHA relationship, 179
(b) Urinary D,17-OS levels in hypertension and 
a proposed theory for the explanation of
steroid abnormalities in this disease, 181
C . An Investigation of the Effect of DHA on Steroid
Hydroxylation in Human Adrenal Tissue, 193
1, Analytical techniques. 193
(a) Source of tissue, 193
(b) Preparation of tissue. 193
(c) Incubation procedure. 193
(d) Extraction of steroids, 193
(e) Purification and quantitation, 193
(f) Radioactive measurement of steroids and
derivatives. 193
Vlll
Page No,
V.C.2* Results, • 193
3. Discussion. 197
(a) Hypertension. 200
D . Studies on the Effect of Salt Loading, Salt 
Restriction, and Saline Infusion on the Excretion
of Individual D .17-OS Sulphates and Glucuronides, 203
1, Salt loading and salt restriction, 203
2« Saline infusion. 204
3, Analytical techniques. 204
4. Results, 205
(a) Salt loading and salt restriction, 205
(b) Saline infusion. 221
5» Discussion, 225
E , Individual Urinary D .17-08 Sulphates and Glucuronides : 
Values for Male Patients suffering from Gout, 238
1. Patients studied, 238
2. Analytical techniques. 239
3. Results. 239
(a) Sulphate conjugates, , 239
(b) Glucuronide conjugates. 242
(c) Sulphate plus glucuronide conjugates. 244
( d ) Discriminant function analysis. 244
4. Discussion. 245
Page No
F, Individual Urinary D.17-OS Sulphates and 
Glucuronides: Values for Normolipidaemic
and Hyperlipidaemic males. 255
1. Subjects studied, 255
2. Analytical techniques. 256
3. Results. 257
(a) Sulphate conjugates. 261
(b) Glucuronide conjugates. ' 261
(c) Sulphate plus glucuronide conjugates. 262
(d) Correlations. 262
(e) Discriminant function analysis. 266
4. Discussion. 267
G , Individual Urinary D.17-OS Sulphates and 
Glucuronides: Values for Male Myoc^ dial
Infarct Patients. 272
1. Subjects studied. 272
2. Analytical techniques. 272
3. Results. 273
(a) Sulphate conjugates, 273
(b) Glucuronide conjugates, 276
(c) Sulphate plus glucuronide conjugates, 276
4. Discussion, 278
VI. SUMMARY. 286
VII. BIBLIOGRAPHY. 291
page No,
LIST OF TABLES
1. Retention times of A, E, DHA and epiA relative to
pregnenolone on 3% QF-1, 98
2. The ratio of the peak heights of individual D.17-OS
TMSE to pregnenolone TMSE, 99
3. Reproducibility of the method for estimation of
individual urinary D.17-OS,S and D.17-OS,G, 101
4. Recovery of A, E , DHA and epiA added to water. 102
5. Recovery of A, E, DHA and epiA added to urine, 103
6. Recovery of 7a-^H-pregnenolone sulphate (64,375 dpm)
and 7a-^H“pregnenolone (148,080 dpm) added to urine, 105
7. Excretion of individual urinary D.17-OS by normal 
males (mg.free steroid/24 hr.) and serum uric acid
levels. 124
8. Excretion of individual urinary D.17-OS by normal 
females (mg.free steroid/24 hr.) and serum uric
acid levels, 125
9. Comparison of the individual D,17-08 urinary levels of
normal adult males and females, 128
10, Matrix of correlation coefficients for normal males, 132
11, Matrix of correlation coefficients for normal females. 133
12, Comparison .of individual urinary D.17-OS.S and 
D,17-OS.G levels from four different authors
(mg.free steroid/24 hr,). 138
XI
Pao;e No
13. Comparison of individual urinary D.17-OS,(S+G) 
levels from eight different authors (mg,free steroid/
24 hrs.). 139
14. Excretion of individual urinary D.17-OS by 
idiopathic hypertensive males (mg.free steroid/24 hn)
and serum creatinine and uric acid levels. 156
15. Comparison of the individual D,17-OS urinary levels of
idiopathic hypertensive male patients and normal male 
controls. 158
16. Excretion of individual urinary D.17-OS by idiopathic 
hypertensive females (mg, free steroid/24 hr.) and
serum uric acid levels, 164
17. Excretion of individual urinary D.17-OS by renal 
hypertensive females (mg, free steroid/24 hr.) and
serum uric acid levels. * 165
18. Comparison of the individual D.17-OS urinary levels
of idiopathic hypertensive female patients and normal 
female controls. 166
19. Comparison of the individual D.17-OS urinary levels
of idiopathic and renal hypertensive females, 167
20. Matrix of correlation coefficients for idiopathic
hypertensive males, 170
21. Matrix of correlation coefficients for idiopathic
hypertensive females. 176
Page No
22. Matrix of correlation coefficients for renal
hypertensive females, ' 177
23a. Evidence for the identification of steroids
isolated from the incubation containing 3.8x10 \l-DHA. 194 
23b. Evidence for the identification of steroids
isolated from the incubation without DHA, 195
24. The urinary excretion of individual D,17-OS, total
17-OS, total 17-OHCS and electrolytes by subject ,
2M while on varying sodium intake. 206
25, The urinary excretion of individual D,17-OS, total
17-OS, total 17-OHCS and electrolytes by subject
3M while on varying sodium intake, 209
26. The urinary excretion of individual D.17-OS, total
17-OS, total 17-OHCS and electrolytes by subject
4M while on varying sodium intake. 211
27, The urinary excretion of total 17-OHCS, total 17-OS
and. DHA.S by 3 males before and after administration
of synthetic ACTH (Depot Synacthen, 50 units), 214
28. The effect of varying salt intake compared with the"
effect of ACTH administration (i.m.) on the daily
urinary 17-OHCS/17-OS ratio. 216
29, The urinary excretion of individual D,17-OS, total
17-OS, total 17-OHCS and electrolytes by subject 5M
while on varying sodium intake, 217
Page No.
30. The urinary excretion of individual D.17-OS, total 
17-OS, total 17-OHCS and electrolytes by subject
6M while on varying sodium intake.' 218
31. The urinary excretion of individual D.17-OS, total
17-OS, total 17-OHCS and electrolytes by subject
IF while on varying sodium intake. 220
32. The urinary excretion of sodium and individual D.17-OS 
sulphates and glucuronides by a normal male before
and after intravenous infusion of normal saline. 222
33. Individual urinary D.17-OS levels and serum uric
acid levels for males suffering from gout. 240
34. Comparison of D.17-OS urinary levels and %
overweight values for males suffering from gout
with normal male controls. 241
35. The urinary D.17-OS levels (mg.free steroid/24 hr.)
for normal male subjects divided into two groups 
according to % overweight (% O.Wt.). 251
36. Individual urinary D.17-OS levels (mg.free steroid/
24 hr.), plasma lipid levels (mg./lOO ml.), serum 
uric acid levels and % overweight values for 
normolipidaemic males. 258
XIV
Page No
37. Individual urinary D.17-OS levels (mg. free steroid/
24 hr.), plasma lipid levels (mg./100 ml.), serum 
uric acid levels and % overweight values for 
hyperlipidaemic males. 259
38. Comparison of individual D,17-OS urinary levels
for normolipidaemic and hyperlipidaemic males, 260
39. Matrix of correlation coefficients for
normolipidaemic males. 263
40. Matrix of correlation coefficients for
hyperlipidaemic males. 264
41. Individual urinary D.17-OS levels (mg, free steroid/
24 hr.) for male myocardial infarct patients. 274
42. Comparison of individual D.17-OS urinary levels for
male myocardial infarct patients with normal male 
controls. 275
XV
Page No
LIST OP FIGURES
1. Metabolism of androgens. 85
2a. Linear response of gas chromatographic detector
(TMSE-S/TMSE-P peak height ratio) to varying
D.17-OS/pregnenolone mass ratios. 96
2b. Linear response of gas chromatographic detector
(TMSE-S/TMSE-P peak height ratio) to varying
D .17-OS/pregnenolone mass ratios. . 97
3. Gas chromatographic tracing Of the D.17-OS sulphate
fraction obtained from a normal male urine.
3% QF-1 column at 200^. A) Androsterone, 110
E) Aetiocholanolone, DHA) Dehydroepiandrosterone 
epiA) Epiandrosterone and Preg) Pregnenolone all 
as TMSE derivatives.
4. Gas chromatographic tracing of a mixture of equal
weights of standard D.17-08 and internal standard 
pregnenolone. 3% QF-1 column at 200°.
A) Androsterone, E) Aetiocholanolone, DHA)
Dehydroepiandrosterone, epiA) Epiandrosterone and 
Preg) Pregnenolone all as TMSE derivatives. Ill
5. Gas chromatographic tracing of the D.17-OS sulphate
fraction obtained from a normal male urine.
3% QF-1 column at 200°. A) Androsterone,
E) Aetiocholanolone, DHA) Dehydroepiandrosterone 
epiA) Epiandrosterone and Preg) Pregnenolone all as
TMSE derivatives, , 126
XVI
Page No
6, Gas chromatographic tracing of the D,17-OS
glucuronide fraction obtained from a normal male 
urine, 3% QF-1 column at 200°,
A) Androsterone, E) Aetiocholanolone, DHA)
Dehydroepiandrosterone, epiA) Epiandrosterone
and Preg) Pregnenolone all as TMSE derivatives. 129
7, Gas chromatographic tracing of the D.17-OS glucuronide
fraction obtained from a normal female urine. 3%
QF-1 column at 200°. A) Androsterone, E)
Aetiocholanolone, DHA) Dehydroepiandrosterone,
epiA) Epiandrosterone and Preg) Pregnenolone all as
TMSE derivatives. 130
8, Regression of epiA.S on A.S for normal males.
The equation of the regression line is epiA.S =
0.38 A.S - 0.01, r = 0.97, P<0.001. 134
9a,b & c . Regression of E.S on A.S, E.G on A.G and
E.(S+G) on A.(S+G) for normal males (M) and normal 
females(F). 136
I0a,b & c . Comparison of the ratios of E.S/DHA.S,
E.S/epiA.S and E.S/A.S for idiopathic hypertensive 
males (H) and normal males (N). 160
11a,b & c , Comparison of the ratios of E.G/A.G and
E .(S+G)/A.(S+G) for idiopathic hypertensive males (H)
and normal males (N). 162
X V I 1
Page No
12a,b&c. Regression of E.S on A.S, E.G on A.G and
E.(S+G) on A,(S+G) for idiopathic hypertensive 
males (H) and normal males (N). 174
13. A proposed mechanism to explain the steroid
abnormalities present in hypertension - an
enzymatic block. 187
14. The effect of DHA on steroid hydroxylation:
C-progesterone and H-DOC incubated with 
human adrenal tissue in the presence of DHA. 196
15. The effect of varying salt intake on the
excretion of urinary D.17-OS sulphates and
glucuronides in a normal male subject (2M) . 207
16. The effect of varying salt intake on the
excretion of urinary D.17-OS sulphates and
^ucuronides in a normal male subject (4M), 212
17a. The effect of saline infusion (2 pints,
54 ml./min.) on the excretion of urinary
D.17-OS sulphates in a normal male subject. 223
17b. The effect of saline infusion (2 pints,
54 ml./min.) on the excretion of urinary D.17-08
glucuronides in a normal male subject. 224
18. Suggested biosynthetic pathway for the formation
of the hypothetical salt-losing steroid (x,x^ or x.s). 228
XVXll
Page No,
19. Gas chromatographic tracing of the D,17-OS
sulphate fraction obtained from a gouty male 
urine, 3% QF-1 column at 200°,
A) Androsterone, E) Aetiocholanolone,
DHA), Dehydroepiandrosterone, epiA)
Epiandrosterone and Preg) Pregnenolone all as 
TMSE derivatives. 243
20a,b & c . Comparison of the ratios of E.S/A.S,
E.G/A.G and E ,(S+G)/A,(S+G) for myocardial
infarct males (M.I.) and normal males (N), 277
XIX
II. Abbreviations.
Adrenocorticotrophin
Adenosine-5^"triphosphate
2-Amino-2-hydroxymethy1-1,3-propanediol
1,4 Bis“2(4-methyl-5 phenyl-oxazolyl)-benzene
Correlation coefficient
2,5-Diphenyl“Oxazole
Glucose-6"phosphate
Glucose-6-phosphate dehydrogenase
Nicotinamide adenine dinucleotide phosphate
Nicotinamide adenine dinucleotide phosphate reduced
Percentage overweight
Standard deviation
Serum uric acid
Surface area
Trimethylsilyl ether
Trimethylsilyl ether derivative of a D.17-OS 
Trimethylsilyl ether derivative of pregnenolone 
Variation coefficient
ACTH
ATP
TRIS
Dimethyl POPOP 
r
PPG
G-6-P
G-6-P.D,
NADP^
NADPH 
% O.Wt,
S.D.
S. U . A *
S.A.
TMSE
TMSE-3
TMSE-P
V.C.
XX
STEROIDS
TRIVIAL NAME
Androstenedione (A) 
Aetiocholanolone (E) 
Testosterone (T) 
llg-androstenedione 
Androsterone (A) 
Epiandrosterone (epiA) 
Dehydroepiandrosterone (DHA)
SYSTEMATIC NAME
5^"Androst”A"en-^3,17-dione, 
3a"Hydroxy“53“androstan-1.7-one.
17 3-Hydroxy-5f^androst-4-en-3-one. 
llg-Hydroxy-^blT-andros t”4“en63,17“dione. 
3a-Hydroxy“5a~androstan-'17"one. 
3p-Hydroxy-5a-androstan-17-one.
3B"Hydroxyandrost-5-en"17-one,
Aetiocholanolone glucuronide (E.G)
3a“D-Glucopyranos iduronoxy-5 3-andros tan-17-one.
Aetiocholanolone sulphate (E.S) 3a"Sulphoxy-53“androstan-17-one,
Androsterone glucuronide (A.G)
3a-D-Glucopyranosiduronoxy-5a“androstan-17-one,
Androsterone sulphate (A.S) 3a“Sulphoxy-5a-androstan-17-one.
Epiandrosterone sulphate (epiA.S)
33-Sulphoxy-5a-androstan-17-one.
Dehydroepiandrosterone glucuronide (DHA.G)
33-D-Glucopyranosiduronoxyandrost-5-en-17-one.
Dehydroepiandrosterone sulphate (DHA.S)
33"Sulphoxyandrost-5”en-17-one,
Progesterone 3^-Pregn-4-en€;3,20-dione.
113-Hydroxyproges terone ll3"Hydroxy->S^-pregn^4~en-3,20-dione .
17a-Hydroxyproges terone 17a-Hydroxy-^-pregn-4”Cnfr3,20-dione .
XXI
TRIVIAL NAME 
Deoxycorticosterone (DOC) 
Corticosterone 
ll“Deoxycortisol 
Pregnanediol 
Cortisone 
Aldosterone
Cortisol
Pregnanetriol 
Tetrahydrocortisone
6B"Hydroxycortisol
6a~Hydroxycor tisol
203-Hydroxycortisol
20a-Hydroxycortisol
Aliotetrahydrocortisol
Pregnenolone (Preg)
17a-Hydroxypregnenolone 
Pregnenetriol
Deoxycorticosterone acetate (DOGA)
SYSTEMATIC NAME
21“Hydroxy"5^-pregn-4-en«-3,20-dione ♦
II3,21”Dihydroxy~^~pregn-4-ene3,20-dion
lia? 21“Dihydroxy“5^-pregn“4-ene3,20-dion
3a,20a“Dihydroxy-5 g-pregnane,
17a, 21”Dihydroxy~^-pregnan-3 ,11,20-trio
llg, 21“Dihydroxy-^~pregn-4-ent-3,20-dion
18-al,
113,17a,21-Trihydroxy-5^-pregn-4-enCr
3,20-dione,
3a,17a,20a“Trihydroxy-53~pregnane »
3a, 17 a, 21-Trihydroxy-5 g-pregnan-r-11,20-
dione .
6 3,113,17a,21-Tetrahydroxy-^#-pregn- 
4-ene3,20-dione,
6a,113,17a,21-Tetrahydroxyy5#-pregn- 
4-en*3,20-dione,
113,17a,203,21-Tetrahydroxyy5^-pregn- 
4-enc3,20-dione.
ll3,17a,20a,21-Tetrahydroxy^^^-pregn- 
4-ene3,20-dione,
3a,113,17a,21-Tetrahydroxy-5a-pregnan-
20-one.
33"Hydroxypregn-5-en-20-one.
3 3,17a-Dihydroxypregn-5-en-20“one
3 3,17a,20a“Trihydroxypregn-5-en~20-one,
21“Acetoxy-^”pregn-4-ene3,20-dione,
TRIVIAL NAME 
Pregnenolone sulphate
SYSTEMATIC NAMES
33“Sulphoxypregn“5-en-20-one,
17o-Hydroxypregnenolone sulphate 3B“Sulphoxy-17a™hydroxypregn-5'
en-20-one.
Cholesterol
21-Hydroxycholes terol 
Cholesterol sulphate
33“Hydroxycholest“5-ene.
33,21-Dihydroxycholest“5“ene, 
33“Sulphoxycholest-5-ene.
17-Oxosteroids 17-OS 
17-OHCS 
D.17-OS
17a-Hydroxycorticosteroids
11-Deoxy-17-0X0steroids
ll-Deoxy-17-oxosteroid sulphates D.17-OS.S
11-Deoxy-17-0X0steroid glucuronides
D.17-OS.G
ll-Deoxy-17-oxosteroid sulphates plus glucuronides
D,17-OS.(S+G) or D.17-OS.
III. INTRODUCTION.
A. Hypertension.
Ever since Johnson(1868) advanced the concept that hypertension 
results from the contraction of arterioles throughout the body there 
has been ceaseless clinical and experimental investigation in search 
of the factors responsible for arteriolar constriction in hypertension.
Two main facets have been considered in the mechanism of arteriolar 
constriction during the last century: neurogenic and humoral.
It has been known since the time of Claude Bernard (1851) 
that stimulation of the sympathetic nerves produces vasoconstriction 
(except in the heart), the intensity of the effect varying from one 
organ to another. Also cutting the sympathetic nerve or temporarily 
interrupting it by local anaesthesia increases the blood flow through 
the affected tissues (other than brain and kidney). When we add to 
these facts the marked pressor response induced by such emotions as 
fear and anger it does not seem surprising that a nervous pathogenesis 
of idiopathic hypertension has been considered from the earliest 
studies. As long ago as 1852, Rokitansky, the morphological pathologist, 
attributed idiopathic cardiac hypertrophy, doubtless predominantly our 
modern idiopathic hypertension to a disturbance of innervation, 
haycock, another early student, suggested in 1873 that Bright's disease 
results from primary disturbance of the nervous system. With the 
establishment of evidence that increased peripheral resistance is the 
immediate mechanism of the rise in blood pressure, the line of thought
that neurogenic factors contribute directly to increased vascular 
resistance in hypertension was rendered all the more appealing. 
Nevertheless 3 the rapid progress in experimental medicine through 
the availability of synthetic compounds, the introduction of radio­
isotopes and the various forms of chromatography, to name but a few 
of the advancements, has helped to throw more light on the patho­
genesis of hypertension. The results have strongly supported 
partisans of the "humoral" aetiology of this disease.
Various vasoconstrictive substances, found in the body fluids 
of hypertensive patients have been described. In 1904, Elliot noted 
the similarities between the effect of stimulation of sympathetic 
nerves and that of adrenaline. It was suggested that the autonomic 
nerves might produce their effect by releasing at their termination 
compounds with specific affinity for the receptors of the motor units 
activated. The classical works of Dale (1933) and Von Euler (1951a) 
resulted in the isolation of these substances and their identification 
as adrenaline and noradrenaline, both of which have been shown to be 
secreted by the adrenal medulla. The discovery of adrenaline and 
noradrenaline ultimately permitted the recognition of a group of
S  *
patients, albeit a small one, whcvê hypertension was clearly due to 
excessive catecholamine production as a primary cause - the phaeo- 
chromacytoma (Von Euler 1951b). These findings gave rise to a 
constantly increasing interest in the adrenal gland as an important, 
if not causative factor in hypertension. This stimulated an
intensive search for other humoral agents which could be 
responsible for elevating blood pressure. The central point of 
subsequent investigations has been shifted from the adrenal medulla 
to the adrenal cortex.
The first description of hypertensive changes secondary to 
an adrenocortical tumour was reported in 1897 by Neusser, and a 
further hint of a possible relationship between the adrenal gland 
and hypertension was made by Josué in 1903. Little notice, however, 
was given to this association until the more extensive observations 
of Oppenheimer and Fishberg in 1924.
In 1932, Cushing described a clinical syndrome which he 
thought was due to a basophil adenoma of the pituitary gland. 
Hypertension was one of the cardinal features of this syndrome. 
Subsequent work has shown that the cause of the disturbance described 
by Cushing was an increased production of the adrenocortical steroids 
by either a tumour or hyperplasia of the adrenal cortex. Various 
authors have commented upon the elevated blood pressure in patients 
with tumours and hypertrophy of the adrenal gland and contrasted it 
with the reduced blood pressure of Addison's disease (1855), in which 
"cortical atrophy" was found to be responsible for the signs and 
symptoms, including arterial hypotension which invariably accompanies 
this disease.
It is now generally accepted that the elevation of blood 
pressure in Cushing's syndrome is the effect of an increased production 
of adrenocorticosteroids whereas the low pressure in Addison's disease
is due to adrenocortical hypofunction. In 1939 Loeb, Atchley,
Ferrebee & Ragan called attention to two patients with Addison's 
disease whose arterial pressure exceeded normal limits while being 
treated with deoxycorticosterone (DOC). Several years later Perera 
(1945) reported a hypertensive patient who developed Addison's 
disease and as a result the blood pressure fell to subnormal levels. 
Hypertension recurred on administration of steroids, but therapy 
with salt alone resulted in a drop in blood pressure to normal 
limits, even though the patient was maintained in water and electrolyte 
balance. ’’One could not help but conclude that the adrenal cortex or 
appropriate steroid substitution therapy was important for the 
development or maintenance of this man's essential hypertension,"
This was confirmed by Thorn, Harrison, Merril, Criscitiello, Frawley 
& Finkenstaedt (1952), who also reported a fall of blood pressure to 
normal level in a hypertensive patient who developed Addison's disease.
Conn (1955) described a new clinical entity, "primary aldo­
steronism", A syndrome caused by an adrenocortical tumour secreting 
increased amounts of aldosterone which in turn induced potassium 
wastage and sodium retention both in association with mild hypertension.
Countless experiments on animals have indicated that the adrenal 
cortex plays an essential part in hypertension. Goldblatt (1937) in 
his pioneer investigations showed that, while the elimination of both 
adrenal medulla does not interfere with the production of renal 
artery constriction hypertension in dogs, the blood pressure falls to
normal after bilateral adrenalectomy. Moreover the hypertension ■ 
is restored by administration of cortical extracts or deoxycorticosterone 
acetate (DOCA) (Page & Lewis, 1951). However, doses of cortical 
extract or cortisone which maintain -hypertension in adrenalectomized 
dogs or rats do not raise the blood pressure in normal animals. 
Adrenalectomy also interfered with the development or maintenance 
of hypertension produced in animals by various procedures other than 
renal artery constriction; Jeffers, Lindàuer & Lukens (1937) 
demonstrated this in experimental hypertension produced by the intra- 
cisternal ingestion of kaolin in dogs; Page & Reed (1945) in 
hypertension evoked with dihydroxyphenylalani^e and related compounds 
in rats; McCann, Rothballer, Yeakel- & Shenkin (1948) in hypertension 
obtained by auditory stimulation in rats; Ledingham (1951) and Ployer 
(1951) in the development or maintenance of renoprival hypertension 
in single and parabiotic rats.
The effect of adrenalectomy on hypertension in animals has
been commented upon by many workers. It has been assumed " this
effect can be partly accounted for by salt deficiency, the extra­
cellular fluid being depleted of sodium, and hence of water, because 
of the failure of the kidneys to conserve sodium" (Pickering, 1955). 
However, a direct action of corticoids was sought by other investigators, 
Ramey, Goldstein and Levine (1951) demonstrated in a series of well 
designed experiments that a single injection of adrenal cortical 
extract, but not DOC, would potentiate the response to noradrenaline 
in adrenalectomized dogs, though not in normal controls. Moreover,
Fritz & Levine (1951) found that the vessels of the mesoappendix 
of the adrenalectomized rat became refractory to the repeated 
application of noradrenaline while those of the normal rat did not. 
The responsiveness of the vessels was restored by ll-oxysteroids 
injected intramuscularly or when applied locally in much smaller 
doses. They concluded that these corticoids are necessary to 
obtain the optimal response of the blood vessels to noradrenaline.
The elevation of blood pressure following the administration 
of various steroids has been reported by many workers. Selye, Hall 
& Rowley (1943) reported wide spread lesion^ similar to those seen 
in human nephrosclerosis and in the accelerated phases of idiopathic 
hypertension, cardiac hypertrophy, and decreased adrenal size on 
treatment of several animal species with massive doses of DOCA and 
salt. Selye (1946) and Knowlton, Loeb, Stoerk & Seegal (1947) 
demonstrated that the hypertensive action of DOCA was potentiated 
by salt. Friedman & Nakashima (1952 & 1953), in a screening
test for renal and cardiovascular effects of different adrenal 
hormones in rats, demonstrated that cortisol had the most pronounced 
hypertensive effect of all the corticosteroids tested. They 
suggested that this steroid might exercise a direct action on the 
vascular bed, in contrast with DOCA.
In man, the administration of adrenocortical hormones 
likewise causes elevation of arterial pressure. The rationale 
behind these administrations probably originates from earlier
studies on salt metabolism. Ambard & Eeauyard (1905) demonstrated 
that the blood pressure of hypertensive patients is further elevated 
by ingestion of salt and lowered by a salt free diet; from this they 
conclude that hypertension is caused by abnormal salt retention.
In support of this Allen & Sherrill (1922), Volhard (1931), Kempner 
(1946 & 1949)', and Corcoran, Taylor & Page (1951) succeeded in 
markedly lowering the blood pressure in many patients with hypertension 
by a poor salt diet. With the detection of the electrolyte 
regulation properties of certain corticoids, the central point of 
investigations, concerned with a possibility of disturbance of the 
salt metabolism in hypertension, was transferred 'directly to the 
adrenal cortex. This confirmed the'work of Loeb et al (1939) who 
reported development of hypertension in two patients suffering from 
Addison's disease, after treatment with DOC esters, and the work 
of Thorn & Firor (1940) and McCullagh & Ryan (1940) who reported 
similar findings. This pressor effect has also been demonstrated 
in uncomplicated hypertensive vascular disease but not in normo- 
tensive subjects (Perera & Blood, 1947). The prompt rise in blood 
pressure in the hypertensive group could not be ascribed to salt 
and water retention, as there were similar changes in the normal 
group. Finally, since the introduction of cortisone and cortisol 
to wide clinical use, it has become well known that over dosage 
or prolonged treatment with these steroids frequently results in 
an elevation of blood pressure, which returns to normal on with­
drawal of the steroid or reduction of its dosage (first reported
by Hench, Kendall, Slocumb & Polley, 1949),
Adrenocorticotrophin (ACTH) was also shown to elevate 
blood pressure, Hench et al (1949) and Perera (1950) reported 
that ACTH may raise the blood pressure of normotensive patients.
In hypertensives it causes a marked increase in arterial pressure.
These observations of the pressor action of ACTH were subsequently 
confirmed by many clinical reports.
All these findings supported the introduction of bilateral 
adrenalectomy as a surgical procedure in the treatment of severe 
hypertension. DeCourcy, DeCourcy & Thuss (1934), Allen & Adson (1937), 
Crile (1938) and Neuhof (1948), performed partial'or subtotal 
adrenalectomies together with other surgical procedures in patients 
with severe idiopathic hypertension. However, total adrenalectomy 
became feasible only with the introduction of cortisone for clinical 
use. Since then many reports of total or subtotal adrenalectomy 
for hypertension have appeared, but it is difficult to assess their 
value, as they were combined with various other surgical procedures, 
mainly sympathectomy. Green, Nelson, Dodds & Smalley (1950) were 
the first to describe a patient with malignant hypertension and 
diabetes mellitus whom they treated by total adrenalectomy alone.
The operation was followed by a fall in blood pressure and a dramatic 
remission of the diabetes, this still continuing 15 months after 
adrenalectomy. Wolferth (1953), Bowers (1954), Pickering, Wright 
& Heptinstall (1952), Thorn et al (1952), Rosenheim (1954) and
Wilson (1955) reported the effect of subtotal and total adrenalectomy 
combined with, in some cases, various types of sympathectomy for the 
treatment of high blood pressure. However, in most of these studies 
the data are not sufficient to assess accurately the effect of 
adrenalectomy on the hypertensive state. The work of Arnott, Crooke, 
Donovan & Taylor (1957) furnishes more comprehensive and valuable 
information about the patient's condition during a long post­
operative period .and gives a detailed account of the electrolyte 
balance in the patients studied. In the light of the conclusive 
evidence supplied by this investigation, the results of previous 
workers can be reassessed and better understood. It now seems 
established that, in patients with severe hypertension who have 
had bilateral adrenalectomy, blood pressure can be maintained at 
normal levels if the daily cortisone dose is low enough to keep the 
patients in a state of mild "adrenocortical hypofunction". The 
authors conclude, "it is clear that the vascular disease has been 
retarded or, perhaps even arrested by a state of slight adreno­
cortical insufficiency but it appears that the liability to 
excessive constriction of the arteriolar vascular bed, which is 
fundamental to essential hypertension, persists and a slight 
increase in the dosage of cortisone quickly recalls a severe 
hypertensive state".
In the light of all the facts and findings described above, 
it seems to be proved beyond doubt that the adrenal cortex plays 
an essential part in the development and maintenance of arterial
hypertension. However, the exact nature of this relationship, 
and the way in which adrenocortical secretion influences the 
mechanism of high blood pressure has not been as yet elucidated.
All the evidence derived from previous research suggested two 
possible mechanisms (Kernel, 1959):
1. The role of the adrenal cortex in hypertension is
of merely permissive nature. This is to be understood as follows:
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adrenocortic/51 secretion, or more precisely mineralocorticoid 
secretion, is essential for the maintenance of the proper sodium 
and potassium intracellular concentrations; these concentrations 
are responsible for the general muscular tone, including that of 
the vascular musculature, thus conditioning the response of the 
arterioles to various vasoconstrictive agents.
2. Adrenocortical hormones per se contribute directly to 
the increased and normal vascular resistance, either acting as 
pharmacodynamically active compounds on nerve endings in the 
arteriolar wall (or on the muscle directly) or increasing the 
responsiveness of the arterioles to noradrenaline or other vaso­
constrictive substances.
Bearing the above mechanisms in mind, it would be more 
purposeful to be selective, rather than exhaustive in further review 
of biochemical investigations and controversies related to hyper­
tensive disease, with special emphasis on those aspects most closely 
related to the authors subsequent experimental studies. Further 
review will be subdivided into the following sections;- glucocorticoids,
11
mineralocorticoids and adrenal "androgens".
1. Glucocorticoids :
The recognition of the association of cortisol over­
production with a form of hypertension at once raises the possibility 
that some patients with hypertension who did not have Cushing's 
syndrome even in mild form, might yet' suffer from hypersecretion 
of cortisol, which for some reason was not producing clinical 
evidence of its presence. An added stimulus for research along 
these lines was the fact that exogenous cortisol will induce hyper­
tension even in the absence of dietary sodium (Freidman, "^reidman & 
Nakashima, 1953; Knowlotn, Leob, Stoerk, White & Heffernan, 1952).
Cooper, Touchstone, Roberts, Blakemore, Rosenthal & Kasparow 
(1958) studied steroid formation by slices of human adrenal glands, 
excised for the treatment of hypertension and incubated in autologous 
plasma. The results showed a negative correlation between cortisol
s
formation per g. of tissue and diatolic blood pressure of the 
individuals from whom the glands were removed (r = -0.64, P<0.01). 
This decline in cortisol formation was also associated with a fall 
in the ratio of the formation of cortisol/corticosterone due to the 
fact that corticosterone formation declined significantly less with 
increasing diastolic pressure than cortisol. From this Cooper et al 
concluded that, "since cortisol and corticosterone arise from the 
same precursors, the shift of ratio indicates changes in the 
functional capability in the adrenocortical cells rather than in
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supply of substrates. The fall of the cortisol/corticosterone 
ratio suggests that there develops a deficiency of 17a-hydroxylase 
with progressing hypertension". In support of these findings 
Cooper, Kasparow, Blakemore & Rosenthal (1958) reported that the 
cortisol output by adrenals in situ, computed from rate of blood 
flow and steroid concentration in the adrenal venous blood at 
operation prior to excision of the gland, showed- a negative 
correlation to diastolic blood pressure of the patient similar to 
that in the corresponding adrenal incubates.
However, in 1959 Touchstone, Cooper & Blakemore reported 
increased mean level of 11-deoxycortisol in adrenal venous blood 
of nine hypertensive patients, which does not substantiate their 
theory that there is a deficiency at 17k-hydroxylase level.
Further evidence against decreased cortisol or increased corti­
costerone output by the adrenal gland of hypertensive subjects 
comes from the studies of Genest, Nowaczynski, Koiw, Sandor & 
Biron (1961). They found no essential difference in the mean 
excretion of cortisone, cortisol and their tetrahydro derivatives 
and the tetrahydro derivative of 11-deoxycortisol in groups of 
patients with idiopathic, renal and malignant hypertension as 
compared to that of normals. Finally using the Porter Silber 
reaction (1950) which is specific for steroids with a dihydroxy- 
acetone side chain, (steroids loosely grouped as 17-hydroxy- 
corticosteroids) Vermeulen & Van der Straeten (1963) measured the
13
daily urinary excretion of free and total Porter Silber chromogens. 
They compared the daily urinary levels of these steroids in idio­
pathic hypertensive patients with a control goup and found no 
statistical difference. More elaborate studies by the same 
investigators where cortisol and corticosterone production rates 
were measured again showed no difference on comparison of the 
controls with patients suffering from idiopathic hypertension.
Direct support of the theory that there is progressive 
diminution of 17a-hydroxylase activity in the course of arterial 
hypertension ironically enough comes from the findings of Genest 
et al (1960) and Vermeulen & Van der Straeten (1963) who reported 
significantly decreased urinary excretion levels of pregnanetriol 
the catabolic product of 17o-hydroxyprogesterone.
The studies of Nowaczynski, Kiow, & Genest (1964) lend 
very impressive support to a 17ct-hydroxylase impairment in 
hypertension. They estimated the excretion of pregn-5-en^33,
17o.,203"triol the catabolic product of 17a-hydroxypregnenolone, 
in a group of male and female patients with idiopathic, renal 
and malignant hypertension and found the mean excretion of this 
compound to be significantly decreased (P<0.001) in the three 
types of hypertension when compared with the mean levels in normal, 
males and females.
For proper interpretation of urinary levels of any compound, 
knowledge of the precursors of that compound must be available.
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Urinary pregnanetriol is mainly derived from 17a-hydroxyprogesterone 
but it may also derive from 17a- hydroxypregnenolone. The studies 
of Landau & Laves (1959) have shown that part of the urinary 
pregnanetriol may originate also from the testes. However, Roberts, 
Vande Wiele & Lieberman (1961) have shown that pregn-5-ene36,17a,20d- 
triol is the main metabolite of 17a-hydroxypregnenolone and possibly 
derives solely from that steroid. In addition, Decourcy (1956) did 
not obtain any pregn-5-ene36,17a,206-triol from 17a-'hydroxyprogesterone 
administered to a man. This shows that the A^-3-oxo configuration is 
not converted in vivo into A^-33-ol configuration. ^
As several steroids have been shown to give rise to urinary 
pregnanetriol it cannot be assumed that the determination of urinary 
pregnanetriol necessarily reflects the production or metabolism of a 
single steroid. However, as 17a“hydroxypregnenolone appears to be 
the unique precursor of pregn-5-ene3g,17a,20g-triol, it might, 
therefore, be concluded that the decrease in the urinary excretion 
of this compound indicates an inability of the adrenal cortex of 
hypertensive patients to hydroxylate pregnenolone at the 17a position.
The most impressive evidence implicating glucocorticoids with 
essential hypertension comes from the work of Kernel, who, in a very 
thorough study described in a series of papers covering a decade 
unequivocally^established a relationship between glucocorticoid 
metabolism and idiopathic hypertension (Kernel, 1957; Kernel, 1960; 
Kornel, 1962; Kornel, 1964; Kornel, 1965; Kornel & Motohashi, 19-65, and
Kornel & Takeda, 1967). Studying the urinary excretion of
17“hydroxycorticosteroids (17-0ÏÏCS) as free, glucuronide and
sulphate fractions in normotensive and hypertensive patients he
demonstrated that:-"l) excretion of 17-OHCS glucuronides was
lower in hypertensive patients; 2) excretion of 17-OHCS sulphates
was higher in these patients; 3) the higher excretion of sulphates
in hypertensives was mainly due to an increase in the more polar
steroids, mainly 6a-hydroxycortiso], 6g-hydroxycortisol and another
still more polar steroid in this fraction; 4) the lower excretion
of glucuronides was due only to a decrease in the less polar
steroids (mainly allotetrchyhrocortisol, tetrahydrocortisol and
tetrohydrocortisone) in the glucuronide fraction," These results
closely correlated with those of an analogous study in plasma. In
support of this Touchstone, Kasparow & Blaemore (1965) have shown
in vitro that the biosynthesis of 20a and 203-hydroxycortisol are
increased in the adrenal tissue of hypertensive subjects: also
Besh, Brownwell, Hartman & Watson (1962) demonstrated in dogs with
experimental hypertension a 50% increase in the formation of
206-hydroxycortisol. Kornel suggests that the more polar sulphated
17-OHCS, which are increased, may be directly involved in the
mechanism of increased arteriolar resistance, the fundamental
finding leading to arteriolar hypertension. He also suggests the
possible secretion of these sulphated steroids directly by the
adrenal gland as happens with dehydroepiandrosterone sulphate (DHA.S) 
and possibly corticosterone sulphate (Vande Wiele, MacDonald, Gurpide
& Lieberman, 1963; Lebeau & Baulieu, 1964),
Kornel suggested that the increase in sulphate fraction 
of the 17-OHCS in the hypertensive patients was due to a decreased 
ability of the patients to reduce ring A of the steroid nucleus 
(necessary for the formation of C-3 glucuronide conjugates) with 
the resulting increase in a compensatory sulphation pathway which 
does not require ring A reduction. Interpretation of this theory 
would suggest an increase in the sulphation of all the 17-OHCS, 
not just the more polar 17-OHCS and through this a decrease in all 
glucuronide conjugated 17-OHCS, However, this was not reported 
by Kornel, but it may possibly be that inhibition of ring A 
reduction applies only to the more polar steroids. Therefore, 
one would expect an increase in only the more polar sulphate 
steroids. Another explanation could be the further hydroxylation 
of cortisol sulphate, as happens in the further metabolism of DHA.S
2. Mineralocorticoids:
Interest in a possible role of aldosterone in the patho­
genesis of at least some forms of hypertension sprang originally 
from two main facts. Firstly aldosterone was found to be an 
extremely potent sodium retaining hormone, with properties similar 
to, but much stronger than deoxycorticosterone which, as already 
mentioned, could produce hypertension in animals. Secondly, there 
was the recognition by Conn in 1955, of the hypertensive state 
associated with cortical adenoma producing aldosterone in excess.
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However, the role played by aldosterone in essential 
hypertension has never been clear. Genest, Lemieux, Davignon,
Koiw, Nowaczynski & Steyermark (1956); Garst, Shumway, Schwartz & 
Farrell (I960); Genest, Koiw, Nowaczynski & Leboeuf (1958);
Venning, Dryenfurth, Dossetor & Beck (1961) and Genest et al (I960) 
all found elevated urinary levels of aldosterone in patients with
idiopathic hypertension: most of these reports did not give clinical
details of their patients to indicate the severity of the hyper­
tension and whether or not steps had been taken to exclude renal 
factors. In particular, information was lacking as to whether or 
not patients had been treated with hypotensive drugs or diuretics 
and as to the amount of dietary sodium permitted.
Elevated urinary levels of aldosterone were also found in 
patients with severe and malignant idiopathic hypertension and it 
was suggested by Genest et al (1956) that "human arterial hyper­
tension could be caused by a mild and chronic hyperaldosteronism',
In a subsequent report Genest et al (1958) confirmed their previous 
findings, but were more cautious in their interpretation.
On the other hand Hernando, Crabbe, Ross, Reddy, RenoId, 
Nelson & Thorn (1957) and Cottier, Muller & Schmid (1959) failed 
to find elevated urinary aldosterone levels in untreated mild 
hypertensive patients on a normal sodium intake. In the
evaluation of urinary aldosterone levels it must be remembered
that the amount of aldosterone appearing in the urine is only a
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portion and often a variable portion, of the amount secreted. 
Therefore, it does not always mirror the secretion rate. Thus 
studies reporting secretion rates will tend to be,more, 
authoratative. Laragh, Ulick, Ganuszewicz, Deming, Kelly &
Lieberman (I960) measured aldosterone secretion rates in 7 
untreated idiopathic hypertensive patients and found them to be 
within the normal range. Two years later Cope, Harwood & Pearson 
(1962) confirmed these findings.
More recent reports confirm the findings that many patients 
in the advanced stages of hypertension secrete and excrete increased 
amounts of aldosterone in relation to sodium balance (Laragh, Sealey 
& Sommers, 1966). However, the more recent reports do not completely 
clarify the role of aldosterone in idiopathic hypertension. Genest 
(1965) still claims to find increased urinary aldosterone excretion 
in patients with idiopathic hypertension, whereas Ledingham, Bull & 
Laragh (1967), estimating aldosterone secretion rates in 113 patients 
with uncomplicated idiopathic hypertension and 56 controls present 
very convincing evidence to the contrary. This group also 
desaonstrated a very close relationship' between rate of salt excretion
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and the rate of. aldosterone secretion over a\ery wide range of urinary 
sodium in 58 normal subjects and showed that in general, a strikingly 
similar relationship is apparent in patients with essential hyper­
tension; only 5 out of 113 showed abnormal large amounts of aldo­
sterone in relation to urinary sodium.
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Laragh, Cannon & Ames (1963) have concluded that 
"increased aldosterone secretion does not occur in essential 
hypertension, unless renal involvement has reached a stage when 
secondary aldosteronism is induced." In this context Cade,
Shires, Barrow & Thomas (1967) describe very unexpected steroid 
patterns in renovascular hypertension, a condition generally 
associated with elevated aldosterone rates (Gowenlock & Wrong, 1962;
Laidlaw, Yendt, Bird & Gornall, 1963 and Slaton & Biglieri, 1965).
They found grossly abnormal diurnal rhythm of plasma cortisol 
concentration with hi^ gh late evening levels and low to normal 
norming levels. However, the aldosterone excretion was normal 
in all the 13 patients studied.
The role of aldosterone in experimental hypertension is 
as uncertain as its role in idiopathic hypertension in man.
Aldosterone produces hypertension in rats but not in dogs, cats
or rabbits, and like DOC it produces hypertension only if certain
minimal quantities of sodium are present in the diet. Hypertension 
could not be produced in adrenalectomized, unilaterally nephrectomized 
rate by the administration of 40 yg of d-aldosterone in sesame oil 
(Gross, Loustalot, Meier, 1955); this amount had sodium retaining 
activity equal to 1 mg of DOCA, the administration of which resulted 
in hypertension. Later the same authors succeeded in producing 
hypertension in unilaterally nephrectomized salt loaded rats given
0.5 mg of dl~aldosterone monoacetate daily (Gross, Loustalot &
Meier, 1957). Hypertension has been produced in rats by the
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prolonged administration of only one-thousandth of this dose, 
that is 0.5 yg of d.aldosterone administered sub~cutaneously 
in ethanol every second day, increasing to 1 yg daily after 
3 months (Kumar, Hall, Nakashima & Gornall, 1957). Hypertension 
appeared after 100 days. These investigators surprisingly 
found that the substitution of 1% saline for drinking water made 
no difference in the rate at which blood pressure becarae elevated. 
When a similar dose of aldosterone was given to adrenalectomized 
rats, hypertension developed earlier than when given to intact rats. 
Singer, Losito & Salmon (1963) working with rats with their renal 
artery clipped were able to demonstrate, that elevated aldosterone 
secretion was unnecessary for development of persistent hyper­
tension. In rats with a clip on one renal artery and an opposite 
normal kidney, the aldosterone secretion rate was elevated. After 
removal of the normal kidney, though the blood pressure remained 
elevated, the aldosterone secretion rate dropped to normal.
The mechanisms by which mineralocorticoids are implicated 
in the pathogenesis of hypertension are complex. There is 
evidence that whenever vascular smooth muscle contracts more than 
normal, such as produced by chronic infusion of noradrenaline, the 
muscles tend to accumulate sodium, and as thenuscle hypertrophies 
it accumulates more sodium in proportion to the increased volume 
of vascular tissue as well as because of increased concentration. 
Gross (1961) and Mendlowitz, Naftchi, Bobrow, Wdf & Gitlow (1963)
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have shown that mineralocorticoids not only favour renal retention 
of sodium, but also may have a direct effect on the tissues in 
terms of a shift of ions into or out of smooth muscle cells. 
Aldosterone causes more renal retention of sodium in normo- 
tensives than in patients with idiopathic hypertension, however, 
aldosterone produces a greater increase in vascular reactivity in 
the hypertensive group, which Mendlowitz et al (1961) suggest is 
a direct effect on vascular smooth muscle. On the other hand 
glucocorticoids have little effect on the retention of sodium 
by the kidney, yet they increase responsiveness of blood vessels 
in normotensive subjects, but not in hypertensive patients, 
(Mendlowitz, Naftchi, Weinreb & Gitlow, 1961).
3. Adrenal "Androgens'';
Bruger, Rosenkrantz & Lowenstein (1944) were the first 
to estimate 17-oxosteroid (17-OS) excretion in urine (24-hour 
specimens) 5 using a method based on the ^immermanicolour reaction. 
They selected only female subjects for their investigation, in an 
attempt to eliminate the contribution of androgenic steroids of 
testicular origin. Fourteen normotensive^" and 40 hypertensive 
subjects were investigated. The urinary excretion of the 17-OS 
was found to be significantly lower in the hypertensive group, 
although it was still within the lower limit of the excretion of 
the normal subjects. The authors suggested that their findings 
may indicate an altered pattern of corticoid production or a 
hypofunction of adrenal cortex due to exhaustion under the constant
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strain imposed upon it by the persistent elevation in blood 
pressure. A low urinary excretion of 17-OS was also reported 
by Selye (1947) in 12 of 18 hypertensive patients. However, 
Sayers (1950) thought the determination of "androgenic" 
steroids (17-OS) in hypertension did not seem to have a strong 
rationale as their concentration in urine or blood hardly reflects 
adrenocortical activity, although they partly constitute the 
metabolic product of the glucocorticoids.
Hetzel & Mine's (1952) investigation of urinary 17-OS 
level showed no difference from normotensive controls. The 
authors concluded that "there is no,evidence for a significant 
disturbance of adrenal cortex in'hypertension". In a series 
of 19 patients with severe types of renal disorders and probably 
all exhibiting an elevated blood pressure, Wallace, Christy & 
Jailer (1955) measured urinary 17-OS and blood urea nitrogen.
In 1 case of acute glomerulonephritis, 3 cases of chronic 
glomerulonephritis and 1 of 2 hypertensive patients low urinary 
17-OS were found.
Warter, Schwartz & Block (1960) looked at 17-OS levels 
in patients with idiopathic hypertension, who were split into two 
groups; patients with elevated urinary aldosterone levels and 
patients with normal urinary aldosterone levels. They found' no ■ 
difference in 17-OS between the two groups. However, they point 
out that urinary dehydroepiandrosterone (DMA) and 17-OS were often
subnormal in patients with idiopathic hypertension, but that 
the variation of the aldosterone DHA ratio was not significant.
The authors interpreted the often subnormal urinary DHA and 
17-OS levels found in their studies as alterations met with 
in all deficiency states.
t^ fhile investigating the range of values for individual 
17-OS in normal subjects Feher (1966) and Keutmann & Mason (1967) 
have shown urinary DHA to be absent or very low in childhood and 
old age, and present in varying amounts in normal adults. In 
seeking to determine factors which could influence both uri- 
cosynthesis and blood pressure KBlbel, Gregorova & Sonka (1964,
1965a) found a relationship between the absence of urinary DHA 
and elevated serum uric acid levels in hypertensive patients.
They found that 18 out of 23 (74%) hypertensive males and 12 out 
of 23 (52%) hypertensive females had no DHA in their urine. Full 
details were not supplied but in almost all the patients showing 
an absence of urinary DHA the serum uric acid was elevated.
Hypertension is not the only disease in which an absence 
of urinary DHA has been described. Sonka, Gregorova & Krizek (1964) 
reported the absence of urinary DHA in patients suffering from gout, 
a disease in which one of the cardinal features is grossly elevated 
serum uric acid levels. In female obese diabetics Sonka &
Gregorova (1964) reported the absence of urinary DHA in 27 out of 
the 32 patients. The same authors have also reported lowered
urinary DHA levels in patients with toxaemia of pregnancy and 
have related this decrease to the elevated plasma lipids normally 
displayed in this disease (Kotasek, Passati, Sonka, Brestak,
Gregorova & Passati, 1967).
A/Î unifying theory to encompass the above conditions, 
all of which are associated with a deficiency of urinary DHA, 
was postulated by Sonka, Gregorova, Jiranek, Kolbel & Matys (1965b).
It stems from the studies of Marks & Banks (I960) who demonstrated 
that DHA, pregnenolone, epiandrosterone and to a lesser degree 
several other 17-OS at concentrations of 1x10 or less, inhibit 
mammalian glucose-6-phosphate dehydrogenase (G-6-P.D.) activity.
All the steroids with inhibitory action had a ketone group at 
C-20 or C-17; progesterone, oestrogens, testosterone, corti­
costeroids and steroids with hydroxyl groups at C-17 or C-20 had 
little or no inhibitory action. The inhibition was shown to be 
non-competitive and left the steroid unchanged at the end of the 
experiment. Similar findings have been reported by McKerns &
Kaleita (1960), G-6-P.D. is the rate limiting enzyme in the
pentose phosphate pathway which is very important for the reduction
of nicotinamide adenine dinucleotide phosphate (NADP^).
Reduced nicotinamide adenine dinucleotide phosphate (NADPH)
is necessary for the reduction synthesis of fatty acids (Gibson, Jacob, 
Porter, Tietz & Wakil, 1957; Dressier & Wakil, 1961; Wakil & Dressier, 
1962), unsaturated fatty acids (Bloomfield & Block, 1958), sphingomyelin 
(Brady & Koval, 1958), cholesterol (Popiak, Gosselin, Gore & Gould, 1958;
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Tchen & Bloch, 1957.) , and steroids (Hayano, Saba, Dorfman & Hecter, 
1956; Ryan & Engel,1957). It also serves as a coenzyme in 
reduction of folic acid to tetrahydrofolic acid (Hatefi, Osborn, '
Kay & Huennekens, 1957) and is capable of reducing disulphidic 
bonds (Lynn, Earnhardt & Brown, 1961) .
Thus through a reduced level or a complete absence of 
DHA in the urine which is extrapolated to low secretion rates 
Kolbel et al (1965b) suggest that certain biosynthetic pathways 
are stimulated, resulting in:- 1) increased fat synthesis and 
deposition causing obesity; 2) elevated plasma lipids as displayed 
in toxaemia of pregnancy; 3) elevated blood glucose levels 
through excessive reduction of the disulphidic bridges (-S-S- -S-H,
H-S-) joining chains A and B of the insulin molecule, therefore, 
deactivating the hormone; 4) elevated plasma uric acid levels, 
caused by excess tetrahydrofolic acid stimulating overproduction 
of purine the precursors of uric acid.
The above responses, if mediated through a lack of DHA 
will all be, to a certain extent, dependent on blood levels of 
DHA. Yet Kolbel et al in all their communications give little 
or no reference to DHA blood levels, which are very small relative 
to blood dehydroepiandrosterone sulphate (DHA.S) levels, and 
would appear to be inadequate for the inbitory task suggested.
For, according to Lopez-S, Krehl & Woon (1967), they only obtained 
13% reduction of red blood cell G-6-P.D. activity after oral 
administration of 100 mg of DHA per day for 3 days, and from their
Zb
calculation based on observations of Sjovall, Sjovall, Maddock
& Horning (1966) oral consumption of 100 mg would elevate blood
DHA levels 80^moles/100 ml to a blood level very unlikely to be
met with under normal or pathological conditions. Kischner,
Lipsett & Collins (1965) reported DHA levels of 1.0 and l.Syg/
100 ml for females and males respectively, while Plager (1966)
reported DHA.S levels of 46 and 100 mg/100 ml for females and
males respectively. Thus, although DHA.S does not inhibit
G-6-P.D. (Tomkins, Yielding & Curran, 1961) it is interconvertible
with DHA (Chapdalaine, MacDonald, Gonzalez, Gurpide, Vande Wiele
fit Lieberman, 1965) and, therefore, is a potentially' more powerful
inhibitor of G-6-P.D. than DHA.
Tsutsui, Marks & Reich (1962) neglected blood levels
and examined inhibition of G-6-P.D. by DHA at the site of its
«
biosynthesis, namely the adrenal cortex. . They studied the effect
of exogenous DHA on whole rat adrenal homogenates incubated with 
+ .
NADP in concentrations “which did not limit the rate of
oxidation of 1-^^C glucose or 1-^^C glucose-6-phosphate to ^^CO
oxidation of 1-^^C glucose or 1-^^C glucose-6-phosphate to ^^CO
and found a decrease in the rate of formation of and
2
generation of NADPH.
1-1 Glucose-6-PO —p---- ^6-phosphogluconate + l^CO
NADP
NADPH
When the concentration of NADP was sufficiently low to limit the
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rate of oxidation, addition of DHA stimulated the rate of formation
of and NADPH. The authors conclude that it is possible that
2
DHA and perhaps related steroids which can influence the rate of 
generation of NADPH, may, thereby affect the biosynthesis of 
steroids in the adrenal gland.
On the question of the relationship, if any, of absence of 
urinary DHA to the aetiology of hypertension Kolbel et al (1965a) 
offer two explanations, "Pirstly, "NADPH is essential in the 
synthesis of aldosterone, Cohen & Crawford (1963) showed that a 
sodium free diet enhanced the intensity of the pentose phosphate 
cycle in the adrenal cortex, and that overproduction of NADPH is 
connected with overproduction of aldosterone." Secondly, "over­
production of NADPH in DHA deficient tissues could also maintain 
a larger quantity of sulphydryl groups of amino acids in the 
reduced state in the smooth muscle of the arterial wall. If 
these groups are important for the action of sympathomimetic amines 
(Trinus, 1961), oversensitivity to physiological amounts of these 
compounds could result".
Villee & Hagerraan (1959) have shown that 20a and 203“hydroxy- 
cortisol all stimulating ,G-5-P.D. activity, the hypertensive patient 
will have adrenals particularly efficient at hydroxylating stenoids-. 
One would, therefore expect hypertensive patients to display 
excessive production of polar steroids. This is substantiated by 
’the work of Kornel & Motohashi (1965) and Kornel & Takeda (1967% who 
demonstrated elevated levels of polar steroids in plasma and urine 
of hypertensive patients.
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B, Salt Metabolism.
1, Salt retention:
It is not the author’s intention to review the literature 
pertaining to the influence of the mineralocorticoid aldosterone 
on salt metabolisTU, but to point out that in any investigation or 
discussion relating to salt metabolism, the role of aldosterone 
must surely always merit major consideration. Aldosterone, 
secreted by the zona glomerulosa of the adrenal cortex, plays a 
major role in the hormonal control of sodium and potassium levels 
in the body. Its secretion is under the control of the renin- 
angiotensin system, plasma potassium level and to a lesser extent 
pituitary ACTH. All aspects of the present knowledge concerning 
aldosterone, including biosynthesis, regulation of secretion, 
mechanism of action and influence on salt metabolism are amply 
covered in the following reviews - Poss (1964), Baulieu & Robel 
(1964), Peart (1965), Mulrow (1967) and Holgan & Blair-West (1967).
2. Salt excretion:
The isolation of the salt retaining compound aldosterone 
in 1953 by Simpson, Tait, Wettstein, Neher, & Reichstdren at once
stimulated a renewed search for a hormonal steroid with the reverse 
action, that is, one which stimulated sodium, diuresis. As early 
as 1948, Wilkins & Lewis suggested the existence of such a steroid 
to explain the excessive salt loss seen in some cases of congenital 
adrenal hyperplasia. However, as yet, there has been no success
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in finding such a hormone, despite active research by many 
investigators. Nevertheless, a great many and often independent 
observations all suggest that such a substance does exist.
It is well known that patients with Addison’s disease 
are sensitive to small doses of DOC, and readily develop excessive 
sodium retention if the dose is too large, whereas normal subjects 
will frequently resist very large doses of DOC with only slight 
increases in sodium retention. This suggests the presence of 
some substance in the normal subject which is capable of antagonising 
the sodium retaining properties of DOC. Since patients with 
Addison’s disease have virtually no adrenal glands, the source of 
the substance or some precursor of it is probably the adrenal gland,
Fraser (1967) in a normal male subject showed that sodium 
restriction induced a gradual decrease in urinary sodium well before 
increases in plasma aldosterone levels were observed. This confirms 
the work of Leutscher & Lieberman (1958) who followed urinary sodium 
and aldosterone levels of normal subjects on low salt intake and 
observed salt retention before urinary aldosterone levels increased, 
suggesting a decreased production of some sodium excreting factor 
prior to the increase in aldosterone production.
An inverse relationship exists between the amount of sodium 
excreted in the urine and the excretion (Thorn, Ross, Crabbe &
Van’t Hoff, 1957) or secretion (Laragh et al, 1966) of aldosterone. 
This relationship, however, ceases to be significant at physiologicO-l
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levels of aldosterone exretion that cover the range of normal 
circumstances of salt and water equilibrium (Thorn et al, 1957). 
This suggests that, under normal conditions, aldosterone does not 
regulate the amount of sodium excreted into the urine, A further 
observation lending support to this conclusion is the two hour 
delay before an effect of aldosterone on the kidney is observed 
in man. This data suggests that aldosterone is not responsible 
for quick changes in sodium excretion. Further, Crabbe, Ross & 
Thorn (195 9) have shown that the amount of aldosterone excreted 
in the urine, and presumably the amount secreted, rises to a 
maximum in response to a low sodium diet, but often falls again 
towards, and in some subjects to, the level found before the diet 
was administered. Despite this, sodium excretion falls 
exponentially and continues at a level equal to, or below, the 
intake. These observations suggest a dual control of salt 
homeostasis with aldosterone regulating retention and some other 
substance regulating excretion of sodium.
In the adrenal gland of the newborn baby the ratio of C^g 
to steroids produced is very high. This is thought to be due 
to high production of C^g steroids by the large foetal zone and 
minor production of hydroxycorticosteroids by the small adult zone 
This production ratio of C^^iC^^ steroids very quickly decreases 
over the first three weeks of life as the foetal zone involutes 
and the adult zone grows (Prader, 1967). Yet, under these 
circumstances of minimal C^^ steroid production, New, Killer &
Peterson (1956) using a double isotope derivative technique 
report very high urinary levels of free aldosterone and normal 
levels of the tetrahydroglucuronide and the 3-oxoconiugate of 
aldosterone, all calculated per square metre of body surface 
area and compared with the respective levels in adults measured 
in the same units. The very high free urinary aldosterone 
levels could possibly be explained by postulating active 
secretion of a salt excreting hormone by the foetal adrenal zone 
and the elevated aldosterone necessary as a compensatory mechanism 
to maintain salt balance, with the urinary aldosterone level 
decreasing to normal as the excessive secretion of the salt 
excreting hormone declines with the involution of the foetal zone. 
Since the foetal zone is producing primarily C^g steroids the salt 
excreting hormone could possibly be one of these.
From a different direction comes suggestive evidence for 
the existence of a sodium excreting hormone. In the earlier 
days of aldosterone investigation, bioassay was necessary for the 
estimation of aldosterone levels. Several groups at the same 
time including Leutscher, Deming, & Johnson (1952), Singer & Venning 
(1953) and Cope & Garcia-Llaurado (1954) all experienced difficulty 
in carrying out satisfactory bioassays of the sodium retaining 
factor present in urine extracts. Typical of these are the 
findings reported by Singer & Venning (1953). Urine, collected 
from two patients with nephrosis, over time periods ranging from
5 to 40 minutes, was extracted and injected into sodium ^^Na 
loaded, adrenalectomized rats and the excretion measured.
The results indrcated that the effect of the sodi.um retaining 
factor extracted from the urine was being inhibited. For 
example, of the extracts of 10, 20 & 30 minute urine collections 
from one patient the extract of the 20 minute urine volume showed 
maximum sodium r^ fteining ability while the 10 and 30 minute urine 
extracts showed equal sodium retaining ability.
To some extent in these earlier studies difficulties were 
due to impurities in the urinary extracts, and a better dose 
response curve could be obtained if the extracts were partially 
purified. However, this was not always so and Dryenfurth & 
Venning (1959) suspected that the interference was caused by a 
substance antagonising the action of aldosterone present in the 
extracts, and preventing the development of a proper dose response 
curve. As further evidence they found some urine extracts which 
seemed actually to increase sodium output when injected into
adrenalectomized mice.
The original concept of a salt excreting hormone stems
from studies on infants with congenital adrenal hyperplasia of 
the salt-losing type. Congenital adrenal hyperplasia, a rare 
disease appearing in infants, has virilism as one of its cardinal 
features, caused by excessive androgen production. The 
association of a clear and severe salt losing state with some 
cases of congenital adrenal hyperplasia had been recognised by
clinicians for many years. It seems to have been first reported 
by Butler, Ross & Talbot (193) and Wilkins, Fleischman & Howard 
(1941). Darrow (1944) drew attention to the paradoxical situation 
in some of these patients, who while manifesting a severe hypoadrenal 
state had grossly hyperplastic adrenal cortices and he also 
described a patient in Addisonian crisis who needed large quantities 
of DOG for full restoration. Darrow suggested that the excessive 
androgen production characteristic of this disease may in some way 
be interfering with sodium and potassium metabolism. In 1949 
Lewis & Wilkins were able to show that ACTH administration to 
children with congenital adrenal hyperplasia, resulted in a large 
rise in the already high urinary excretion of 17-oxosteroids, but 
there was only slight increase in the already low excretion of 
corticosteroids. This together with the tendency to enter 
Addisonian crisis, strongly suggested an inadequate production of 
corticosteroids in this disease. Until 1950 attempts to treat 
congenital adrenal hyperplasia by medical or hormonal means had no 
success, then Wilkins, Lewis, Klein & Rosemberg in 1950 discovered 
that the characteristically elevated urinary 17-oxosteroid levels 
found in this condition could be promptly lowered to normal levels 
by treatment with cortisone. Kelley, & Raile (1952) reported
that plasma 17-hydroxÿcorticosteroids were abnormally low in 
untreated cases of this disorder and that no rise in plasma corti­
costeroids levels resulted from ACTH administration. Syndor,
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Kelley, Raile, Elk & Sayers (1953) were able to show that 
elevated and measurable amounts of ACTH were present in the 
plasma of untreated patients, but could not be detected after 
cortisone treatment. Credit for the first recognition of 
the nature of the defect in this disease goes to Bartter, 
Albright, Forbes, Leaf, Dempsey & Caroll (1951) who explained 
that excessive ACTH is being produced in these infants and 
inducing adrenal hyperplasia which results in grossly elevated 
urinary 17-oxosteroid levels, presumably from excessive adrenal 
androgen production. However, despite this hyperactivity 
insufficient cortisol is being produced to suppress pituitary 
ACTH secretion and the pituitary, in turn, secretes more ACTH 
and induces even greater adrenal hyperplasia, but still very 
little cortisol. A form of vicious circle is thus created. 
After treatment with cortisone plasma cortisol levels rise and 
the secretion of pituitary ACTH is inhibited, adrenal hyper­
activity declines as does urinary 17-oxosteroid levels and on 
continued cortisone therapy adrenal function apparently returns 
to normal. This transition can take place in 24 to 36 hours, 
but unfortunately does not always cure salt-loss. Elucidation 
of the actual metabolic block responsible for the failure to 
synthesise cortisol is attributed to Dorfman (1954) and 
Eberleira & Bongiovanni (1955) who suggested that the primary 
defect in the disease was a lack of the "21 hydroxylase" enzyme 
This might be illustrated as follows:-
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Cholesterol
ACTH All16r 1 or Pituitary-
Progesterone
"21" block
17“hydroxy 
Progesterone
A N D R O G E N S
'^’“Cortisol
1. Simple virilism
2, Simple virilisa S: salt loss
About a third of the patients with congenital adrenal hyperplasia 
are salt-losers. The pathogenesis of this phenomenum is not 
fully understood. Three major hypotheses have been advanced to 
explain it.
The first was suggested by Crigler, Silverman, & Wilkins 
(1952), who observed an increase in sodium diuresis in patients 
treated with ACTH (Wilkins, Klein & Lewis, 1950), as well as a 
decreasing requirement for DOCA when treated with cortisone.
These findings supported the earlier observation of Darrow (1944) 
who had noted that patients with salt-losing congenital adrenal 
hyperplasia required amounts of DOCA or salt, or both, which were 
larger than those needed by Addisonian patients and of Barnett
3b
& McNamara (1948) who had shown that the electrolyte disturbance 
in adrenal hyperplasia was different from that observed in 
patients with Addisons disease. All these findings were inter­
preted as suggesting the secretion of a salt-losing hormone or 
the secretion of a pattern of steroids conducive to salt loss.
Another explanation was advanced by Bongiovanni & Eberlein 
who pointed out that both the saltylosing and the non-salt-losing 
forms of congenital adrenal hyperplasia are caused by the same 
hydroxylation defect of the adrenal cortex, however, in the salt- 
losing form the defect is almost complete (Eberlein, 1958). They 
suggested that "a minimal amount of hydrocortisone is required 
for aldosterone to exert its metabolic action in man" (Eberlein & 
Bongiovanni, 1958). Thus, although untreated salt-losing patients 
may be producing normal amounts of aldosterone, its action is not 
manifested, because only negligible amounts of cortisol are being 
produced.
Blizzard, Liddle, Migeon & Wilkins (1959) studied aldo­
sterone excretion in patients with congenital adrenal hyperplasia 
and found low to normal aldosterone excretion levels in salt-losing 
patients with no increase on salt deprivation. Most of the 
patients with the non-saltrlosing form, of the disease had an 
increased excretion of aldosterone with a further increase on 
salt deprivation. These findings were interpreted as indicating 
that the salt loss was due to inadequate aldosterone production.
3/
Numerous investigators have studied the excretion and 
secretion of aldosterone in patients with congenital adrenal 
hyperplasia, but the results are as yet inconclusive.
Von Prader, Spahr & Neher (1955) reported two cases of simple 
virilizing adrenal hyperplasia in adults and four cases of 
salt-losing adrenal hyperplasia in children, all of whom showed 
normal or greater than normal excretion of the 3-oxo conjugate 
of aldosterone, Leutscher & Curtis (1955) found normal or 
slightly increased excretion of aldosterone in patients with 
the salt-losing syndrome. Jailer, Ulich & Lieberman (1959) 
estimating aldosterone secretion rates by an isotope dilution 
technique, found two salt-losers to be within the normal range 
and two but of three simple virilisers to have elevated secretion 
rates and in the salt-losers sodium loss and adrenal crisis 
occurred after ACTH administration. Rosemberg, Dufault, Bloch, 
Budnitz, Butler & Brera (I960) described a child with salt--losing 
adrenal hyperplasia studied at 18 months and again at 4g years 
who excreted normal to high levels of aldosterone, which increased 
on sodium restriction and ACTH administration, and yet was still 
coincident with a negative sodium balance. Recently Visser & 
Degenhart (1967) described a new born infant with salt-losing 
adrenal hyperplasia who had an elevated aldosterone secretion 
rate (280 pg/day) on normal sodium intake with an increase on 
sodium restriction to 570 jag/day. Fortunately treatment with
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cortisone corrected the salt loss and probably induced a 
decrease in aldosterone secretion.
On the other hand, Lieberman & Leutscher (1960)
demonstrated subnormal aldosterone excretion in infants with
salt-losing adrenal hyperplasia while clinical signs of salt
depletion were evident and Bryan, Kliman & Bartter (1962)
using a double isotope derivative method found extremely low
aldosterone production rates in 5 salt-losers. Mattox and
Lewbart (1959) found excretion of the 3-oxoconjugate of aldo-
2sterone in 25 children to range from 0 .7 to 18 mg per m per 
day. Six patients with simple virilising adrenal hyperplasia 
and six out of 7 salt-losers fell within the normal range, 
however, the salt-losers showed no change on salt deprivation. 
Kowarski, Finkelstein, Spaulding, Holman & Migeon (1965) 
measured aldosterone secretion rates in two adult simple 
virilizers and five salt-losers. In the adults, aldosterone 
secretion rates were above normal and could be further increased 
by salt restriction, though treatment with glucocorticoids 
brought the secretion rates within the normal range. In the 
patients suffering from salt-loss,aldosterone secretion rates 
were below normal in severe cases and normal in milder cases. 
However, they showed no increase on salt restriction. Finally, 
New et al (1966) in an extensive study measured the excretion of 
free aldosterone, the 3-oxoconjugate of aldosterone and tetrahydro- 
aldosterone glucuronide in 40 normal infants and 28 infants and
children suffering from congenital adrenal hyperplasia, 12 of 
whom were salt-losers. When corrected for surface area, the 
excretion of the 3-oxoconjugate of aldosterone and tetrahydro- 
aldosterone glucuronide for normal infants and children with 
simple virilism were within the range for normal adults, though 
in several cases of simple virilism values for the two aldosterone 
metabolites were quite high. In the cases of adrenal hyperplasia 
with salt-loss values tended to be very low, though for 5 of the 
18 cases the excretion of the 3-oxoconjugate of aldosterone was 
well within the normal range.
Without forming any definite conclusions as regards the 
secretion and excretion of aldosterone in congenital adrenal 
hyperplasia, it would appear that in many of the salt-losing 
patients there is normal production of aldosterone and in some 
of these patients there is also a normal aldosterone response 
to sodium restriction. The abnormal salt metabolism in these 
patients provides strong evidence for a salt-losing steroid.
Further, in many of the cases of simple virilism there appears 
to be a higher than normal secretion of aldosterone, this is also 
suggestive of the existence of a salt-losing steroid.
Several steroids have been proposed for the role of a 
salt-losing hormone. Two of them are progesterone and 17a- 
hydroxyprogesterone and the following theory on their mode of action 
in this disease has been cited by several authors (Jacobs, Van der 
Poll, Gabrilove & Soffer, 1961: Degenhart, Hendrick, Visser,
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Wilmink & Croughs, 1965 and Kowarski et al, 1965). There is a 
21-hydroxylation defect in both the salt-losing and non-salt- 
losing forms of congenital adrenal hyperplasia,, and it affects 
both cortisol and aldosterone formation because they both require 
a 21-hydroxylation for their biosynthesis. Since cortisol 
secretion is many times greater than that of aldosterone, a 
limited 21-hydroxylation deficiency might lower the production of 
the former without affecting the secretion of the latter. The 
21-hydroxylation deficiency is always more marked in the salt- 
losing patients, although never complete. This has been 
satisfactorily demonstrated by the estimation of cortisol 
production rates (Kenny, Malvaux & Migeon, I960 and Degenhart et 
al, 1965).
An increased production of various cortisol precursors is 
a constant feature of congenital adrenal hyperplasia. Two of 
these, progesterone and 17a-hydroxyprogesterone are aldosterone 
antagonists (Landau, Lugibihl, 1958 and Jacobs et al, 1961) and 
have been shown to be capable of bringing about negative sodium 
balance in DOG treated patients suffering from Addison’s disease. 
The non-salt-losing patients have a relatively milder 21-hydroxy­
lase defect and are, therefore, able to compensate for these
\
antagonists by an increased secretion of aldosterone. However, 
in patients with a eimter enzyme deficiency, aldosterone 
production is also affected, and they are unable to compensate
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for the presence of these antagonists, and thus develop 
negative sodium balance.
Cortisone treatment of patients with non-salt-losing 
congenital adrenal hyperplasia lowers the secretion of these 
cortisol precursors and through this brings about a decreased 
aldosterone secretion in these patients. Similarly, in the 
mild salt-losers, cortisone treatment alone can sometimes control . 
the electrolyte disturbance (Wilkins, 1965). From these facts 
one could theorise that mild salt-losers have an aldosterone 
secretion in the normal range when untreated and treatment with 
cortisone, by lowering the secretion of the antagonists, enables 
them to achieve sodium homeostasis, whereas in patients with an 
aliaost complete 21-hydroxylase deficiency, aldosterone secretion 
is insufficient even when the production of antagonists are 
lowered by treatment with cortisone. Further, an increased 
urinary sodium excretion after administration of ACTH has been 
observed in both salt-losing and non-salt-losing forms of 
congenital adrenal hyperplasia (Lewis & Wilkins, 1949: Wilkins,
Klein & Lewis, 1950: Jailer, Louchart & Cahill, 1952 and George,
Saucier & Bartter, 1965) and even during therapy with DOCA, 
patients of the salt-losing type show this increased excretion 
of sodium after ACTH administration (Wilkins et al, 1950). This 
sodium loss induced by ACTH administration is attributed to an 
even greater overproduction of cortisol precursors, which antagonise
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the more modest ACTH induced increase in aldosterone.
The above theory holds only if the production of the 
aldosterone antagonists progesterone and 17a-hydroxyprogesterone 
are high enough to inhibit the sodium retaining properties of 
aldosterone. An estimate of how high this production would 
need to be may be calculated from the results of Landau &
Lugibihl (1958) who, in acute studies on two adrenal deficient 
subjects demonstrated that 150 mg of progesterone nullified 
the sodium retaining effect of 20 j&g of aldosterone and from 
the results of Kowarski et al (1965) who reported the mean 
aldosterone secretion rate in patients with non-salt-losing 
congenital adrenal hyperplasia as 290 p^/day and in normal as 
100 pg/day. Thus application of the estimate of the former 
group to the aldosterone secretion rates of the latter group 
indicates that 290-100 ~ 190 fug of aldosterone are secreted by 
the non-salt-losing patients to ameliorate the inhibition caused 
by the overproduction of the cortisol precursors. If we equate 
the inhibitory potency of progesterone and 17a-hydroxyporgesterone 
then the combined total secretion necessary to nullify 290 ftg 
of aldosterone would be 1,425 mg. Further, in the studies reported 
where the patients are salt-losers, secreting normal amounts of 
aldosterone and who continue to lose sodium during salt restriction 
even though their aldosterone secretion has increased, such as the 
case by Visser & Degenhart (1967), the secretion of these two
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steroids progesterone and 17a-hydroxyprofi:esterone would have 
to be very high to inhibit the action of aldosterone which in 
the case cited was 380 mg secreted per day.
Of the two corticosteroids progesterone and 17a-hydroxy- 
progesterone, secretion rates have been estimated, in this 
disease, for only 17a-hydroxyprogesterone. Fukushima, Bradlow, 
Heilman, Zumoff & Gallagher (1961) reported the daily secretion 
rate of 17a-hydroxyprogesterone to be 240-280 mg/day in congenital 
adrenal hyperplasia and 3 mg/day in normals. Assuming 
progesterone to have a secretion rate comparable with 17a- 
hydroxyprogesterone, and this is probably an overgenerous 
assumption, then, the combined secretion rates are still 
insufficient to achieve the degree of antagonism of aldosterone 
postulated by the above theory.
A search for the active steroid in urine of a patient
with salt- losing type of congenital adrenal hyperplasia was made
by Neher, Desaulles, Vischer, Wieland & Wettstein (1958), Large 
volumes of this patient’s urine were extracted, concentrated and
fractionated, the successive stages of concentration of the hypo­
thetical sodium excreting factor being controlled by bioassay on 
rats. From this and from hog adrenals they finally obtained a 
potent fraction from which a crystalline steroid was eventually 
isolated. It proved to be 3B, I6a-dihydroxyallopregnane-20-one. 
Cope & Parry (1959) tested this compound on- patients recovering 
from congestive cardiac failure with oedema, this state being
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considered as one of the most favourable for the demonstration
of any sodium excreting action possessed by this steroid. No
effect on the sodium or potassium excretion of these patients 
could be detected. Negative results were also obtained by 
Coppage, Grant & Liddle (I960) who tested the compound on 5
subjects using doses up to 400 mg.
It is possible that the active substance was lost in the
latter stages of isolation, and that the steroid isolated was an
impurity having similar chromatographic properties. Never­
theless, it is of interest that the steroid contained a 16-
hydroxyl group for this functional group is known to influence
the sodium retaining actbns of the synthetic analogues of 
cortisone. It is the basis, for instance, of the reduced sodium- 
retaining action of triamcinolone. A methyl group at C-16 also 
seems to be equally potent in affecting sodium retaining properties, 
this being seen in dexamethasone. It is possible, therefore, 
that the steroid isolated by Neher et al (1958) was structurally 
similar to some active steroid present in the extracts which also 
had sodium excreting action and also possessed a 16-hydroxyl group.
Klein, Taylor, Papadatos, Laron, Keele, Fortunato, Byers 
& Billings (1958) collected urine from premature ACTH treated 
infants and from two new born infants with salt-losing congenital 
adrenal hyperplasia. When chloroform extracts of the urine, 
after hydrolysis, were run on toluene: propylene glycol system,
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the eluate from the zone between the levels of tetrahydro-A 
and. 11-deoxycortisol was the only one which significantly 
affected sodium excretion. A significant increase in sodium 
excretion which followed a dose response relationship, could 
be induced, and in addition to this, the extracts seemed to 
be more potent after ACTH stimuhtion. Unfortunately the rats 
used in these experiments were intact, not adrenalectomized, 
so that interpretation of observations made is obscured. More 
reliably assayed, because adrenalectomized rats were used, were 
the extracts investigated by Rosemberg et al (1960), They 
used the urine of a 4| year old child with salt-losing congenital 
adrenal hyperplasia. The urine was hydrolysed enzymatically, 
extracted and run on paper in a toluene: propylene glycol solvent 
system, the zone between corticosterone and llg-hydroxy-androst- 
4-ene#d, 17-dione was eluted crystallised and identified as being 
mainly 17a-hydroxvpregnenolone. Twenty mg were obtained, 50pg
of which nullified the sodium retaining properties of 25pg of DOC 
in the rat. However, it was believed that the DOC antagonising 
effect was due to an accompanying impurity.
All the steroids so far considered for the role of the 
salt-losing hormone in congenital adrenal hyperplasia have been 
steroids. Yet the disease’s most prominent characteristic 
is virilism, caused by excessive production of adrenal "androgen" 
(C^g steroids). Darrow (1944) as a result of studies on a severe
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salt-losing infant with congenital adrenal hyperplasia suggested 
that the excessive androgen production may in some way be inter­
fering with sodium and potassium metabolism. However, this, 
suggestion was treated lightly as it had been known since the
work of Thorn & Engel (1938) that male sex hormones cause salt
retention, not excretion. However, this does not exempt all 
C^g steroids. Further, if the hypothetical steroid is present 
in normals it will only clearly manifest itself when overproduced, 
and in congenital adrenal hyperplasia where there is a 21- 
hydroxylase block the compounds shown to be markedly elevated in 
the urine are the C^g,17-OS, Speculating that one of the steroids 
in the adrenal "androgen" biosynthetic pathway does possess salt 
excreting properties it would have to satisfy the available 
clinical evidence indicating the presence of a salt-losing 
hormone. Assuming that changes in total urinary 17-OS mirror 
changes in the hypothetical salt-losing steroid, this can be 
shown to be the case. In congenital adrenal hyperplasia it would
be produced in amounts greatly in excess of normal; this has been
known since earliest investigations into this disease, where 
urinary 17-OS were always markedly increased. In fact Klein 
proposed that elevated urinary 17-OS be one of the criteria for 
diagnosis of this disease. Further 17-OS are decreased to normal 
levels by cortisone therapy, treatment which is known to bring 
salt-losers into sodium balance and lower the elevated aldosterone
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secretion rates in the .non-salt-losers to within the normal 
range. Also 17-OS are produced in -greater amounts after 
ACTH stimulation, treatment which has been shown to aggravate 
the salt-loss in the salt-losing types and to induce salt-loss 
in the non-salt-losing type.
Evidence other than from the'congenital adrenal hyer- 
plasia syndrome which indicates a steroid as the salt 
excreting factor is available,’ As mentioned earlier it is 
possible that the elevated urinary levels of free aldosterone 
in the new born infant could be explained by secretion of a 
salt excreting C^g steroid by the foetal adrenal zone, the 
elevated aldosterone acting as a compensatory mechanism to 
maintain salt balance.
Added to this evidence are the findings of Williamson 
(1965) who reported that the two C^g steroids DHA and andros- 
tenedione could increase sodium excretion when administered 
to water loaded rate and when natiuretic doses of these 
steroids were given to saline-loaded adrenalectomized rats 
they were still effective as natiuretic agents suggesting an 
action independent of aldosterone. However, very large doses,
80 mg of DHA or 100 of androstenedione per kg dissolved in 
sesame oil and injected subcutaneously were necessary to nullify 
the sodiuni retaining properties of 0.13^gand 0.12^ of aldosterone 
respectively. The type of antagonism involved here in the
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inhibition of aldosterone is probably physiologic, that is 
having the same target organ as the compound they inhibit, but 
not necessarily the same site in this organ or even the same 
cell type. That it was physiologic antagonism was concluded 
from the fact that DHA and androstenedione increased sodium 
excretion in adrenalectomized rats,
C. Uric Acid, Lipids, Steroids and Vascular Disease.
1. Hyperuricaemia, gout and hypertension:
Random population sample studies of the prevalence of 
gout have shown an incidence of 0.3% and 0.05% for Caucasian
males and females (Kellgren, Lawrence & Aitken-Swan, 1953);
2.5% for male Filipinos (Decker & Lane, 1959); and 4.2% for 
Maori males and females (Lennane, Rose & Isdale, 1960). The 
incidence of hyperuricaemia in healthy populations is similarly 
racial dependent, tending to be higher in certain pacific races 
(Bremner & Lawrence, 1966). In Caucasians the incidence has 
been estimated between 4.5% and 15% (Talbott, 195 7; Hauge & 
Harvald, 1955; Popert & Hewitt, 1962 and Decker, Lane & Reynolds,
1962).
A striking association between hyperuricaemia and hyper­
tension was recognised in a family with a unique pedigree (Duncan 
& Dixon, 1960). The father and six of seven siblings had hyper­
uricaemia , while the mother and all the siblings had raised blood
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pressure. One must, therefore, enquire whether a high serum 
uric acid (S.U.A.) is common in patients with hypertension. 
Breckenridge (1966) reported elevated S.U.A. levels in 274 (58%) 
of 470 hypertensive patients and of 333 of the 470 not on anti- 
hypertensive therapy 90 (27%) were hyperuricaemic. .This 
prevalence of hyperuricaemia in patients with idiopathic hyper­
tension has been cited by several other authors, Kinsey, Walther, 
Sise, Whitelaw & Sraithwick (1961) found that 183 (46%) of 425 
hypertensive patients had a raised S.U.A. level. Approximately 
half of these patients were untreated and of these 33% had a raised 
S.U.A. Cannon, Stason, Demartini, Sommers & Laragh (1961) found 
that 43% of 141 patients with idiopathic hypertension, 44% of 52 
with renal hypertension, 75% of 24 with malignant hypertension, 
and 38% of all untreated hypertensives had hyperuricaemia.
Itakovitz & Sellers (1963) observed gout in 11 (10.5%) of 105 
patients, and hyperuricaemia in 67% of 5 6 patients, after all of 
them had been subjected to adrenalectomy and sympathectomy as 
treatment for severe hypertension. Also, as previously mentioned 
a high per cent of hypertensive patients studied by Kolbel et al 
(1965a) were hyperuricaemic and 5 of the hyperuricaemic hyper­
tensives reported by Kolbel et al (1964) had manifest gout and 
another had a typical acute gouty arthritic attack during 
treatment with chlorothiazide.
Some of the drugs used in the treatment of hypertension.
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particularly benzothiadiazine diuretics, will elevate S.U.A. 
levels (Laragh, 1958). These, diuretics, however, affect 
uric acid excretion in two ways. At low plasma levels, they 
act on the renal tubules to cause uric acid retention (Dinon,
Kim & Van der Veer, 1958) but at high plasma levels they cause 
increased uric acid excretion and lower the S.U.A.(Demartini, 
Wheaton, Healey & Laragh, 1962). Of the other drugs used in 
the treatment of hypertension, only ganglion - blocking drugs 
raise S.U.A. (Dollery, Duncan & Schum.er, 1960). Neither 
guanethidine (Fry & Barlow, 1962) or methyldopa (Daley & Evans,
1962), which are widely used in treatment of hypertension, will 
induce a rise in S.U.A.
Three possible conclusions can be drawn from the 
association of hypertension with hyperuricaemia: first hyper­
tension may arise as a result of hyperuricaemia; second, 
hypertension may cause hyperuricaemia; and third, there may 
be some other factor common to these two conditions (Breckenridge 
1966) . The first view was put fom\^ard by Duncan & Dixon (I960) 
who described a family comprising a father, mother, and seven 
children. The father had hyperuricaemia but not gout; the 
mother was hypertensive, 6 of the 7 children had raised S.U.A.; 
all seven developed renal disease and hypertension from which 
three of the children later died* This is a rare pedigree and 
one hesitates to think of the problem of hypertension in hyper­
uricaemic individuals in such dramatic terms.
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Progressive renal disease is a common cause of death 
in patients with advanced tophaceous gout, the incidence was 
shown to vary from 22% to 30% (Mayne 1956; Talbott & Terplan, 
1960) and many of these patients were also hypertensive. In 
gouty patients without advanced tophi, however, renal failure . 
and hypertension are rare. Gout is widely recognised by life 
assurance companies as a benign condition (Talbott & Lilienfeld, 
1959). Thus, it has been shown that physicians treating hyper­
tension frequently observe hyperuricaemia, but those concerned 
with treatment of gout rarely find severe hypertension.
As regards the possibility that hypertension is the 
cause of the raised S.U.A., it is thought that hyperuricaemia 
can result either from overproduction or from underexcretion of 
uric acid. Reliable evidence of overproduction is gained from 
measurement of miscible uric acid pool size and uric acid turn­
over rates using isotope dilution techniques (Benedict, Forsham 
& Stetten, 1949), Of 4 hyperuricaemic hypertensive patients 
studied by Breckenridge (1966) none had evidence of over­
production of uric acid. In all four patients the turnover 
rate of labelled uric acid was within normal limits, while the 
miscible uric acid pool size was increased. Breckenridge 
suggested that these findings indicated a failure in uric acid 
excretion and that this was responsible for the elevated S.U.A. 
levels.
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Blood uric acid is completely filtered by the kidney 
glomeruli, then reabsorbed by the proximal tubules and is 
finally secreted by the distal tubules to give the uric acid 
which appears in the urine (Gutman, Yu & Berger, 1959;
Poulsen & Praetorius, 1954 and Lathem, Davis & Rodnan, 1960).
The results of studies by three independent groups indicate 
that the mechanism of the hyperuricaemia in hypertension is a 
renal tubular abnormality of uric acid handling (Itskovitz & 
Sellers, 1963; Cannon et al, 1966 and Breckenridge, 1966).
The latter author studied renal handling of uric acid by three 
groups, each of 8 subjects, the first group was normouricaemic 
normotensive individuals, the second group normouricaemic hyper­
tensive patients and the third group hyperuricaemic hyper­
tensive patients. All the hypertensive patients showed reduced 
glomerular filtration rates. The excretion of uric acid and the 
uric acid clearance were lower in all the hypertensive patients 
than in the normal group. In the hypertensive hyperuricaemic 
patients, however, although the ^meruli filtered load was higher 
than in the other two groups of patients, the uric acid clearance 
was lower. llhen the uric acid clearance was expressed per 100 ml 
of glomerular filtrate, there was no significant difference 
between the normal subjects and the normouricaemic hypertensive 
patients, but the difference between those- grbups and the 
hyperuricaemic hypertensive patients was significant and suggested
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to Breckenridge a renal tubular abnormality. These results 
basically agree with Cannon et al (1966), but these investigators 
further observed that, though many hyperuricaemic hypertensive 
patients had relatively normal rates of glomerular filtration, 
they still had reduced uric acid clearances and the investigators 
suggested renal tubular transport as the cause and most probably 
reduced tubular secretion.
Tissue hypoxia has been suggested as the cause of the 
abnormal tubular handling of uric acid in hypertension (Itskovitz 
& Sellers, 1963 and Cannon et al, 1966). In support of this: 
high levels of lactic acid have been demonstrated in the venous 
and arterial blood of patients with renal and idiopathic hyper­
tension (Demartini, Cannon, Stason & Laragh, 1965); infusion of 
lactic acid was shown ,to reduce renal excretion of uric acid in 
normal subjects. In addition, elevated blood lactic acid has 
been associated with reduced uric acid excretion and hyper­
uricaemia: in normal subjects during exercise (Quick, 1935 and
Nichols, Miller & Hiatt, 1951); in glycogen storage disease 
(Rolling, 1963); and in toxaemia of pregnancy (Handler, 1960). 
However, Cannon et al (1966) could not satisfactorily correlate 
hyperuricaemia with hyperlacticacidaemia.
There is abundant evidence that elevated blood levels 
of uric acid in primary and secondary gout (Gutman & Yu, 1957 and 
Gonick, Rubini, Gleason & Sommers, 1965), familial hyperuricaemia
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(Duncan & Dixon, I960), and glycogen storage disease (Rolling,
1963) may induce or accelerate kidney damage possibly through 
the effects of filtration and reabsorption.of increased 
concentrations of uric acid. In addition, uric acid loading 
in a variety of animal studies has impaired renal function 
(Epstein & Pigeon, 1964 and Duncan, Wakin & Ward, 1965), and 
produced renal damage (Smith & Lee, 195 7 and Duncan, Wakim &
Ward, 1963). It has, therefore, been suggested that, once 
hyperuricaemia is established in hypertension, it contributes 
to the deleterious effects of hypertensive vascular disease in 
the kidney. '
Support of this comes from several studies including 
Cannon et al (1966) who described changes in renal tissue 
obtained at post-mortem examination from selected patients 
who had clearly become hyperuricaemic during the course of their 
hypertensive disease. These changes were similar to those 
described by Gonick et al (1965) for "gouty" kidneys and they 
included glomerular capillary thickening and sclerosis, tubular 
atrophy, pigment deposits, and degeneration especially in the 
loops of Henle and extensive interstitial deposits of uric 
acid in renal medullary tissue. These lesions are not 
ordinarily seen in kidney sections from hypertensive patients 
without hyperuricaemia (Sommers, Reiman & Smithwick, 1958).
Of possible interest in the aetiology of hyperuricaemia 
in hypertension are the recent findings of Ferris & Gorden (1968), 
who studied the effect of angiotensin and noradrenaline upon
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urate clearance in man and found that quantities of these vaso­
constrictors capable of raising the diastolic pressure 20 mmtîg 
caused a marked reduction in uric acid clearance which could 
not be attributed to a reduced glomerular filtration rate, but 
appeared.to be related to a decrease in effective renal bloe# 
flow. They suggested that these findings may be casually 
related to hyperuricaemia found in the various forms of hyper­
tension.
Gout is classified among the inborn errors of metabolism 
(Garrod, 1931), but unlike the majority of such disorders no 
single specific metabolic defect has yet been found to account 
for hyperuricaemia characteristic of this disease (Seegmiller, 
Taster & Howell, 1963). Although impaired renal excretion of 
uric acid is responsible for the hyperuricaemia of some patients, 
an increased rate of purine biosynthesis de novo contributes to 
the hyperuricaemia in the majority of gouty patients (Seegmiller, 
Grayzel, Taster & Liddle, 1961). In affected members of certain 
families excessive production of purines is the sole cause of 
their hyperuricaemia (Seegmiller, 1962).
2. Urinary 17-oxosteroids in relation to gout and hyperuricaemia:
In 1949 Wolfson, Guterman, Levine, Conn, Hunt & Rosemberg, 
described 11 cases of gout who had urinary 17-OS levels of less 
than half of the minimal normal values. The decrease could not 
be related to the stage of disease, or the age of the patient
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and since it was not uniformly present in non-gouty hyper­
uricaemia the authors concluded that it was not a necessary 
consequence of hyperuricaemia. Neither could the low urinary 
17-OS levels be attributed to the arthritides since normal 
levels were found in mild rheumatoid arthritis. Two of the 
11 patients were females and they had urinary 17-OS levels of 
less than 1 mg/day, suggesting that the deficiency in gout was 
of adrenal origin. The authors concluded that "in gout, 
biologic androgen activity is maintained by an androgenic 
hormone which does not make an important contribution to 
urinary 17-OS when metabolised".
Their results were confirmed by Robinson, Conn, Block, 
Louis & Katz (1949), but not by the studies of Butt & Marson 
(1952) who studied 33 gouty patients and found the urinary 
17-OS levels to show no significant deviation from normal 
values. Sonka et al (1964) studied total and individual 
17-08 in males and females suffering from gout. The total 
urinary 17-OS levels in all cases were in the lower limits 
of normal. Of the individual 17-OS, DHA was unique by its 
complete absence from the urine of 26 of the patients as 
compared to levels of 2.5 + 0.46 mg/day in controls. A 
further 3 patients with uric acid stones, but no arthritis 
showed normal S.U.A. and urinary DHA levels, while one patient
57
with the same complaint had a high uric acid level and no 
urinary DHA. The only patient with gout who also excreted 
DHA had a normal S.U.A. level. All the patients were over­
weight and excreted much larger volumes of urine than controls. 
Sonka et al (1964) explained the relationship of high serum 
uric acid to absence of urinary DHA as follows:- " High uric 
acid content may be considered as a manifestation of enhanced
purine biosynthesis ------  DHA acta as a remote inhibitor of
purine biosynthesis by exerting its known inhibitory effect 
on G-6-P.D. This enzyme is utilised in the pentose phosphate 
cycle which produces NADPH. This in turn is required for the 
production of tetrahydrofolate, a necessary coenzyme in purine 
biosynthesis.” The same authors (Kolbel et al, 1964) also 
reported low levels of total urinary 17-OS and the absence of 
urinary DHA in 26 hypertensive hyperuricaemic males (14) and 
females (12), 5 of whom had manifest gout and another had a 
typical gouty arthritic attack during the study.
The findings of Sonka et al (1964) and Kolbel at al 
(1964) were partly confirmed by Beck, Casey, Solmon & Hoffman 
(1967), In their studies 7 of 13 men with gout excreted no 
DHA, 4 excreted only a trace and the other 2 excreted DHA in 
normal concentrations. A further 5 men with other joint 
diseases, 3 of whom had normal S.U.A. levels, showed as a 
group very low levels of urinary DHA, only one of normouricaemic 
patients showing a normal urinary DHA level.
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Evidence other than that from urinary 17-OS levels 
in gout suggests the existence of a relationship between uric 
acid metabolism and adrenal steroids. In 1948 Eorsham, Thorn, 
Prunty & Hills demonstrated the now well knoxm fact that ACTH 
administration markedly increases the urinary uric acid levels.
In 50 normal subjects the increase in uric acid: cretinine
ratio amounted to 87%; whereas in 30 patients with Addison's 
disease the mean increase was only 16%, Twenty mg of cortisol 
administered to patients with Addison's disease elicited a mean 
increase in uric acid: creatinine ratio of 48%, However, their
experiments did not determine whether the increased uric acid 
excretion was through increased production or increased clearance 
of uric acid.
Thus it would appear that the bulk of the evidence would 
suggest some form of adrenal insufficiency in association with gout 
Though in argument against this, it is noteworthy that gout has 
been reported on only one previous occasion in a patient with 
Addison's disease (Rudner & Bale, 1959), and not one case out of 
77 patients with Addison's disease was found by Itskovitz &
Sellers (1963).
3. Vascular disease:
The existence of a correlation between gout and obesity 
has been accepted since ancient times, the alleged common 
denominator being gluttony. The validity of this belief has
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not been adequately tested and has been questioned (Talbott,
1964). Despite the long appreciated associations between 
obesity and atherosclerosis, studies of relationships between 
hyperuricaemia, with or without gout, and atherosclerosis 
have been undertaken only in recent years. The first systematic 
investigation of this kind was reported be Gertler, Garn & Levine 
(1951). They found hyperuricaemia to be present four times as 
frequently in a group of 92 men who had suffered a myocardial 
infarction than in control subjects. Subsequently, various 
investigators demonstrated correlations between hyperuricaemia 
and diseases caused by or associated with atherosclerosis: 
arteriosclerosis oblitérons (Kramer, Rrilstein & De Madeiros, 1958), 
myocardial infarction (Eidlitz, 1961; Kohn & Prozan, 1959) 
cerebral thrombosis (Hansen, 1965; Meyer, Kypros & Gilroy, 1964), 
idiopathic hypertension (Breckenridge, 1966; Cannon et al, 1966; 
Kolbel et al, 1965a; Kinsey et al, 1961), diabetes mellitus (Weiss, 
Segaloff & Moore, 1957; Beckett & Lewis, I960; Whitehouse & Cleary, 
1966).
Elucidation of questions pertaining to relationships 
among hyperuricaemia, gout and these diseases requires more 
knowledge of roles played by other variables such as serum 
lipids and possibly steroids, than is now available.
(a) The relationship between plasma lipids and vascular disease.
It has been known for centuries that degenerative changes
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in arteries are associated with the appearances of lipids in
the lesions and Vogel (1847) discovered that cholesterol was
5
a constituent of atheromatou^ plaques. Antischkow (1913) 
performed the experiment that has been performed countless times 
since, namely the feeding of cholesterol to rabbits, which 
produces lesions bearing a close similarity to certain lesions 
occurring spontaneously in man. Much of the older literature 
on this aspect of the subject is reviewed in a monograph (Cowdry, 
1933).
The administration of cholesterol to the rabbit results 
in a marked plasma hypercholesterolaemia, and the severity of 
the arterial lesions produced in this species correlates fairly 
well with both the plasma cholesterol level and with the length 
of sustained hypercholesterolaemia. Using modified dietary 
techniques, this generalisation is true for various other species 
such as the rat (Wissler, Eilerb, Schroeder & Cohen, 1954), dog 
(Steiner & Kendal, 1946), chick (Kesten, Meeker & Jobling, 1936) 
and many other birds and animals. Experimental atherosclerosis
has been reviewed by Katz & Stamler (1953).
There is a great deal to support the general thesis that 
the plasma cholesterol concentration tends to be higher in 
individuals presenting with coronary artery disease than in 
normals matched for age, sex, weight, etc. (Morrison, Hall & 
Chaney, 1948; Steiner, Kendall & Mather, 1952; Technical group 
of the Committee on Lipoproteins and Atherosclerosis, 1956;
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Stamler, 1960 and Kagan, Dawber, Kannel & Revotskie, 1962).
The difference between the mean plasma cholesterol levels 
of the two groups is highly significant, but the overlap 
is great, and hence the plasma cholesterol level has a limited 
value as a prognostic test when applied to a given individual. 
Variations of.this simple test have been proposed such as the 
cholesterol/phospholipid ratio, but once again there is little 
gaii^ if any, in discriminating between the total cholesterol 
and the cholesterol/phospholipid ratio (Ahrens & Kunkel, 1949).
Since almost all the plasma cholesterol is carried as 
lipoprotein complexes with a- and 3“ globulins, this led to 
the estimation of cholesterol in the a and 3 fraction and results 
expressed as the a/3 ratio. This ratio was found to be reduced 
in patients with coronary artery disease (Barr, Russ, & Eder,
1951 and Oliver & Boyd, 1953), but the a/3 lipoprotein ratio was 
no better as a predictor of atherosclerosis than the plasma 
cholesterol or plasma cholesterol/phospholipid ratio.
Perhaps one of the most significant contributions made 
by recent investigators is the demonstration that an increased 
sensitivity to simple carbohydrates may be quite widspread among 
apparently healthy persons (Brown & Doyle, 1966), while it is 
exaggerated in the great majority of atherosclerotic patients 
(Kuo, 1967). This increased sensitivity to dietary carbo­
hydrate is frequently manifested by an increase in the lipids 
of the pre, 3-lipoprotein fraction (Levy, Lees, & Fredrickson, 1966).
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Since the endogenously synthesised pre,3-lipoprotehns of 
carbohydrate origin are rich in both cholesterol and tri­
glyceride, high concentration of these very low-density lipo­
proteins would account for much of the hypercholesterolaemia 
and hyperglyceridaeraia found in association with atherosclerosis 
(Brown, Kinch & Doyle, 1965; Keys, Taylor, Blackburn, Brozek, 
Anderson & Simonson, 1963; Kannel, Dawber, Friedman, Glennon 
& McNamara, 1964 and Albrink, 1962). 
b) Steroids and lipid metabolism.
The body of circumstantial evidence that has grown 
over the past years implicating elevated serum lipid levels as 
a factor in the development of human atherosclerosis and coronary 
disease has stimulated considerable research on steroids that 
alter lipid metabolism. Indeed many of the reported studies 
on the effects of adrenocortical steroids on lipid metabolism 
have been correlated with their effects on experimentally 
induced atherosclerosis. For example, the retardation of the 
development of atherosclerosis in cholesterol fed rabbits by 
administering cortisone has been reported by several workers 
(Duff & McMillan, 1949; Oppenheimer & Bruger, 1952; Cook,
Ray, Davisson, Feldstein, Calvin & Green, 1952; Gordon, 
Kobernick, McMillan & Duff, 1954; Dury, 1956; and Fisher & 
Tapper, I960). Although the results may be explained on the 
basis of the effects of cortisone on permeability or cellular 
reaction of the arterial wall, one could also assign a 
significant role to the changes in the lipid metabolism such as
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the decrease in serum cholesterol/phospholipid ratio.
The fact that there are differences in metabolic 
responses of the various animal species to adrenocortical 
steroids has led to difficulty in correlating metabolic 
studies in man with those in experimental animals. For 
this reason further review of steroids in relation to lipids 
will be restricted to the human species and the steroids 
reviewed restricted to adrenocortical and androgenic steroids.
i. Adrenocortical steroids:
Since the observations of Aldersberg, Schaefer &
Drachman (1950) that prolonged cortisone therapy frequently 
causes an elevation of serum cholesterol and phospholipids, 
numerous reports have appeared that have substantiated the 
effects of this steroid on lipid metabolism in man. Lipid 
alterations induced by cortisone apparently are more dependent 
upon duration of therapy and the clinical state of the patients 
than on the size irh-e si-g-e of the dose. That cortisone does 
not always induce a rise in serum cholesterol is indicated by 
the observations of Perera, Pines, Hamilton & Vislocky (1949), 
O'Connel & Burns (1950) and Oliver & Boyd (195 6) who noted a 
fall in serum cholesterol. Mann & White (1953) suggested 
that the rise in serum cholesterol during cortisone therapy in 
acutely ill patients may be due to the removal of the disease 
stress with cortisone which then would allow a return to normal
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cholesterol levels. Depression of thyroid activity has been 
observed in some patients that may have contributed to the rise 
in cholesterol during cortisone therapy (Wolfson, Beirwaltes, 
Robinson, Duff, Jones, Knorpp & Eya, 1950). Evidence for 
depression of thyroid activity included a decrease in basal 
metabolic rate, decrease in plasma 'protein-bound iodine and 
diminished uptake of radioactive iodine.
It has been suggested that with ageing, there may be 
a decrease in adrenal 11-oxosteroid production that stimulates 
production of ACTH. This increase in ACTH stimulates adreno­
cortical activity and restores the 11-oxosteroid level, but at 
the same time raises the adrenal output of androgenic 17-OS 
precursors that account for the g-lipoproteinaemia. Evidence 
for this mechanism was reported by Danowski & Moses (1962).
The administration of small doses of cortisol to healthy men 
was followed by a decrease in both the urinary excretion of 
17-OS and serum 3-lipoprotein cholesterol levels. This 
hypocholesterolaemic response was maintained for 2 years.
This vrauld appear to be contrary to the findings of Kotasek et 
al (1967) who, while studying urinary steroids in relation to 
plasma lipids in late toxaemia of pregnancy found an inverse 
relationship between urinary DHA and 3-lipoproteins. These 
findings are covered more fully under androgenic steroids in 
relation to lipids.
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Oliver & Boyd (1956) reported daily intramuscular 
injections of DOGA for 5 days lowered the plasma cholesterol 
levels., cholesterol/phospholipid and the 0-lipoprotein cholesterol 
and increased the ^-lipoprotein cholesterol in 6 hypercholestero- 
larmic patients.
ii. Androgenic steroids :
The reports of the effects of androgenic steroids on the 
blood concentration of cholesterol are less consistent than those 
for oestrogens. Thus, testosterone or methyltestosterone has 
been reported to have no effect on serum cholesterol (Looney & 
Romanoff, 1940; Engleberg & Glass, 1955; Furman, Howard, Smith 
& Norcia, 1956), to increase cholesterol (Randall, 1940;
Federman, Robbins & Rail, 1958) or to decrease cholesterol 
(Berezin & Von Studnitz, 1957). These variations could probably 
be attributed to differences in dosage, duration of treatment or 
in analytical methods used to estimate total cholesterol. The 
effect of testosterone on serum lipoprotein levels appears to be 
more consistent. In a study of the influence of gonadal 
hormones on proteinlipid relationships in human plasma, Russ,
Eder & Barr (1955) noted that the androgens produced a decrease in 
the relative and absolute amounts of cholesterol and phospholipid 
ino-lipoproteins and an increase in the 3-lipoproteins, Similar 
alterations in the lipo-protein composition on the electrophoretic 
pattern have been reported by Oliver & Boyd (1955, 1956); Berezin 
& Von Studnitz (1957); Furman, Howard, Norcia & Keaty (1958) and 
Eder (1959).
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Studies on the lipid effects of combinations of oestrogens 
and androgens in attemps to overcome some of the feminizing 
properties of oestrogen therapy and yet retain the possible 
beneficial effect on lipid metabolism have th-frs far been dis­
appointing. The use of simultaneous physiological doses of 176" 
oestradiol and testosterone gave no consistent changes in serum 
lipids or low density lipoproteins (Englesberg & Glass, 1955).
The reports by Heilman, Bradlow, Zumoff, Fukushima & 
Gallagher, 1959a,b) on the hypocholesterolaemic effects of 
androsterone in hyper- and normo-cholesterolaemic patients 
stimulated interest in androsterone and androsterone like steroids 
for the treatment of hypercholesterolaemia. The hypocholestero­
laemic activity of androsterone was most striking in myxoedematous 
patients. In these patients, the daily excretion of androgen 
metabolites, aetiocholanolone and especially androsterone, were 
very low. Also the ratio of urinary aetiocholanolone;andro­
sterone for exogenous testosterone and endogenous precursors of 
androsterone and aetiocholonalone was extremely high. 
Administration of triiodothyronine to myxoedematous patients 
altered this defect in metabolism of endogenous and exogenous 
"androgens” by restoring the normal ratio of aetiocholanolone: 
androsterone, but not correcting the low urinary level of the two 
17-OS, ■ Administration of triiodothyronine to a euthyroid subject 
also produced an increase in aetiocholanolone:androsterone ratio.
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From these results Heilman et al (1959a) postulated that some 
of the peripheral actions of thyroid hormones might be mediated 
by androsterone. Thus, the hypo-cholesterolaemic action of 
this steroid was referred to as a "thyromimetic" activity. The 
observations of Heilman et al were confirmed by Cohen, Higano, 
Robinson & Lebeau (1961) and Furman & Howard (1962). The former 
workers observed that androsterone induced an average serum 
cholesterol reduction of 36 mg/100 ml, the najor portion of which 
was the result of a decrease in the cholesterol of the g-lipo- 
protein fraction. They also reported a reduction in serum tri­
glyceride levels. The latter investigators found essentially 
the same type of response, namely, a reduction of serum cholesterol 
of 16% with the greatest decrease in the cholesterol content of 
the very low density lipoprotein fraction. In all the above 
studies androsterone was administered parenterally.
Subsequent studies with androsterone as a hypocholesterol­
aemic agent was with the androsterone dissolved in clofibrate- 
atromid, and administered orally. Atromid was shovm to effectively 
lower serum cholesterol and triglyceride (Oliver, 1962; Carlson, 
Hogstedt & Oro, 1963 and Carson, McDonald, Pickard, Pilkington,
Davies & Love, 1966). However, further studies showed that the 
active principle was the dofibrate (Atromid-S) and this administered 
alone was as effective as when administered with androsterone 
(Oliver, 1963 and Heilman, Zumoff, Kessler, Kara, Rubbin & Rosenfeld,
1963). Studies on the mode of action of clofibrate indicate that
it acts by potentiating the effects of endogenous hormones 
particularly thyroxine and androsterone (Thorp, 1962; Thorp, 1963a,b, 
and Thorp & Waring, 1962).
Certain recent urinary studies have suggested possible 
relationships between lipids and urinary steroid levels. Patients 
with toxaemia of pregnancy generally have elevated plasma phospholipids 
and 3-lipoproteins (Boyd, 1935 and Kotasek, Fassati, Brestak & Link,
1965). Kotasek et al (1967) studying such patients found them to have 
very low urinary DHA levels when compared with normal non-pregnant and 
pregnant women. Further, there was a statistically significant 
inverse correlation between urinary DHA levels and the mean level 
of serum 3-lipoproteins in normal non-pregnant, normal pregnant women 
and women with toxaemia of pregnancy. The elevated 3"lipoprotein 
levels in toxaemia of pregnancy could not be attributed to reduced 
thyroid function since protein-bound-iodine levels were comparable 
with the normal pregnancy group. Kotasek et al (1967) proposed 
that DHA influenced the level of serum 3“lipoprotein. They 
suggested lowered excretion of DHA stimulated G-6-P.D. which 
stimulates the pentose phosphate cycle, which in turn stimulates 
lipid synthesis. Indirect support of this DHA - lipid relation­
ship is the hypocholesterolaemic effect of orally administered DHA, 
in rats rendered hypercholesterolaemic by propylthiouracil treatment 
(Ben-David, Dikstein, Bismuth & Sulman, 1967),
Further support for a relationship between lowered urinary
DHA levels and elevated G-6-P.D, comes from the studies of Lopez-S 
& Krehl (1967), They noted a positive correlation between percentage 
excess body weight and G-6-P.D, activity of red blood cells and at 
the same time a negative correlation between urinary DHA levels and 
percentage excess body weight, and, therefore, an inverse relationship 
between urinary DHA levels and G-6-P.D, activity of red blood cells. 
They further observed an increase in urinary DHA with decrease of 
body weight while patients were on weight reducing diets. Contrary 
to the findings of Hendrikx, Heyns, Steeno & De Moor (1965) who 
reported a marked drop in DHA, androsterone, aetiocholanolone in 
patients on a starvation diet. Though, it is possible the disparity 
in diets, one starvation and the other low in carbohydrates, may 
explain the difference. Lopez-S & Krehl (1967) speculated that 
DHA may possibly influence carbohydrate metabolism, which is in turn 
related to the development and perpetuation of obesity.
Patients with diabetes mellitus, a disease associated with 
atherosclerosis and gout (Whitehouse & Cleary, 1966; Berkowitz, 1966 
and Pell & D'Alonzo, 1967), have recently been sho^m to excrete lower 
levels of androstenetriol, pregnanetriol and pregnenetriol than 
controls (Charro-Salgado, Clarke, Shackleton, Duncan & Mitchell,
1968). It is interesting that these steroids, pregnanetriol and 
pregnenetriol, were the ones which Genest et al (1961) and Kowaczynski 
et al (1964) found to be low in idiopathic, renal and malignant 
hypertension. Added to this is the recent renewed interest in
/u
the association of diabetes mellitus and hypertension. Pell 
fit D'Alonzo (1967) studied 662 diabetics and an equal number of 
controls and found the incidence of hypertension in two groups 
to be 36% and 24% respectively.
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D, Nature of the Present Investigations.
The present investigations were mainly concerned with
the individual urinary ll-deoxy-17-oxosteroid levels in vascular 
disease.
Kolbel et al (1964, 1965a) found zero urinary levels of 
DHA in hyperuricaemic, hypertensive patients. Since DHA and 
DHA.S are interconvertible in vivo, .and DHA is excreted in the 
urine conjugated with either sulphuric acid or glucuronic acid, then 
the absence of DHA from the urine may be due to depressed secretion 
of DHA and DHA.S, and/or to altered metabolism. Secreted DHA 
and DHA,S are metabolised as in fig.l (p. 85). It is, therefore 
possible that qualitative and/or quantitative differences in the 
metabolites of DHA and DHA.S might be found between hyperuricaemic 
hypertensive patients, normouricaemic hypertensive patients and 
normal controls. In the present study DHA, epiandrosterone, 
aetiocholanolone and androsterone in the sulphate and glucuronide 
fractions of urine were estimated. However, before measuring 
the urinary levels of these ll-deoxy-17-oxosteroids in normals and 
in patients with vascular disease a suitable method of estimating 
them was developed.
Steroid production is controlled by NADPH availibility, 
which in turn is controlled by the activity of G-6-P.D, an enzyme 
shown to be inhibited by DHA (Marks & Banks, 1960 and Tsutsui et al, 
1962). Therefore, since hypertension may be a disease where adrenal
ri
DHA production is abnormal the effect of DHA on adrenal steroid 
hydroxylation was studied.
Salt metabolism has long been intimately associated with 
hypertension, and many studies have attempted to verify the 
existence of a salt-losing steroid. Some of the results from 
previous studies have suggested that this hypothetical steroid 
may be an ll-deoxy-17-oxosteroid, therefore experiments were 
carried out to observe any changes in the urinary excretion of 
individual ll-deoxy-17-oxosteroid, which might be induced by 
varying the salt intake of normal and hypertensive subjects.
Kolbel et al (1965a) suggested that abnormally low urinary 
DHA levels found in hypertension were related to the elevated serum 
uric acid levels since they had previously demonstrated the same 
abnormality in gout, a disease characterised by elevated serum uric 
acid levels. Gout is now regarded as being intimately related 
with vascular disease. Therefore the individual ll-deoxy-17- 
oxosteroid levels were studied in this disease. On the basis of 
the low results found from this study of gouty individuals a comparison 
of the urinary levels of same steroids in normolipidaemia and hyper- 
lipidaemia was made and to obtain confirmatory evidence of the low 
urinary ll-deoxy-17-oxosteroid found in hyperlipidaemia and gout, 
myocardial infarct patients were then studied, since this is a 
condition characterised by elevated plasma lipids.
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IV. EXPERIMENTAL PART I.
A. Routine Biochemical Methods.
1. Urinary electrolytes.
(a) Sodium and potassium. Urinary sodium and potassium were 
estimated on the Eel Flame Photometer (Evans Electroselenium Ltd., 
Harlow, Essex.) by the method employed at the Biochemistry Dept., 
Glffigow Royal Infirmary (1957).
(b) Chloride. Urinary chloride was estimated on an Eel Chloride 
Meter which employs a coulometric titration and gives a digital read 
out.
2. Kidney function tests.
(a) Serum urea. Serum urea nitrogen was estimated on the 
Autoanalyzer (Technicon, London) using a procedure based on the 
methods of Skeggs (1957) and March, Fiagerhut & Kirsch (1957).
The final colour reaction is based on the direct reaction of urea 
with diacetyl monoxime in the presence of strong acid and the 
intensity of the colour measured at 480 mp in a flow cuvette.
(b) Serum creatinine. Serum creatinine x<ras estimated ly the 
method of Folin & Wu (1919) as modified by Stevens & Skeggs (1964) 
for automation on the Autoanalyzer. The final colour reaction, 
which is essentially the Jaffd reaction, is formed by creatinine 
in the presence of alkaline picrate.
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(c) Urinary creatinine. Urinary creatinine was estimated by 
the method of Bonsnes & Taussky (1945) which also uses the Jaffd 
reaction for the final colour formation.
3. Plasma lipids.
(a) Cholesterol. Total serum cholesterol was estimated using
the method of Pearson, Stern & McGavack (1953) with minor modifications 
This method employs colour development by a sulphuric acid:acetic 
acid;water mixture in the presence of a colour stabiliser p-toluene- 
sulphonic acid and quantitation of colour formed is achieved by 
measuring the optical density at 625 mp,
(b) Phospholipids. Lipids were extracted into an alcohol: ether 
mixture and digested with sulphuric acid and hydrogen peroxide 
according to the method of Youngburg & Youngburg (1930). The 
phosphorus thus converted to phosphate was estimated by the method 
of Fiske & Subbarrow (1925) as modified by Barlett (1959).
(c) Glycerides. Total serum glycerides were estimated by the 
method of Van Handel & Zilversmith (1957). In this procedure the 
extracted glycerides are hydrolysed in alkali and the liberated 
glycerol oxidised with periodate to formaldehyde, which is then 
measured colorimetrically after reaction with chromotropic acid,
4. Serum uric acid.
Serum uric acid was estimated on the Autoanalyzer by an 
automated procedure adapted from the method of Folin (1933),
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This method involves the quantitative reduction of a phosphotungstate 
complex to a phosphotungstite complex by uric acid and the colour 
formed intensified by the presence of cyanide.
5, Blood and urine collection.
The blood samples for the estimation of serum urea, serum 
uric acid, serum creatinine, serum cholesterol, serum phospholipids 
and serum glycerides were collected in plain bottles, and after 
clotting the serum removed and stored at 0° till processing. Where 
serum glycerides were estimated the subject fasted overnight prior 
to blood collection.
Twenty-four hour urines for the estimation of electrolytes, 
creatinine, total 17-OS, total 17-OHCS and individual ll-deoxy-17- 
oxosteroid sulphates and glucoronides were collected in plain poly­
thene bottles, volumes measured and suitable aliquots frozen until 
processing. To avoid any hydrolysis of steroid conjugates, which 
has been found to occur with repetitive thawing and freezing (Patti 
& Stein, 1964), separate aliquots of urine, for estimation of 
individual ll-deoxy-17-oxosteroid sulphates and glucuronides, were 
deep frozen.
6. Group urinary steroid analyses.
(a) 17-Oxosteroids (17-OS). Total urinary 17-OS were estimated 
by the method recommended in M.R.C. Committee on Clinical Endocrinology 
Memorandum (1963) as modified by James & Caie (1964). This method 
employs hot acid hydrolysis, methylene chloride extraction of free
steroids, Zimmerman reaction on the dry steroid residue followed 
by ether extraction of the Zimmerman chromogens and finally 
quantitation using DHA as standard.
(b) 17-Hydfoxycorticosteroids (17-OHCS). Total urinary 17-OHCS 
were estimated by the method of Few (1961) as modified by James &
Caie (1964) which employs borohydride reduction of the 17-hydrox - 
corticosteroids at the C-20 position, removal of excess reducing 
reagent, metaperiodate oxidation of the reduced 17-OHCS to the 
corresponding 17-OS, alkaline hydrolsis of oxidation induced 
formates, methylene chloride extraction, Zimmerman reaction on the 
dry steroid residue followed by ether extraction of the Zimmerman 
chromogens and finally quantitation using DHA as standard.
B. Incubation Techniques.
1, Source of adrenal tissue.
Human adrenal tissue was obtained at operation on a patient 
undergoing treatment for breast cancer. The gland from this 
patient was assumed to be normal (Grant, Forrest & Symington, 195 7).
The tissue was chilled to about 0^ after removal from the subject 
and transferred at this temperature to the laboratory. The time 
interval from extirpation to incubation was 1 hour.
2. Preparation of tissue.
The adrenal tissue (1.25 g) was scraped from the capsule 
and homogenised at about 0° in 13 ml of 0.5M-2-amino-2-hydroxymethyl-l, 
3-propanediol (TRIS) buffer of pH 7.6 containing 0.02M-magnesium chloride
in a Potter-Elvehjem homogenizer. Three ml of the homogenate 
were added to 1.5 ml of a solution containing 5x10 ^M-adensosine- 
5-triphosphate (ATP), 1.7x10 M-NADP and 3.9x10 M-glucose-6- 
phosphate (G-6-P).
3. Method of incubation.
Radioactive steroids in benzene__meth.anol (9:1 v/v) , were 
added to the incubation vessels along with 100 pi of propylene 
glycol. The benzene and methanol were evaporated in a stream of 
air at about 40° leaving the steroids dissolved in a film of 
propylene glycol. The adrenal tissue preparation in their 
incubation media were added to the flask and placed in a water bath 
at 37° and incubated with shaking for 1.5 hours.
At the end of the incubation period the reactions were 
stopped by the addition of 20 ml of acetone and refrigerating at 
-15°, The unlabelled carrier steroids were added shortly after 
this stage in a small volume of alcohol.
Radioactive steroids were purchased from the Radiochemical Centre, 
Amersham, Bucks., and were stored at -15° at an approximate 
concentration of Ipc/ml (^^C-steroids) or lOpc/ml (^H-steroids) 
in a mixture of methanol:benzene (1:9 v/v). The purity of these 
compounds as claimed by the makers was checked by thin layer 
chromatography and scanning with a Packard Radiochromatogram Scanner, 
Model 7200.
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Non~labelled steroids were obtained from Koch-Light Laboratories, Ltd., 
Colmbrook, Bucks., Steraloids Ltd., Croydon, Surrey and Ikaphann, 
Ramat-Gan, Israel,
4. Extraction of steroids.
The incubation mixtures were homogenised in a Silverson mixer 
with 3x50 ml of acetone and again with 50 ml of ethanol. After 
filtering through a sintered glass funnel, the acetone : ethanol mixture 
was taken to dryness under reduced pressure and the residue partitioned 
between 70% aqueous methanol and light petroleum (60-80°). The light 
petroleum fraction was back extracted with 70% aqueous methanol. The 
methanol:water mixture was taken to dryness under reduced pressure, 
adding ethanol to facilitate the evaporation of residual water.
Solvents purifications was as described in Section XV.C.2.b.
5. Preparation of thin-layer chromatograms.
Glass plates (20 cm x 20 cm) were coated by a Desaga
applicator (Camlab Glass Co., Cambridge) with a slurry of Merck
silica gel HE (25 g in 65 ml water). After 20 minutes
254/366
drying at room temperature, the thin layers were activated at 110° 
for 60 minutes. The steroids were applied in chloroform and the
3 chromatograms developed in appropriate solventsystems.
6. Detection and elution of steroids from thin-layer chromatograms.
The A^-3-oxosteroids were visualised in light of wavelength 
254 my (Universal U.V. Lamp, Camag, Muttenz, Switzerland.) as dark 
spots on a green background, and A^-33“hydroxysteroids were located 
in light of wavelength 350 my.
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All steroids were eluted by scraping the silica gel 
containing the steroid on to black glazed paper, transferring it to 
a tube containing 1 ml of water plus 5 ml of ethyl acetate and 
thoroughly mixing the contents using a Whirlmixer (Scientific 
Industries, International Inc. (U.K.) Ltd., England). After 
centrifugation the upper layer was removed and the aqueous layer re­
extracted with a further 5 ml of ethyl acetate. The combined 
extracts were evaporated in a stream of air at a temperature not 
exceeding 50°.
Recovery of steroids by this method is normally 90-100%.
7. Preparation of derivatives.
(a) Acétylation. Steroids were acetylated by the procedure 
of Zaffaroni & Burton (1951). Re-distilled acetic anhydride and 
pyridine (3 drops of each) were added to the dried steroid and the 
reaction allowed to proceed overnight at room temperature in a 
tightly stoppered test-tube. The reaction mixture was then 
diluted with 1 ml methanol and the solvents evaporated completely 
in a stream of air.
(b) Saponification. Steroid acetates were saponified by the
e
method of Neher, U#saulles, Vischer, Wieland & Wettstein (1958) as 
modified by Ward & Grant (1963). A solution (250 yl) of 2% aqueous 
KgCOg (w/v) was added to the steroid dissolved in 1 ml methanol and 
the mixture allowed to stand overnight at room temperature. Water 
(2 ml) was then added and the steroids extracted with ethyl acetate.
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(c) Reduction. The reduction mixture was made up by dissolving
5 mg NaBH^ in 10 ml methanol at 0°. An aliquot (200 y 1) of this 
solution was added to the dried steroid residue in a tube standing 
in crushed ice and the mixture maintained at 0°for 45 minutes.
This is a modification of the method of Southscott, Bandy, Newson
6 Darrach (1956). The reaction was stopped by the addition of 
one drop of glacial acetic acid and the steroids extracted with 
ethyl acetate after the addition of 2 ml of water.
8 . Quantitation of steroids.
Following purification by chromatography, the A^-3- 
oxcsteroids were dissolved in 5 ml or 2 ml of ethanol, and their 
extinctions measured at 240 my against ethanol in 1 cm cells of 
a Unicam SP 500 spectrophotometer. Quantitation was achieved by 
use of extinction coefficients and by comparison with standard 
solutions. Similar amounts of the chromatographic silica gel, 
taken through the elution procedure, served as blanks for 
extinction measurements.
9. Measurement of radioactivity in extracts.
Portions of steroid residues to be counted were placed in 
glass vials of low potassium content (Wheaton Glass Co., Millville, 
N.J.) and dissolved in 10 ml toluene containing 3g/l of 2,5-diphenyl' 
oxazole (PPG) and O.lg/1 of 1,4-bis-2(4-methyl-5-phenyl-oxazolyl)- 
benzene (dimethyl POPOP). Radioactivity was determined using a 
Packard Tri-Garb Liquid Scintillation Spectrometer, Model 3214
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(Packard Instrument Co., Inc., La Crane, Illinois). Tritium and
were determined simultaneously at voltage tap 3.797 with channel I 
voltage discriminator gate of 50-210 and amplifier gain of 25%, 
giving efficiencies of counting of approximately 3.8% for and
18% for Channel II was set with a voltage discriminator gate
of 190-1,000 and amplifier gain of 5%', giving efficiencies of 
counting of approximately 33% for ^ a n d  0% for Absolute
quantities of. tritium were calculated using a slight modification 
(Packard, 1962) of the standard equations of Okita, Kabara,
Richardson & LeRoy (1957) and of from direct readings on 
channel II since, as stated above, no tritium counts appear on this 
channel under the conditions specified.
Standard equations.
R = A E + A E
r 1 ir 2 2r
R = A E + A E
g 1 Ig . 2 2g
Where R . = counts/min. in red channel or channel I. r
R - counts/min. in green channel or channel II. 
g
A “ activity of isotope I (^H)*
A = activity of isotope II (^^C).
2
= efficiency of counting for isotope I in channel I,
E, " " " ” " I " " II.Ig
E^^ = " " " ■'* " II " ” I.
E = " " ” ” " II " ” II.
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C. Quant itat ion of Urinary ll-Deoxy~17-oxosteroid (D.17-OS)
Sulphates and Glucuronides.
1. Introduct ion.
Since the first practical application of gas chrom­
atography by James & Martin (1952) its utilisation in the biomedical 
field has grown rapidly. One of the most important uses of gas- 
liquid chromatography is in the field of steroid biochemistry.
The first practical demonstration of the separation of 
steroids by gas chromatography was described by Vandenlleuvel, Sweeley 
& Horning (I960) who were able to separate several androstane and 
pregnane derivatives on SE-30 columns at 200-220°. A short time 
later Wotis & Martin (I960) reported the separation, identification 
and measurement of the three classical oestrogens. Although earlier 
workers, among them Eglington, Hamilton, Hodges & Raphael (1959) 
using apiezon columns, Sweeley & Horning (I960) using a thermostable 
polyester phase, and Beerthuis & Recourt (I960) using a silicone 
phase, were all able to separate steroids by gas chromatography, they 
were unable to prevent breakdown of the steroids caused by the high 
temperatures and long retention times required for their separation, 
VandenHeuvel, Sweeley & Horning (I960) were the first to succeed in 
demonstrating that by using thinner films of liquid phase in the 
column, it was possible to reduce both the retention time and the 
temperature, and thus achieve separation of steinlds without their 
breakdown. Then in 1961 Luukkainen, VandenHeuvel, Haahti &
Horning demonstrated that the 17-OS could be completely separated
Oû
by gas-liquid chromatography as their trimethyIsilyl ether (TMSE) 
derivatives.
Several investigators have reported on the gas chromato­
graphic separation of urinary D.17-OS using the free steroids, 
trifluoroacetates and TMSE derivatives. Haahti, VandenHeuvel 
& Horning (1961) determined the percentage composition of synthetic 
mixtures containing androsterone (A), aetiocholanolone (E) and DHA, 
using two stationary phases SE-30 and NGS. Later VandenHeuvel,
Creech & Horning (1962) resolved a mixture of the same D. 17-OS as 
TMSE derivatives requiring an NGS column only. Garret, Creech,
Horning & DeBakey (1962) , employing the latter technique, studied 
the urinary excretion of A, E and DHA in patients with athero­
sclerosis. Kirschner & Lipsett (1963), also using TMSE 
derivatives, published a quantitative procedure for the determination 
of the same D. 17-OS. Since then there have been many methods 
published on the quantitation of urinary 17-OS and related steroids 
as their TMSE, among them are Chamberlain, Knights & Thomas (1963); 
France, Rivera, McNiven & Dorfman (1965); Jungmann, Calvary & Schweppe 
(1967); Cawley, Musser, & Tretbar (1967) and Rivera, Dorfman & 
Forchielli (1967). However, none of these investigators have 
published values for the urinary levels of the D.17-OS 33-hydroxy- 
androstan-17-one (epiandrosterone, epiA). ■ Yet the TMSE derivatives 
of DHA and epiA can be satisfactorily separated on stationary phase 
QF-1.
Sparagana, Keutmann & Mason (1963) reported a gas 
chromatographic method for the estimation of three & DHA)
and three 0  ^ as the free steroids, and incorporated the use of 
an internal standard ( 1 1 hydroxyandrost-4-en“3, 17-dione). It 
was introduced at the start of the analysis, thus correcting for 
loss throughout the entire extraction and purification procedures, 
as well as removing the difficulty of injecting exact microlitre 
quantities of organic solvents into the gas chromatograph.
Quantitation of urinary steroids by the unspecific 
detection of a gas chromatograph requires adequate and efficient 
prepurification of the urinary extracts before gas-liquid chrom­
atography. The method of Kirschner ,& Lipsett (1964a) employed a 
single thin-layer chromatographic step which provided a good 
separation of 17-OS from non-steroidal contaminants as well as from 
17-OHCS. The presence of 17-OHCS would otherwise have interfered 
with further analysis, since they undergo pyrolysis in the gas 
chromatographic column, yielding the corresponding 17-OS (VandenHeuvel 
& Horning, I960). A more rapid method than thin-layer chromatography, 
if a reasonably large number of urines have to be assayed, with equally 
effective purification was employed by France et al (1965). They 
used silica gel columns. Similarly, Jungmann et al (1957) and Heyns 
& De Moor (1965) employed alumina columns for their purification step 
prior to gas chromatography.
The urinary D.17-OS are metabolites of the androgens 
DHA, DHAS, androstenedione and testosterone, which in men are 
secreted by the testis and adrenal gland and in the female by 
the adrenal gland. DHA, DHAS, androstenedione and testosterone 
are metabolised to D.17-OS as in fig.l (Vande Viele, MacDonald, 
Gurpide & Lieberman, 1963). With slight modification this may 
be illustrated thus:
DHÂ.S-
DHA.S
.DHA -t*- A-
DHA.G
EpiA. S
V
T.G
E.S
E.G
A - Androstenedione 
T = Testosterone 
G = glucuronide 
S = sulphate
A.S.
A.G
Fig. 1. Metabolism of Androgens.
Thus, the 17-OS appearing in urine are present conjugated to 
glucuronic acid and sulphuric acid. Yet, out of plethora of 
publications on urinary levels of 17-OS only three groups of 
investigators have reported the levels of both the 17-OS glucuronide 
and sulphate fractions (Kellie & Wade, 1957; Mauvais-Jarvis & 
Baulieu, 1962 and Menini, 1966). Of these investigators Menini 
(1966) employed gas chromatography for the separation and 
quantitation of the 17-03.
In the present method for the quantitation of individual 
D.17-OS an attempt has been made to avoid the incorporation of
obvious disadvantages illuminated by previous work, (a) the 
separation of D.17-OS as free alcohols involves long retention times 
and poorer separation, (b) the use of an internal standard added 
just prior to injection into the gas chromatograph does not allow 
for losses of material occurring during extraction and purification. 
Further, the use of radioactive steroids added prior to hydrolysis 
as internal standard necessitates the provision of expensive 
radioactive counting equipment and a further internal standard must 
still be added prior to the gas chromatographic step, (d) many of 
the methods, through unsuitable selection of stationary liquid 
phase, measure only A, E and DHA and in many cases probably the 
estimated DHA is an estimation of both DHA and epiA, (e) inadequate 
purification of steroids prior to gas chromatography leads to 
unacceptable gas chromatographic tracings.
The following method estimates the four urinary D.17-OS, 
A,E,DHA and epiA in urinary sulphate and glucuronide fractions. 
Pregnenolone sulphate and pregnenolone were employed as internal 
standards for the urinary D.17-OS sulphate and glucuronide fractions 
respectively. The internal standards were introduced at the start 
of the analysis. Alumina column chromatography was used for pre-gas 
chromatography purification. The D.17-OS were chromatographed as 
their TMSE derivatives on a 3% OF-1 column.
2. Materials and Methods.
(a) Reagents. Trimethylchlorosilane, dimethylchlorosilane and
o/
gas“Chrom P (100-120 mesh) were obtained from Applied Science 
Laboratories, P.O. Box 140, State College, Pennsylvania, U.S.A.
The diethylamine (B.D.H.Analar grade) was stored over KOH pellets.
QF-1 stationary phase - Perkin Elmer Ltd., Beaconsfield, Bucks. 
Chromatographic grade alumina - Martindale Samoore Ltd., London. 
Kon-labelled steroids. See Section.IV.B,3.
Radioactive compounds. 7&-^H-pregnenolone (specific activity 2.5 c/mM) 
was obtained from the Radiochemical Centre, Amersham, Bucks. The 
7ot-^H-pregnenolone sulphate (specific activity 16c/mM) was obtained 
from the New England Nuclear Corp., Boston, Mass., U.S.A. (for 
storage and purity of radioactive steroids see Section IV.B.3.) 
Tritiated toluene was obtained from the Pakcard Instrument Co.,
Downers Grove, 111,, U.S.A.
^-Glucuronidase, preparation from limpet visceral sacs. Limpets 
were collected, the visceral sacs were removed and homogenized in 
water. Four volumes of ice-cold acetone were added with continuous 
stirring. The mixture was allowed to stand for 30 minutes and 
then Buchner filtered using Whatman No.l filter paper. The 
precipitate was resuspended in ice-cold acetone, allowed to stand 
for a further 30 minutes and again filtered. The precipitate was 
washed with acetone until the filtrate was colourless. The 
resulting acetone powder was air dried overnight and placed in a 
desj^icator' to remove the last traces of acetone.
The aceonjfe powder was assayed for 3-glucuronidase activity 
by the method of Fishman (1963), using phenolphthalein glucuronide
oo
as substrate. The p-glucurcrnidase activity was expressed in 
Fishman units, where 1 unit is the weight of acetone powder- 
necessary*to liberate 1 yg of phenolphthalein from phenolphthalein 
glucuronide.
(b) Solvents.
Ethyl acetate (B.D.H, AnalaR grade) was purified by washing with 
3 X 0.1 volume of water, drying over anhydrous calcium chloride 
and glass distilling.
Ethanol and methanol (Burroughs AnalaR grade) were used without 
further purification.
Hexane (B.D.H. AnalaR grade) was washed with 3 x lOO ml of 
concentrated HySO^/litre for 1 hour on a mechanical shaker, followed 
by two washes with lOO ml of 2N.NaOH/litre and finally with water 
until neutral. It was then dried over calcium chloride and glass 
distilled.
Acetone; ether and toluene (B.D.H. AnalaR grade) were used without 
further purification.
Benzene (B.D.H, AnalaR grade). Thiqphene and other impurities were 
removed by shaking with 3 x 0.1 volume of concentrated HgSO^ for one 
hour, followed by water washes until neutral. The benzene was then 
dried over calcium chloride and twice glass distilled.
Methylene chloride (B.D.H. AnalaR grade) was purified by shaking for 
one hour with 3 x 0.1 volume of concentrated H 2S0^, washing with 
water until neutral, drying over calcium chloride and twice glass 
distilling.
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(c) Choice of internal standard.
The choice of an internal standard is subject to the 
following considerations:
1) It must not occur in the urine.
2) It must be as similar as possible in chemical structure to the
compounds under investigation.
3) It must have a similar elution volume on column chromatography,
4) It must be separable on gas-liquid chromatography from the other
compounds to be investigated.
5) It must have a detector response which is linearly related to 
the amounts present.
6) The position at which it emerges on the gas chromatographic trace 
must be free of other contaminating peaks.
Pregnenolone appears to fulfill these requirements. It is 
not present in urine in detectable amounts; on column chromatography 
it has an elution volume similar to that of the D.17-OS; it is 
easily separable from the D.17-OS by gas-liquid chromatography on a 
variety of columns including OF-1 and its peak free of, extraneous 
contamination. Its structure is very similar to DHA, which is the 
most labile of the D.17-OS. However, under the standardised 
conditions employed, no significant degree of breakdown has been 
observed for any of the steroids investigated.
(d) Solvolysis of ll-Deoxy-17-oxosteroid sulphates (D.17-OS.S).
To 25 ml of a 24 hour urine specimen were added 10-75 ug of
internal standard pregnenolone (as pregnenolone sulphate), the 
exact amount depending on the level of the total urinary 17-OS 
which had been previously measured. The steroid sulphate conjugates 
were then solvolysed by the method of Bur/Tstein & Lieberman (1958),
In this method urine is acidified to pH 1 by the addition of AN-H^SO^ 
after the addition of 20% w/v of NaCl and twice extracted with equal 
volumes of ethyl acetate. The combined ethyl acetate extracts are
incubated for 18 - 20 hours at 37°.
(e) Hydrolysis of ll-Deoxy-17-oxosteroid glucuronides (P.17-OS.G).
To 25 ml of a 24-hour urine specimen were added 20-75 yg 
of pregnenolone, depending on the level of total urinary 17-OS 
previously measured. Pregnenolone was used as the internal 
standard as the glucuronide was not available. The steroid 
conjugates and the standard pregnenolone were extracted by the
method of Edwards, Kellie & Wade (1953), which involves saturation
of the urine with ammonium sulphate and 3 extractions with equal 
volumes of ether : ethanol (3:1). The combined extracts were taken 
to dryness in a rotary evaporator. Steroids were leached from the 
dry residue with 10 ml of ethanol, and the ethanol evaporated to 
dryness. The conjugates were then hydrolysed with limpet
3-glucuronidase, Five ml of 0,5M-acetate buffer (pH 4.7) containing
5 “3
lO units of enzyme and 0.25 x 10 moles of phosphate to inhibit
steroid sulphatases (Roy, 1956), were added to the dry steroid residue
and incubated at 37° for 2 days. After incubation, 4 volumes of
water were added and free steroids extracted twice with equal volumes
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of ether:ethyl acetate (1 :1).
From this stage D,17-OS.S and D,17-OS.G fractions were 
treated alike. The extract was washed with one-tenth volume of 
IN-NaOH 2 to 3 times, until no further pigments were removed.
Alkali was removed by washing three times with one-tenth volume of 
water. The washed extract was dried by passing through anhydrous 
sodium sulphate and evaporated under a stream of air in a water bath.
(f) Alumina column chromatography.
Alumina was deactivated by the addition of 4% water and 
its suitability for the chromatography step was checked periodically 
by estimating the recovery of DHA standard taken through the 
following procedure. The column (0.6 cm l.D.) was prepared by the 
addition of Ig alumina suspended in dry benzene with a topping of 
sand. The dry steroid extract was quantitatively transferred to 
the column using two 3 ml volumes of benzene. The chromatogram 
was developed with a further 10 ml of benzene and 20 ml of 0.5% 
ethanol in benzene. The 0.5 % ethanol in benzene eluate containing 
the internal standard pregnenolone, together with any A, E, DHA or
epiA was taken to dryness (Heyns & De Moor, 1965).
(g) Trimethylsilyl ether (TMSE) formation.
Since moisture can prevent quantitative formation of TMSE 
(Lau, 1966), the steroid containing residues were dried in a vacuum
desiccator. TMSE were prepared accorfng to the technique of
Thomas & Walton (1966). To tube A were added 5 ml of hexane and
0.4 ml of diethylamine and to tube B, 5 ml of hexane and 0.7 ml of 
trimethylchlorosilane. The contents of tube A were added to tube B , 
stoppered, mixed, centrifuged to deposit the thick white precipitate 
and 0.5 ml of supernatant added to dry residues. The tubes were 
stoppered, mixed and left overnight at room temperature. The 
reaction mixture was taken to dryness in vacuo.and the residue 
leached with hexane to dissolve the TMSE, The amount of hexane 
added was such that the pregnenolone concentration was about 0 .2 yg/yl. 
This was determined after preliminary experiments had indicated the 
recovery at this stage. The mixture was centrifuged, since breakdown 
of TMSE occurs on the gas chromatographic column, if any particles of 
the ammonium chloride precipitate are simultaneously injected.
Each day that samples were etherified, a mixture of equal 
weights of pregnenolone, A, E, DHA and epiA was treated similarly, 
thus giving a check of éthérification and peak height ratio of the 
steroids under analysis relative to pregnenolone,
(h) Gas liquid chromatography.
1. Preparation of column packing. The support, gas chrom P (100- 
120 mesh) was treated with concentrated KCl for 12 hours with 
occasional stirring. The acid was removed by suction and this 
procedure repeated three times. After treatment with acid the 
support was washed in distilled water with gentle stirring. After 
2 minutes finely divided particles were removed by decanting them 
off. The support was repeatedly washed and decanted in this manner
until the final wash was neutral. The support was dried by 
treating with acetone, filtering and preliminary drying at room
temperature overnight before final drying in an oven at 80°.
Approximately 20 g of the dry support was silanized by
treatment-with 100 ml of 5% dichlorodimethylsilane in toluene in 
a Buchner filter flask. Air bubbles were removed from the 
surface of the support by gentle shaking under reduced pressure.
The support was then filtered, washed repeatedly with methanol 
and again dried at room temperature before heating in an oven at 
80°.
The acid-washed deactivated support was well mixed with 
the rquired amount of liquid phase dissolved in methylene chloride 
and the methylene chloride completely evaporated on a rotary 
evaporator. The coated support was then air dried and finally oven 
dried at 80°.
ii. Packing of column. Glass columns and glass wool used for 
packing were treated with 5% (v/v) dichlorodimethylsilane in toluene 
overnight and repeatedly washed with toluene and methanol and dried 
before use.
Columns were packed by plugging one end with glass wool 
and the coated support was then introduced gradually with the help 
of suction. While the support was being added the column was 
repeatedly tapped to ensure even packing. Before use, newly 
packed columns were conditioned to 230° in a stream of nitrogen 
for 24 hours. This pre-treatment ensured reirioval of volatile 
products which may contaminate the detector and prevent a stable 
recorder baseline.
ill. Gas chromatography. A Pye series 104, model 14, gas 
chromatograph equipped with a flame ionisation detector was employed. 
Seven foot (4mm l.D.) glass columns packed with pretreated gas chrom 
P and coated with 3% OF-1 were used. The nitrogen carrier gas 
purified by Molecular Sieve 5a (W.G.Pye & Co. Ltd.) was maintained 
at an inlet pressure of 30 p.s.i. which gave a flow rate of 50 ml/ 
minute respectively. All flow rates were measured at the outlet of
the detector using a soap bubble flow meter. The. Leeds & Northrup
recorder was used at a chart speed of lO'Vhour.
All injections were made with a 3.5” needle, 10 yl
Hamilton syringe (Hamilton Co, Inc., Whittier, California, U.S.A.
The Pye 104 gas chromatograph is not equipped with a flash heater 
zone, and injections were made on to the column. For this reason, 
it was important to use a long needle syringe to avoid introducing 
the sanple near the top of the column where the temperature was 
lower than the analyser oven. Volumes of hexane solution injected 
ranged from 0.5 - 3 yl.
(i) Calculation of results.
Quantitative evaluation of the recorder tracings was 
carried out by measuring the height of peaks appearing at the 
retention times of reference steroid TMSE derivatives and the 
peak height of the internal standard TMSE derivative. This, 
together with the known peak height ratio (f) for each steroid 
derivative (TMSE-S) relative to pregnenolone derivative (TMSE-P)
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and the amount of internal standard added to the original 25 ml 
of urine, was used for the calculation of steroid urinary 
concentration. Thus
Peak height TMSE-S yg internal std, 24 hr urine vol. i„,,
------- ^ ---------  X —  -r----------- X ----r-— - V  - - mg/24hr.
Peak height TMSE-P f.lOOO 25 ml
(3 ) Measurement of radioactivity.
-Radioactivity was measured as described in Section IV.B,a.
Steroid sulphates were dissolved in 1 ml of methanol and 9 ml of
scintillator solution. This system gives rise to a significant
amount of quenching, which was corrected by the use of internal
standardisation i.e., a known amount of radioactivity (^H-toluene)
was added to the quenched samples after an initial radioactivity
count and the degree of quenching of standard ^H-toluene calculated
after a second radioactivity count.
3. Results.
Evaluation of reliability of the method for determination of D.17-QS.
Complete TMSE formation of D.17-OS can be demonstrated on 
stationary phase QF-1 where the TMSE have shorter retention times 
than their parent alcohols. Using standard D.17-OS no free steroids 
could be detected after derivative formation.
The response of the detector to the TMSE derivatives of 
the D.17-OS relative to the response of the pregnenolone TMSE 
derivative was satisfactory. A straight line was obtained when 
the ratios of masses of individual D.17-OS to pregnenolone (0.1 to 10) 
were plotted against the ratios of corresponding TMSE derivative peak 
heights (fig. 2a & b).
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The retention time of individual TMSE derivatives relative 
to internal standard pregnenolone TMSE was found to be constant 
throughout the study (Table 1),
TABLE 1. Retention times of A, E, DHA and epiA relative to
pregnenolone on 3% OF-1. Conditions as in text.
RELATIVE RETENTION TIRES
AUTHENTIC STEROIDS URINARY STEROIDS
STEROIDS
n X S.D. n X S.D.
A 25 0.572 0.006 25 0.572 0.006
% 25 0.633 0.007 25 0.633 0.007
DHA 25 0.716 0.006 25 0.714 0.008
epiA 25 0.798 0.018 25 0.798 0.008
n - Number determinations.
X “ Mean relative retention time.
S.D ” Standard deviation.
The T?^ SE derivative peak height ratio factor (f) used in 
the calculation of individual D.17-OS urinary concentration was 
checked regularly and re-estimated if necessary (Table 2).
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TABLE 2. The ratio of the peak heights of individual 
D.17-OS TMSE to pregnenolone TMSE.
D.17-OS/PREGNENOLONE
STEROIDS
n
Mass 
Rat io
Peak Height Ratio 
X S.D
A 10 1 1.975 0.037
E 10 1 • 1.771 0.048
DHA 10 1 1.631 0.034
epiA 10 1 1.468 0.039
n - Number of determinations. 
X - Mean,
S.D - Standard deviation.
(a) Specificity.
The specificity of the method was based onî
1) The use of alumina column which ensured preferential isolation 
of the steroids in question.
2) The urinary steroid TSME derivatives were identified by their 
retention times relative to pregnenolone TMSE which were identical 
with authentic standard TMSE derivatives (Table 1),
3) Authentic steroids added to the urine for recovery studies only 
increased the respective peak areas without formation of new peaks,
4) The shape of the peak in both analytical and standards were 
identical, with no evidence of contamination from other unknown peaks
(b) Sensitivity.
The sensitivity of the method was determined firstly by the
iü O
sensitivity of the gas chromatograph detector and secondly by 
the linear response relationship of the TMSE derivative peak 
height ratio to the mass ratio (figs. 2a & b). The limit of 
sensitivity set by these criteria was O.lpg steroid/25 ml of urine.
(c) Precision.
The reproducibility of the method was checked by replicate 
analyses of urine pools from males between the age of 18 and 35, 
taken through the entire procedure. The results are summarised 
in Table 3 and demonstrate a satisfactory degree of reproducibility 
for each steroid under analysis. This is evident from the very 
low variation coefficients, E.S having the highest, 8.6 and 6,5% 
for urine pools 1 and 2 respectively.
(d) Accuracy.
The accuracy of the method was assessed by measuring the 
relative recoveries of B.17-OS added to water and to urine with 
pregnenolone sulphate and pregnenolone as internal standards, and 
by measuring the absolute recoveries of internal standards 
pregnenolone and pregnenolone sulphate,
i. Relative recoveries.
Recovery of D. 17-OS added to water. Androsterone, E, DHA (50iig of 
each) and epiA (25]ig) were added to twenty, 25 ml volumes of water 
and 10 taken through the complete procedure for estimation of 
urinary steroid sulphates and 10 through the procedure for urinary
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steroid glucuronides. The results are recorded in Table 4. 
TABLE 4. Recovery of A,E, DHA and epiA added to water.
STEROID
ADDED
]ig
ADDED
REC01ŒRY BY 
SULPHATE PROCEDURE 
n X S.D
RECOVERY BY 
GLTJCURONIDE PROCEDURE 
n X S.D
A 50 10 99 3.2 10 96.8 9.3
E 50 10 102.2 2.5 10 100.2 3.6
DHA 50 10 103.3 1.7 10 96.8 4.1
epiA 25 10 102.2 2.0 .10 101.4 4.9
n Number of determinations.
X “ Mean %.
S.D “ Standard deviation %.
The mean % recovery in all the 8 cases was very good. It was
within ±4% of the ideal recovery 100%, in every case. The standard
deviation which indicated satisfactory reproducibility was less than
5% in every case excluding A.G where it was 9.3%,
Recoveries of D.17-OS added to urine. The D.17-OS sulphates and 
glucuronides in 25ml aliquots of a normal male urine pool were first 
measured by method already described and results present in TaHe 3,
A, E, DHA (50pg of each) and epiA (25yg) were added to another twenty, 
25 ml aliquots of the same pooled urine and processed in an identical 
manner. The results of the relative recoveries of the added D.17-OS 
are recorded in Table 5. The results were not just as accurate as 
those for recoveries from water, but are still satisfactory.
i ü j
TABLE 5. Recovery of A, E, DHA and epiA added to urine.
STEROID
ADDED
yg , 
ADDED
RECOVERY BY 
SULPHATE PROCEDURE 
n X S.D
RECOVERY BY 
GLUCURONIDE PROCEDURE 
n X S.D
A 50 10 97 5.1 10 108.1 6.1
E 50 10 88.4 3.2 10 105.2 2.6
DHA 50 10 89.0 3.6 10 99.8 2.2
epiA 25; 10 102.4 6.9 10 85 .6 3.3
n " Number of determinations 
X - Mean %.
S.D - Standard deviation%.
The mean % recovery was best for the glucuronides, where the only 
low values recorded were for epiA.O, and as this glucuronide has 
as yet to be demonstrated in significant amounts in normal urine, 
its low recovery relative to pregnenolone is of little interest.
The mean % recoveries of A, E and DHA were low compared to the 
recoveries from water. However, the standard deviation in all
cases was satisfactory. Thus, although the relative recoveries 
were not 100% the reproducibility of the recoveries was good,
ii. Absolute recoveries. The absolute recoveries of the internal 
standards was achieved by adding tritium labelled pregnenolone sulphate 
or tritium labelled pregnenolone to urine samples and estimating the 
recovery of radioactivity at various stages in the method.
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7a-^H"pregnenolone sulphate was diluted with non-radioactive 
pregnenolone sulphate and 50yg (containing 148,080 dpm) were 
added to each of ten, 25 ml aliquots of pooled urine and processed 
according to the method described for steroid sulphates.
Recoveries were estimated after solvolysis (step 1) and after 
column chromatography (step 2). The results are sho^m in Table 6,
The overall mean recovery of 85.0% for added ^H-pregnenolone sulphate 
was very satisfactory, especially as the precision was very good.
The variation coefficient was 3.5%.
7a %-pregnenolone was diluted with non-radioactive pregnenolone 
and 50pg (containing 64,375 dpm) were added to each of ten, 25 ml 
aliquots of pooled urine and taken through the method described for 
steroid glucuronides. Recoveries were measured after extraction 
of ^“glucuronidase incubate (step 1) and after column chromatography 
(step 2). The results are presented in Table 6. The mean recovery 
of the added ^H-pregnenolone (72.5%) was not as high as for the 
sulphate procedure. This is natural when the additional steps 
involved in the glucuronide procedure are taken into consideration.
The precision was again very good with a variation coefficient of 
4.2%.
4. Discussion.
The Zimmerman colour procedure for the estimation of 17-OS 
is an inexpensive, simple and readily available assay (M.R.C. Committee 
on Clinical Endocrinology Memorandum, 1963). However, total
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Zimmerman chromogens are of limited physiological significance, and 
often clinically are completely inadequate. When it is considered 
that Sonka et al (1964) found DHA totally absent from every case of 
gout studied and yet the values of their total urinary 17-OS were, 
still within the normal range, it becomes apparent that fractionation 
into individual 17-OS is necessary.. And obviously further 
fractionation into individual 17-OS sulphates and glucuronides can 
only be an advantage.
Urinary D.17-OS are found conjugated with glucuronic acid 
and sulphuric acid. The hydrolytic methods used to cleave these 
ester linkages are very important, since isolation of the steroids 
without structural alteration is essential. Hot acid hydrolysis 
will cleave both 17-OS sulphates and glucuronides and although 
suitable for total Zimmerman routine assays, this hydrolysis is 
believed too vigorous for more delicate analyses. It causes 
pigmentation, non-steroidal chromgen formation, and degradation of 
certain steroids (Peterson & Zettner, 1963) in particular DHA is 
known to undergo decomposition (Cawley, Musser, Faucette, Beckloff 
& Learned, 1965). Vestergaard (1962) carefully re-investigated 
the use of mineral acids hydrolysis of glucuronides and concluded 
"hydrolysis with ^“glucuronidase is at the present time a necessary 
step in analyses for individual 17-ketosteroids if maximal yields 
are sought", though other studies concerning steroid sulphates as 
well as glucuronides suggest that the use of low concentrations of 
perchloric acid in organic solvents free of water will prove
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satisfactory (Burjffstein & Lieberman, 1958a; Jacobsohn, & Lieberman, 
1962 and DePaoli, Nishizawa & Eik-Nes, 1963).
B“glucuronidase is specific for only the glucuronide moiety 
of glucuronate conjugates, therefore the extent of hydrolysis by the 
3“glucuronidase is dependent on the enzyme to glucuronate ratio 
irrespective of the nature of the non-glucuronide portion of the 
conjugate. It is, therefore, of prime importance that patients 
be taken off medication, the by-products of which may be metabolised 
to glucuronates and, therefore, compete with steroid glucuronides 
for a site on the g-glucuronidase, e.g. salicylates (Stempfel,
Sidbury & Migeon, I960). The p-glucuronidase preparation obtained 
from limpets contains an appreciable amount of steroid sulphatase, 
an enzyme which shows preference for sulphate conjugates which have 
a 3 3 - h y d r o x y , or a 33-hydroxy-5a- structure (Roy, 1956). DHA 
and epiA are, therefore, substrates for the enzyme. However, 
phosphate, a potent inhibitor of steroid sulphatase, was included 
in all the 3-glucuronidase incubates.
The 17-OS sulphates were extracted and then solvolysed by 
a procedure specific for sulphate conjugates and without effect on 
glucuronides (Jacobsohn & Lieberman, 1962) and phosphates (Burnstein 
& Lieberman, 1958a), This procedure also proved to be efficient 
for the extraction and cleavage of the internal standard pregnenolone 
sulphate. It gave 93.3% mean recovery for %-pregnenolone after the 
addition of ^H-pregnenolone sulphate to the urine (Table 6), The
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93.3% recovery was assumed to be for the free steroid and not 
sulphate since subsequent alkali and water washes contained no 
radioactivity.
Although there have been many applications of gas-liquid- 
chromatography to the measurement of steroids in biological fluids, 
the limitations of the technique have not always been fully 
appreciated. Unlike colorimetry, where a specific steroid or 
group of steroids can be quantitated, without interference in 
presence of other dissimilar steroids, in gas chromatography all 
organic substances in the eluting gas are detected and measured 
by the flamuionisâtion detector. Because of the sensitive 
detectors employed in gas-liquid-chromatography, the presence of 
interfering substances is of great concern. For this reason, 
pre-purification of biological extracts before gas chromatography 
is of the utmost importance. Where urinary steroids are present 
in high concentrations, e.g. urinary pregnanediol in pregnant subjects, 
the pregnanediol concentrations may be so much larger than any 
extracted urinary contaminants having retention times similar to 
pregnanediol, that it may be analysed without further purification. 
Thus, Seegar-Jones, Turner, Sarlos, Barnes & Cohen (1962) and Cox 
(1963) have measured pregnanediol in pregnancy urine after hydrolysis 
and extraction only. However, when these relatively simple methods 
were applied to non-pregnant subjects* urine, the chromatograms
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obtained showed poorly separated, ill defined peaks and the resulting 
precision of the method was very bad.
This example clearly confirms the necessity for pre­
purification of urinary extracts before gas chromatography. In 
the method presented, alumina column chromatography was used as 
the purification step, as it was simple, rapid and allowed the D,17-OS 
to be eluted together in a small distinct polarity group. This, 
permits subsequent analysis of the steroids to be carried out under 
optimum conditions. Recovery experiments using tritium labelled 
steroids show that losses incurred by introducing alumina column 
purification were small, 8.8% and 5.8% for steroid sulphate and 
glucuronide procedures respectively (see Table 6). The gas 
chromatographic tracings of normal human urine processed by the 
present method are devoid of interfering substances as is amply 
demonstrated by fig. 3 which is comparable even with a gas 
chromatographic tracing of pure steroids (fig. 4). The precision 
of the method is to a certain extent determined by the quality of 
the gas chromatographic tracings. They should show clear sharp 
peaks free from extraneous detector responses which cause "shoulders" 
and unsettled baselines. The clear tracings obtained by the present 
procedure confirm the satisfactory precision data recorded in Table 3. 
This reproducibility was maintained in the analysis of normal male 
and female urine specimens, where in general duplicate estimations 
of D.17-OS.S and D.17-08.G still retained a variation coefficient
J.XU
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•H
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963 21
Fig. 3. Gas chromatographic tracing of the D.17-OS sulphate 
fraction obtained from a normal male urine. 3% QF-1 column at 
200^. A) Androsterone, E) Aetiocholanolone, DHA) Dehydroepi- 
androsterone, epiA) Epiandrosterone and Preg) Pregnenolone all 
as TMSE derivatives.
I l l
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15. 24
Fig. 4. Gas chromatographic tracing of aimixtnre of equal 
weights of standard D.17-OS and internal standard pregnenolone. 
3% QF-1 column at 200°. A) Androsterone, E) Aetiocholanolone, 
DHA) Dehydroepiandrosterone, epiA) Epiandrosterone and Preg) 
Pregnenolone all as TMSE derivatives.
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within 9.0% for all the steroids investigated.
When the present method was applied to 24 hour urines 
collected from normal males and females, and from patients 
suffering from a variety of different complaints, total urinary 
17-OS were first estimated in all cases. This acted as guide 
as to the amount of internal standard to be introduced in each 
25 ml urine sample prior to analysis. This procedure was found 
to be essential as the peak heights of the individual D.17-OS TMSE 
relative to the pregnenolone-TMSE peak height had to be within 
prescribed limits (see figs. 2a &b). The importance of maintaining 
the proper ratios in all quantitative work utilising gas chromatography 
was pointed out by Horning, Maddock, Anthony & VandenHeuvel (1963).
The linearity of the detector response for varying amounts of 
pregnenolone TMSE relative to constant amounts of individual D,17-OS 
TMSE and vica versa covered a range, of 0.1 to 10. This 
proportionality of internal standard to the D.17-OS was determined 
regularly and re-estimated if necessary (Table 2).
The necessities for an internal standard reside in the
difficulty of injecting exact microliter amounts of solvent into a
gas chromatograph and in the importance of correcting for losses
which occur during isolation steps. It was for these reasons
that pregnenolone and pregnenolone sulphate were introduced as
internal standards at the beginning of the glucuronide and sulphate 
procedures. Pregnenolone sulphate was a very satisfactory internal
standard correcting not only for losses, but also checking on the
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solvolysis of the steroid sulphates. Unfortunately, up to the 
present time pregnenolone glucuronide is not commercially available, 
and free pregnenolone was used as the internal standard for the 
glucuronide fraction. In order to check on a routine basis the 
3-glucuronidase hydrolysis, a pooled urine sample of known 
individual D.17-OS concentrations was repeated with each batch of 
analysis. The validity of using a single internal standard for 
the measurement of four D.17-OS was demonstrated by the recovery 
experiments (Tables 4 & 5). The recoveries of steroids added to 
water were very good, the relative recoveries in all cases being 
very close to 100% and precision with which that exercise was carried 
out was also very satisfactory, only in the case of added A, and its 
recovery as A.G, was the precision data (recovery 96.8 + 9.3%) 
not just as satisfactory. The recoveries of same steroids added 
to urine were not just as efficient, however in all cases the 
precision with which the recoveries were carried out was very 
satisfactory. It could be concluded that the results of the 
recovery experiments justified the use of pregnenolone and 
pregnenolone sulphate as internal standards.
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D . Statistical Procedures.
1. Tests of significance.
(a) Student's t-test* The student's t-test is used to compare
the means of two independent samples and from the result conclude if
the samples are from the same or different populations.
Given a sample of n values with x , x , x , ........ .x
 ^ 1 2 3 n
denoting the sample values, with a sample mean x = -—E(x) and sample
estimate of variance S^ ~ E
n-1
(x-x)^
To test the null hypothesis - y^ at a% significance against
the alternative H : y ^ \x  * Therefore reject H if It _ i > t ,
1 - 1 2  0 (a/2)
where t - ~ (x-y)/n and a is obtained from the "t-distribution" 
n-l — g---
tables. The conditions which must be satisfied to make the Student 
t-test a powerful one, and in fact before any confidence can be placed 
in any probability statement obtained by the use .of the t-test, are at 
least the following.
1. The values must be independent.
2. The values must be drawn from normally distributed populations,
3. These populations must have the same variance or in special cases, 
they must have a known ratio of variances.
(b) The Mann-Whitney U test. The Mann-X'Thitney U test is used
to test whether two independent samples have been drawn from the same 
population. This is one of the most powerful nonparametric tests and 
is used as an alternative to the parametric t-test when it is wished 
to avoid the assumptions of the t-test.
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Method. Let n = the number of values in the smaller of the two-----  j
independent samples, i.e. sample 1.
n " the number of values in the larger samples, i.e.
2
sample 2.
Assign the rank of 1 to the lowest value in the combined (n + n )
1 2
sample of scores. Calculate
■U = n n + n (n h-1) ■- R
1 2. 1 1 1
where R^ - sum of the ranks assigned to sample 1,
It has been shown (Mann & T*71iitney, 1947) that as n n increases
1 2
in size, the sampling distribution of U rapidly approaches the normal 
distribution with
mean
n n 
1 2
and standard deviation = /n n (n +n + 1)
1 2  1 2
  12  ..
That is when n^  20 we may determine the significance of an observed 
value of U by __
u - - p
z =
n n (n +n +1) 
1 2  1 2
12
which is practically normally distributed with zero mean and unit 
variance.
To test the null hypothesis H : y- = y at a% significance against
0 1 2
the alternative hypothesis H : y r y . Therefore reject H if
1 1 2  0
where a is obtained from tables of "The Normal 
Distribution Function".
i i p
2. Correlation and regression.
In measuring the association between two normal variables,
it is convenient first to generalize the variance estimate used for
measuring the variability of a single variable. Suppose then we
have observed the variables x and y on n individuals, obtaining
values X. ,y ; x ,y ; ....... ;x ,y . The variance of x and y are
1 ^ 2  1 2  n'^n
estimated by
S2
X
E(x-x) 
n-l
_ E (y-y) ^ 
■y " n-l
A simple first measure of the association between x and y is the 
covariance, which is estimated by
C _ ECx-x)(y-y)
The covariance estimate is a simple measure of association, but it
is not easy to interpret because it depends on the scale on which
the variables are measured. A more useful quantity is the
coefficient of product - moment correlation (correlation coefficient)
estimated by • ' . CCovariance xy
r -
S.D of X X S.D of y S S
X y
It may be shovm that the correlation coefficient never exceeds 1 in 
numerical value, i.e., -1^ r_< 1. When r - 1 the sample relationship 
is a straight line with x and y increasing together and when r = -T
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the relationship is again a straight line with, y now decreasing when x 
increases. Intermediate vaines of r are less easy to interpret, 
however, in general it may be said that values of r near to +1 or -1 in­
dicate a close relationship with little departure from linearity.
The correlation coefficient tells us how close the 
relationship is, but does not indicate which straight line best 
represents the relationship. This is determined by linear regression 
analysis,
Linear regression is applicable to data in the form of pairs of
observations y^,x^; y^jX^;........ ; y^,x^, where y (the dependent
variable) is not random. Let the line best fitted to pass through 
these n points be y = Bx + a. The parameters of the line B and a 
cannot be estimated simply from the plotted n points as these will 
deviate randomly from the above line. The "best” estimates of 
these parameters are those obtained such that the sum of the squares
of quantities d are a minimum
X
that is, such that S - Z(y-a-gx)2 is a minimum. The least
118
squares estimators of a and B are
a = y - Bx
Zx.y - n.x.y
B
- nx^
If we make the further asumption that the y ’s are each distributed 
normally and independently with common variance o^, we may go on to 
test the null hypothesis,
: B = Bq with B^ = 0.
This gives an anser to the question * is there any linear 
relationship between the variables x and y , The estimate B 
is a linear combination of the y's, and hence a normal random 
variable. In fact
2
B,
Z(x-x)^
1 ,e
(B~B) A(x-x)^ N(0,1)
In order to test B = B^, an estimate of is required. 
The statistic is used were
(n-2)S^ = %y^ - n.y^ - B^ (Ix^ ~.n,x^)
This expression, which is the sum of squares of deviations from 
the least squares regression line, is called the residual sum of 
squares, and it has expected value of (n-2)a^.
i j . y
We now have that t = (S“
is a t-variate with n^2 degress of freedom under the null 
hypothesis, and so we may test by the critical region
ItI > t^ where t^ is the appropriate 
percentage point of the t-distrobution.
In the studies presenGWin this report the data for 
correlation, linear regression and t-test analysis were all 
processed on the ICL KDF9 computer at Glasgow University.
Since a computer procedure was employed it was decided to analyse 
the data thoroughly. Therefore, in each study all the
available variables on subject studied were processed in all the 
possible combinations of two. In each pair of variables there 
should be one a dependent and the other an independent variable.
This criterion was not strictly observed in order that any hitherto 
unrecognised correlations would be revealed.
Some of the results presented show no obvious reason why one 
variable should be dependent on the other, but the fact there was 
lack of information on this matter does not mean that relationship 
does not hold. Also, when it is considered that many of 
correlations revealed were numerically very high (r > ±0.9), then 
it seemed expedient to present them.
3, Multivariate analysis.
Univariate or bivariate observations are readily visualised
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by 1 dimensional (l.D) and 2,D scatter diagrams. However, 
with trivariate observations this is very difficult and with hexa- 
variate, septavariate, etc., observations it is impossible. 
Therefore, the problem is that of multivariate discrimination;- 
given a sample of members from each of k populations, and the 
values of h variables for each member, then if presented with a 
further member together with the appropriate values for h variables 
a method is necessary for correct assignment of the new member to 
one of the k populations.
In the present study multivariate discrimination analysis 
will be used purely in an attempt to discriminate between normal 
individuals and patients suffering from various vascular diseases 
on the basis of individual D,17-OS urinary levels, with expectation 
in future of classifying new individuals using the same variables.
The method is that of O ’Muircheartaigh (1968) and 
essentially consists of drawing circumscribing ellipsoids around 
each cluster of points obtained for each group of subjects and 
examining the degree of overlap. The individual points are 
obtained by manipulation of the values of the variables on that 
subject and within reason there is no limit on the number cf 
variables per subject. The ellipsoids are special in that
they are centered at the mean of the cluster and their orientation 
is determined by the orientation of the data. They are "drawn"
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to go through the outermost points of the cluster. The 
examples below show in 2,D. what would be classed as good, fair 
and poor discrimination.
X
GOOD
Y
X
FAIR
X
POOR
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V. EXPERItlENTAL PART II.
A. Individual Urinary D,17-OS Sulphate and Glucuronides:
Values in Normal Males and Feraales.
1. Subjects studied.
Thirty-seven subjects were studied. There were 22 males 
with a mean age of 44 - 9 years (range 29-69) and 15 females with 
a mean age of 41 ± 9 years (range 25-58). All were free from 
disorders known to influence urinary 17-OS levels such as thyroid 
disease (Heilman et al, 1959), gout (Sonka et al, 1965 and Beck 
et al, 1967), fever (Kappas & Palmer, 1965), obesity (Hendrikx et 
al, 1965 and Lopez-S & Krehl, 1967), diabetes mellitus (Charro- 
Salgado et al, 1968 and Sonka & Gregorova, 1964), and other 
endocrine abnormalities (Loraine & Bell, 1966). Obesity was 
calculated in terms of % overweight from the tables compiled by 
Kerns ley, Billewicz & Thomson (1962).
All subjects had normal renal function as estimated by blood 
urea and serum creatinine, and all had normal blood pressure. They 
were mainly members of staff or ambulant patients awaiting minor 
surgical procedures. All subjects were on normal diets and none 
were taking medication of any sort for one week prior to the study.
2, Analytical techniques.
Collection of blood and urine - Section IV A. 5*
Blood urea & serum creatinine - Section IV A.2.a & b.
Serum uric acid - Section IV A.4.
1 23
17-OS St 17-OHCS. - Section IV A.6.a & b.
D.17-OS.S & D.17-OS.G. - Section IV C.2.
All analysis were duplicated,
3. Results.
The values for the individual urinary D,17-OS sulphates 
and glucuronides levels in males and females are shown in Tables 7 & 8.
There was a wide range of values in both sexes for all the steroids
studied, especially for the two 3g-hydroxysteroids (epiA and DHA).
Only in males could this wide range be correlated with age. The 
inclusion of the four youngest males ages 29-34 greatly elevated the 
mean levels of the individual D.17-OS. For example, they had a 
mean DHA.(S+G) level of 10.38 mg/day compared with an overall mean 
for the 22 males of 3.12 mg/day. In order to see the influence of
these four males on the urinary D.17-OS levels Table 7 gives mean - S.D,
for D.17-OS with and without the values for the 4 youngest males.
(a) Sulphate conjugates. DHA.S was quantitatively the most
important D.17-OS.S in 87% of the males and 40% of the females. In 
one of the other 13% (3) male subjects, E.S and A.S were both greater 
than DHA.S and in a further 2 subjects A.S alone was greater. The 
typical D.17-OS.S urinary excretion pattern for males was DHA >A>epiA>E, 
and is ullustrated in the gas chromatographic tracing in fig.5. Among 
the females 4 subjects had E.S and A.S both greater than DHA.S and 5 
subjects with either E.S or A.S larger than or equal to DHA.S. Thus, 
the females showed no typical steroid sulphate excretion pattern other
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3 12 15 18 21
Fig, 5. Gas chromatographic tracing of the D.17-OS sulphate 
fraction obtained from a normal male urine, 3% QF-1 column 
at 200°. A) Androsterone, E) Aetiocholanolone, DHA) Dehydroepi- 
androsterone, epiA) Epiandrosterone and Preg) Pregnenolone all 
as TMSE derivatives.
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than that epiA.S was the minor steroid sulphate. Males had 
consistently much higher urinary D.17-OS levels than females, with 
the exception of E.S where the mean values for males and females 
were 0.23 and 0,16 mg/day respectively (Table 9).
(b) Glucuronide conjugates. The urinary levels of A.G and E.G
were much higher for males than for females, with less significant 
statistical difference for DHA.G. The predominant glucuronide in 
66% of the males was A.G and E.G in 75% of the females. The typical 
steroid glucuronide excretion patterns in males (A>E>DHA) and in 
females (E>A>DHA) are illustrated by the gas chromatographic tracings 
shown in figs 6 & 7, One subject, a female was unique in having DHA 
as her major urinary glucuronide. It may be relevant that this
female had a history of rheumatic heart disease. No values for epiA.G
are given since in all instances peak heights were negligible and gross 
variation in retention time occurred,
(c) Sulphate plus glucuronide conjugates. In all cases, the
D.17-OS.(S+G) urinary levels for males were much higher than the 
respective levels for females (Table 9), Seventy-seven % (17) of 
the 22 males had urinary levels of A,(S+G) greater than those for
E.(S+G), whereas 80% (12) of the 15 females had E,(S+G) greater 
than A,(S+G), In both sexes the urinary levels of DHA(S+G) tended 
to be much lower than those for either E,(S+G) or A.(S+G), except 
among the younger males and females, where 6 of the 9 youngest males 
and 2 of the 4 youngest females had DHA.(S+G) as their major urinary 
D,17-OS conjugate.
TABLE 9. COMPARISON OF THE INDIVIDUAL D,17-OS URINARY LEVELS
OF NORMAL ADULT MALES AND FEMALES.
MALES 
MEAN ± S.D.
FEMALES 
MEAN ± S.D.
P
VALUE
epiA.S 0.30 ± 0.326 0.05 ± 0.047 0.0008
DHA.S 2.75 + 3.75 0.45 ± 0.99 0.0008
E.S 0,23 ± 0.212 0.16 ± 0.150 0.2
A.S 0.82 ± 0.838 0.16 + 0.149 0.00006
DHA.G 0.37 ± 0.365 0.27 ± 0.520 0.044
E.G 2.61 ± 1.36 1.12 ± 0.82 0.0008
A.G 3.05 + 1.89 0.87 ± 0.691 0.00002
DHA.(S+G) 3.12 ± 4.07 *0,67 ± 1.330 0.0028
E.(S+G) 2.89 ± 1.36 1.28 ± 0.912 0.0012
A. (S+G) 3,87 ± 2.46 1.03 ± 0.823 0.00002
17-OS 12.3 ± 5.3 6.1 ± 3.7 <0.001
17-OHCS 12.7 ± 3.7 7.6 ± 3.4 <0.001
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Preg
DHA
183 15 h6 9 12
Fig. 6. Gas chromatographic tracing of the D.17-OS glucuronide 
fraction obtained from a normal male urine. 3% QF-1 column at 
200^. A) Androsterone, E) Aetiocholanolone, DHA) Dehydro- 
epiandrosteronej epiA) Epiandrosterone and Preg) Pregnenolone 
all as TMSE derivatives,
JL JU
Preg
• H
DHA
6 189 12 15 213
Fig. 7. Gas chromatographic tracing of the D.17-OS glucuronide 
fraction obtained from a normal female urine. 3% QF-1 column at 
200°. A) Androsterone, E) Aetiocholanolone, DHA) Dehydro- 
epiandrosterone, epiA) Epiandrosterone and Preg) Pregnenolone 
all as TMSE derivatives.
' ^ 8 . 1
diatolic + /^ (systolic - diastolic)
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(d) Correlations « Correlation coefficients (Section IV.D,2.)
were calculated by computer for any combination of 2 of the 19
variables collected for all the subjects. The variables involved
were age; serum uric acid; serum creatinine (S.C.); 24 hour urine
volume; surface area (S.A.); % overweight; mean blood pressure
; 17-OS; 17-OHCS; epiA.S;
DHA.S; E.S; A.S; DHA.G; E.G; A.G; DHA(S-fG) and A. (S+G) .
Correlation coefficients for the most highly correlated of the 19
variables are shown for normal males and females in Tables 10 & 11
respectively. Correlation coefficients significant at the 2% level
or less are underlined.
Excretion of all the individual D.17-OS, excluding E.S, by
male subjects showed statistical negative correlation with age,
especially DHA.G were r = -0.72(P<0.001).
Some hitherto unrecognised correlations between individual
D.17-OS were demonstrated. EpiA.S was highly correlated with all
other D.17-OS sulphates and glucuronides and particularly so with
DHA.S (r = 0.92) and A.S (r = 0.97). Fig. 8 illustrates the
regression of epiA.S on A.S. The equation for the regression line
is
epiA.S = 0.38 A.S - O.Ol r = 0.97 P<0,001.
The two steroids E.(S+G) and A.(S+G), whose ratio is continually
referred to in the literature (Rubin, Dofrman 8 Pincus, 1954; Kellie & 
Wade, 1957; James, 19 61 and Hamman & Martin, 1964, to mention a few)
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Fig. 8. Regression of epiA.S on A.S for normal males. The equation 
of the regression line is epiA.S = 0.38A.S - 0.01, r = 0.97, P<0,001.
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showed a high degree of correlation (r = 0.89, P<0.001), as did 
their fractionation products, that is, E.S versus A.S (r - 0.79, 
P<0,001) and E.G versus A.G (r - 0.86, P 0.001),
Female urinary D.17-OS levels showed little correlation 
with age but diowed surprisingly consistent and significant 
correlation with serum creatinine and urine volume. They also 
correlated well with total urinary 17-OHCS levels, unlike the 
males. The interrelationships of the individual D.17-OS were 
numerous though the degree of correlation was not just as high as 
it was for males. This, confirms and extends the observations 
that the gas chromatographic tracings for males tended to follow 
a more definite pattern than did those for females especially the 
female D.17-OS sulphate urinary patterns.
The simplest way of estimating the degree of interdependence 
of two variables from a set of data is by the constancy of the ratio 
of the two variables. The regression equation calculated from the 
same data demonstrates more accurately the degree of interdependence 
than does the constancy of the ratio of the two variables. Further, 
it demonstrates it in a more statistically sound fashion by means of 
r and P values. If the slope of the regression line passes through 
or close to the origin, arithmetically the value of the slope will 
be very similar to the above mentioned ratio.
Inspection of the male and female regression equations for
E.S on A.S,
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female E.S = 0,66 A.S + 0.058 r = 0.66 P<0.01
male E.S = 0.20 A.S + 0.068 r 0.79 P<0.001
(fig,9a), shows that in both cases there is a high degree of 
correlation. The difference in the slopes of the lines 0,66 
and 0,20 which are to a certain extent equivalent to the ratio 
of E.S/A.S indicates that there is more E.S relative to A.S 
excreted by females compared to males. This difference in the 
excretion of E relative to A by females and males for their sulphate 
conjugates is repeated for their glucuronide conjugates,
female E.G = 1.05 A.G + 0.22 r ^ 0.89 P<0.001
male E.G = 0,62 A.G + 0.73 r = 0.86 P<0.0Q1
(fig.9b), and for the sum of their sulphate and glucuronide conjugates 
(fig,9c) ,
female E. (S+G) = 0.97 A. (S+G) + 0.29 r - 0.87 P<0.001
male E,(S+G) = 0.53 A.(S+G) + 0.81 r = 0.89 P<0.001
4. Discussion.
(a) Comparison of data with those of other investigators. Apart 
from the authors referred to in Table 12, previous investigators have 
reported the total amounts of individual urinary D.17-OS (Table 13) 
present without distinguishing between the contribution made by
sulphate and glucuronide fractions. Some of the variations in
results shown in Tables 12 & 13 may be due to choice of subjects or
methodology. Aspects of methodology have been covered in Section IV,C.4.
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TABLE 13. CO^iPARISOH OE INDIVIDUAL URINARY D, 17-OS. (S+G) LEVELS FROM 
EIGHT DIFFERENT AUTHORS (mg free steroid/24 hr).______________
MALES;
1 2 3 4 5 6 7 8
AGE 29 - 69 18 - 43 40 - 49 40 - 49 - - 20 - 30 -
EpiA * 0.30 - - - - - ** -
0.01 - 1.29 - - - - - - -
DHA 3.12 * 2.3 S 1.7 - * 0.58 • * 0.72 * 3.5 * 1.1
0.13 - 13.01 0,8 - 6.4 3.14 - 0.03 - 1,66 0.2 - 1.71 0.4 - 9.3 0.2 - 5.7
E 2.89 2.8 4.4 - 1.5 2.5 3.3 5.0
0.39 - 6.10 1.4 - 5.1 1.89 - 0,41 - 2.86 1.4 - 5.4 1.5 - 5.3 1.3 - 11.4
A 3.87 3.4 4.53 - 2.16 2.6 4.4 4.4
0.99 - 9.26 1.5 - 6.0 1.33 - 0.75 - 3.82 2.1 - 3.8 2,4 - 6.7 0.6 - 7.9
FEMALES;
EpiA 0.05 - - - - - - -
0.01 - 0.18 - - - - - - -
DHA 0.67 1.1 0.21 0.53 1.05 0.56 2.1 0.5
0.06 - 4.77 0.10 - 2.6 0.27 0.0 - 1,7 0.11 - 4.59 0.2 - 1.13 0.5 - 5.7 0.2 - 1.4
E 1.28 2.7 2.27 2.15 1.18 1.8 3.1 1.7
0.16 - 3.44 0.7 - 4.3 1.19 0.8 - 7.6 0.12 - 2.77 0.6 - 2.2 1.7 - 5.5 0.6 - 4.0
A 1.03 3.1 2.04 1.1 1.37 1.4 2.9 2.0
0.10 - 2.66 0.9 - 4.8 1.12 0.36 - 2.5 0.10 - 3.31 0.9 - 2.6 1.6 - 2.9 0,6 - 5.0
* mean & range; § mean & standard deviation; no values given:
1. Present report, internal standard, alumina column chromatography - gas-liquid chromatography (GLC)
2. Fehér (1966), paper chromatography, Zimmerman reaction,
3. Keutmann & Mason (1967), internal standard, GLC,
4. Solomon et al (1967), silica gel column chromatography, GLC.
5. Rivera et al (1967), silica gel column chromatography, GLC.
6. Kirschner & Lipsett (1964a), thin layer chromatographyj GLC,
7. Vestergaard (1962), column chromatography, .Zimmerman reaction.
8* Cawley et al (1967), GLC.
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Age and sex are important variables (Feher, 1966 and Keutman & Mason, 
1967) . Normal diets are necessary since low calorific diets can 
markedly decrease urinary D*17-OS excretion (Hendrikx et al, 1965 and 
Cawley et al, 1967). Finally a number of diseases are known to 
influence D.17-OS excretion (Heilman et al, 1959a,b; Sonka et al, 1964; 
Kappas & Palmer, 1965; Charro-Salgado et al, 1968 and Foraine & Bell, 
1966).
A wide range of values for the individual D,17-OS in normal 
adult males and females was found by all the investigators listed in 
Table 13, thus confirming the findings of the present study. Since 
this appears to be a common finding by a variety of methods in various 
countries, it could be said that this is a definite characteristic 
of urinary D.17-OS levels in adults. The mean values for the 
individual D.17-OS found by the various investigators, though 
obviously more consistent, still show variation especially in the case 
of DHA. One constant feature of the results in Table 13 is that the 
mean urinary D.17-OS levels for males are always higher than the 
respective levels for females. This held for all steroids studied 
by all investigators, except for the DHA levels reported by Rivera 
et al (1967) where the reverse held.
Inspection of the urinary E/A ratio may be a more valid 
method of comparison of values by the different investigators, since, 
though many variables may affect the total amount of each steroid 
estimated they may not affect the relative amounts of each steroid 
estimated. The E/A ratio for the 8 investigators listed in Table 13 
are shown below.
1 2 3 4 5 6 7 8  
male E/A 0.75 0.82 0.97 - 0.70 0.96 0.75 1.14
female E/A 1.24 0.87 1.11 1.95 0.86 1.29 1.07 0.85
In all cases excluding Cawley et al (1967) number g the E/A ratio 
for females is greater than the respective values for males. 
Generalising it might be said that the E/A ratio for females is less 
than one and greater than one for males. Although comparison of 
the results in this fashion is more favourable, there is still 
definite indication that factors other than those documented are 
to some degree controlling the excretion of D.17-OS,
Some of the comments made above are relevant for the values 
listed in Table 12. There is again a wide range of values for all 
the steroids reported. Males as before have higher values for the 
individual urinary D.17-OS sulphates and glucuronides than females, 
though not in all cases. Kellie & Made (1957) reported higher 
individual D,17-OS values for females than for males, except in the 
case of A.G where the values for males and females were almost equal. 
Also, in all the studies, except the present one, the values for E.S 
in females are higher than in males. Apart from these two 
differences, all other steroid levels reported for males are greater 
than the respective levels for females.
The results of the present study show that the percentage 
conjugation of A and E with sulphuric acid and glucuronic acid are 
in close agreement with those reported by Kellie & Wade (1957), They
142
found 79% of total A and 90% of total E excreted as glucuronide 
conjugates. On the other hand Menini (1966) reported corresponding 
values of 70% and 79%, which were also lower than the values of 72%
and 87% calculated from the results of Mauvais-Jarvis & Baulieu (1962).
A similar trend was found in female subjects where Kel^^ & Wade (195 7) 
found 79% of A and 90% of E were excreted as glucuronide conjugates.
In the present study our results are in close agreement with Mauvais- 
Jarvis & Baulieu (1962), who found 87% of both A and E were excreted 
as glucuronides. Menini (1966) again reported lower values of 74%
and 73%. He also found that 5% of the DHA in males and 12% in
females is conjugated with glucuronic acid. The values calculated 
from the data of Kellie & Wade (1957) are 24% and 34% for males and 
females respectively and we found 12% and 38% respectively.
It may be relevant that Menini (1966) in the procedure for 
estimating sulphates, extracted the conjugates from urine in the 
presence of pyridinium sulphate and solvolysed the sulphate conjugates 
in dioxan without introducing acid, following the method of McKenna 
& Rippon (1965), whereas the other groups listed in Table 12 used 
methods which are essentially solvent extraction of salt saturated 
urine at pH 1, followed by solvolysis over a given time period.
Because of the difficulty of separating epiA from structurally 
similar steroids data on the excretion of this steroid are limited. 
Pesonen (1962), reported urinary epiA values as high as those of DHA, 
Okano, Matsumoto, Akehi, Mizutani, Kikkawa & Seki (1963) obtained 
epiA values of less than 0.1 mg/24 hour in urine of men by the ion- 
exchange chromatographic procedure of Sdd & Matsumoto (1963).
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Lim, Fesler & Dingman (1964) found no sex difference in the 
excretion of epiA. Feher (1967) estimated values of epiA in 
males and females and found mean values of 0.4 and 0,1 mg/day 
respectively. However, none of these authors attempted to 
separate conjugated forms. The results now shown in Tables 7 & 8, 
which agree fairly well with those of Feher (1967), would appear to 
be the first available for urinary levels of epiA in sulphate and 
glucuronide fractions.
Examination of the values for the excretion of A.S and E.S 
shows that men excrete much lower amounts of E.S relative to A.S 
than do women. The E.S/A.S ratios for males calculated from Table 12 
are 0.28, 0.36, 0.42 and 0.55 and for females 1.0, 0,77, 2.57 and 0.69. 
Similarly for the E.G/A.G ratios observed by all the investigators, 
however, with less difference between males (0.85, 0.75, 1.45 and 1.32) 
and females (1.28, 0.79, 2,09 and 1.70).
The urinary values of the individual D.17-OS sulphates and 
glucuronides for females by the present report tend in general to be 
lower than the values given by the other investigators in Table 12.
The same conclusion appears to hold true for the D .17-OS.(S+G) levels 
shown in Table 13, However, the values for males by the present 
report are average and above average on comparison with the values 
of other investigators (Tables 12 & 13). Yet, the levels for males 
and females were estimated by the same method. Accepting that the 
individual urinary H.17-OS for females by the present report are low,
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then this indicates that some factor or factors other than those 
described is, or are, in operation. Valid comparison with these 
levels will probably be indecisive and only in cases where there 
is a marked statistical difference could conclusions be formed. 
However, comparison of the ratios of various individual D.,17-OS 
for normal females, as reported here, with similar ratios for 
other groups of individuals may not be invalidated.
(b) Comparison of males and females. In a considerable 
number of endocrine conditions the determination of urinary 
individual 17-OS has been helpful for both the understanding and 
diagnosis of these conditions. However, in many other problems 
as well as in many so called endocrine problems, the value of the 
test may be limited. At times this may be ascribed to a lack of
appreciation of the large variation in the excretion of these
steroids by normal individuals. This was first pointed out by 
Fraser, Forbes, Albright, Sulkowitch & Reifenstein (1941), who 
found that the daily urinary excretion of total 17-OS for 14 women 
(20 - 40 years) to range from 5.1 to 14.2 mg/24 hour and in 9 males
of similar ages from 8.0 to 22.6 mg/24 hour.
The extent of the variation for all the steroids estimated 
in this report is shown below. In both sexes DHA of all the 
steroids estimated, showed the most striking variation, and this 
was most pronounced for females, who had variation coefficients 
for DHA.G and DGA. (S+G) cf 193% and 199% respectively.
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epiA.S DHA.S E.S A.S DHA.G E.G A.G DHA,(S+G) E.(S+G) A.(S+G)
male 108 132 92 107 97 52 62 130 47 63
female 94 122 94 94 193 73 79 199 ' 71 79
These very high variation coefficients are in close agreement with those 
found by Keutmann & Mason (1967) . These variations in the excretion of 
individual D.17-OS emphasise the difficulty encountered in obtaining 
suitable control data. It follows that conclusions concerning the 
relative excretion of these steroids by different groups of subjects 
should be made only after sound statistical evaluation.
Despite the wide variation in excretion of the D.17-OS steroids 
by both sexes, males excrete much greater amounts of each steroid than
females (Table.9). This is to be expected since it is well known
that total urinary 17-OS levels are much higher in males than in females. 
Further, the main precursors of the urinary D.17-OS, DHA.S, DHA, 
testosterone and androstenedione, excluding androstenedione, are 
secreted in larger amounts by males compared to females (MacDonald, 
Chapdelaine, Gonzalez, Gurpide, Vaiide Wiele & Lieberraan, 1965).
However, in the case of E.S there was no statistical significant 
difference between males and females, this finding tends to be in 
agreement with those of the other investigators whose results appear 
in Table 12, who found urinary E.S levels to be greater in females 
than in males. An adequate explanation for this finding does not 
appear to be available, though it has been shown in females that no 
matter the precursor, E.S excretion in the urine is greater than the
A.S and the reverse in males (Baulieu, 1963 and Mauvais-Jarvis, Floch,
Jung, Robel & Baulieu, 1968).
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By the present report the amount of E.S excreted relative 
to A.S was greater for females than for males. The E.S/A.S ratios 
for females and males were 1 and 0.27 respectively (Table 9, fig,9a),
The same pattern held for E.G and A.G with respect to relative excretion
by male and female, the E.G/A,G ratios for females and males were 1.29
and 0.85 respectively (Table 9, figs. 6,7 & 9b). Similarly for E,(S+G)
and A.(S+G) where the E .(S+G)/A,(S+G) ratios were 1.25 and 0.74 for 
females and males respectively (Table 9, fig.9c).
The ratio between the amount of E and A produced is partly 
under the influence of enzymes concerned with the reduction of the 
unsaturation involving the C-5 atom of the D.17-OS precursors, and 
partly a reflection of the relative amounts of the various D.17-OS 
precursors. The presence of two reducing enzymes, located in the 
liver parenchymal cells, has been demonstrated, A 58-A^ reductase 
located in sol^ulëe cytoplasm of the liver cells (Tomkins, 1956), 
and 5a-A^ reductase in the endoplasmic reticulum, (Forchielli &
Dorfman, 1956 and McGuire & Tomkins, 1958). With both groups of 
enzymes NADPH functions as the hydrogen donor.
It is believed, though now in some doubt, that all the 
A(5&) and E(53) formed from DHA.S, DHA, androstenedione and testosterone 
is derived from androstenedione as a common intermediate (Ungar, Miller & 
Dorfman, 1956, and Dorfman, 1954). According to this concept, 
whatever the precursor(s) the ratio of the urinary androstanes would 
always be the same, that is 1/1. Obviously this cannot be completely
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true since several reports, including the present one, have shown 
that the urinary E/A ratio for males is less than one and greater 
than one for females.
It is interesting that Johnsen (1968) in an extensive study 
of urinary E/A ratio, covering many disorders and involving the 
analysis of 2362 urines, demonstrated that the administration of 
large doses of testosterone to 45 individuals, including 12 normals, 
induced a significant decrease in E/A ratio in the majority of 
patients and in 11 out of the 12 normals. However, contrary to 
this Kirschner & Lipsett (1964b) showed minimal increases in E/A 
ratio after testosterone administration. The mean reported 
secretion rate for testosterone in females is 0.14 mg/day and in 
males 7.0 mg/day (Horton & Tait, 1966; MacDonald et al, 1965 and 
Baulieu & Mauvais-Jarvis, 1964a). Thus the difference in the 
secretion rates of testosterone for males and females might help 
explain the difference in the E/A ratio shown by males and females. 
However, care must be taken in extrapolating the results of the 
metabolism of exogenous steroids to that of endogenous steroids.
If the very high testosterone secretion rate in males, 
relative to females, does influence the E/A ratio, then eunuchs would 
be expected, since they are secreting minimal amounts of testosterone, 
to have E/A ratios lower than normal males and possibly equivalent to 
females. This was found to be true. Johnsen (1968) studied 10 
castrated sex criminals and 13 cases of testicular insufficiency and
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found the E/A ratio as a group to be substantially higher than 
normal. Similarly, Keutmann & Mason (1967) found two castrated 
males to have E/A ratios in the region of that for females.
However, reasoning such as this does not explain the remarkable 
difference between British and Japanese women with respects to 
E/A ratios (Bulbrook, Thomas, Utsunomiya & Hamaguchi, 1967).
They found Japanese women to have E/A ratios much lower than British 
women of the same age group, namely 40-60 years. Unfortunately, 
the E/A ratios for Japanese men i/ere not available, thus the presence 
or absence of the sex difference in Japanese people could not be 
ascertained. The sex difference in E/A ratio could be racial or 
even environmental.
Metabolism of steroids has been shown to influence 
urinary D.17-OS levels, though the extent of the influence may only 
be significant in pathological conditions where large amounts of 
steroids are produced as in Cushing's syndrome and congenital 
adrenal hyperplasia. However, since the metabolism of steroids 
have been shown to favour specific orientations of the hydrogen atom 
attached to the C-5 atom, consideration of their contribution though 
small may have some bearing on the E/A ratio. The oxygen atom at 
C-11 depending on whether it is present as ketone or hydroxyl has 
been shown to favour 5 g and 5a orientation respectively (Slaunwhite, 
Neely and Sandberg, 1964). However, as C^^ steroids with these
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functional groups at C-11 retain them on metabolism to 17-OS, 
they, therefore, have no effect on the E/A ratio. The side 
chain of C^^ steroids has been shown to strongly favour reduction 
of double bond to give 53 steroids, thus metabolism of 11-deoxy 
steroids to urinary 17-OS will elevate the E/A ratio. The 
two C^^ steroids lacking oxygen at C-11 are 17a-hydroxyprogesterone 
and 17a,21-dihydroxyprogesterone. Both these steroids were 
isolated from adrenal vein blood of women with cancer of the breast 
in amounts ranging from 5 - 22 yg/100 ml (Lombardo, McMorris & Hudson, 
1959) and Fukushima et al (1961) reported the secretion rate of 17a- 
hydroxyprogesterone in normals as 3 mg/day. These steroids could, 
therefore, be metabolised peripherally to excretory products 
including D.17-OS. If the proportion of these steroids metabolised 
to D.17-OS in males and females is greater in females, then the D.17-OS 
derived from these two steroids could influence the E/A ratio.
Specific investigations relating to this appear to be lacking though 
Richardson, Touchstone & Dohan (1955) reported appreciable increases 
in 17-OS levels after administration of 17a,21-dihydroxyprogesterone 
to a female with adrenal cortical insufficiency, whereas Brooks 
(1960) found the conversion of exogenous 17a-hydroxyprogesterone to 
A and E in normal man to be 0.2% Fukushima et al (1961) found the 
same conversion in another man to be 1.7%.
■ The results of Baulieu, Corpechot, Dray, Emiliozzi, Lebeau, 
Mauvais-Jarvis & Robel (1965) using tritiated DHA.S and carbon
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labelled DHA indicate that in males the metabolism of DHA.S 
produces more E.G than A.G whereas DHA produces equal amounts of
E.G and A.G, Therefore, the DHA.S/DHA secretion ratio could be 
important in determining the urinary E/A ratio. The secretion 
rates of DHA.S and DHA in normal man were 10.1 and 7.2 mg/day and 
in normal woman 7.7 and 0.7 mg/day respectively (MacDonald et al, 
1965). Assuming the above findings to be typical then the higher 
DHA.S/DHA secretion ratios for females would contribute to an 
elevated urinary E/A ratio in females relative to males.
Recent studies on the metabolism of testosterone have 
uncovered a new catabolic pathway the "173-hydroxy pathway"
(Baulieu & Robel, 1963 and Baulieu & Mauvais-Jarvis, 1964b).
The principal metabolites of this pathway, 5a and 56-androstane- 
3a, 173“diols are formed, not through androstenedione, but through 
testosterone (Baulieu & Mauvais-Jarvis, 1964b). The "173-hydroxy 
pathway" produces very high 5 3/5a urinary androstanediol ratios, this 
together with the fact that androstane diols may be converted in vivo 
to their corresponding androstanes, would result in a tendency to 
elevate the E/A ratio. Therefore, since testosterone is secreted 
in much larger amounts by males, and since it is an important 
substrate in the "173-hydroxy pathway", the net result would be 
the elevation of the urinary E/A ratio in males relative to females. 
However, the pathway is considered as being a very minor one for the 
formation of androstanes. Also contrary to Baulieu & Mauvais-Jarvis 
(1964b), Foreman & Wilson (1966) did not find a consistently high
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urinary androstanediol 5$/5a ratio, but found it to vary from 
individual to individual with no particular trend in favour of a high 
53/5a ratio.
DHA.S was the dominant steroid sulphate in normal male urine, 
and the general pattern for excretion of steroid sulphates by males 
was DHA>A>epiA>E, Females on the other hand had no set pattern and 
DHA.S was not the major steroid sulphate. Baulieu et al (1965) 
ha%< shown that only part of the circulating DHA.S is excreted as 
such in the urine, more in men (0.9 - 15.0%, mean 10%) than women 
(0.3 ” 9.0%, mean 4%) according to a short series of results. The 
findings of Baulieu et al (1965) might, therefore help to explain 
why DHA.S is the dominant sulphate in male and not in females, 
though application of these figures to DHA.S urinary levels in 
younger males would result in very high secretion rates, in the 
region of 100 mg/day whereas in other males it would result in 
minimal secretion rates.
Tables 7 & 8 show no values for epiA.G, for either males 
or females. This is in agreement with earlier results of Jayle (1959) 
and Baulieu (1963) who both found that the administration of large 
doses of epiA resulted in no urinary epiA.G, but did result in the 
formation of appreciable amounts of epiA.S as well as some A.S.
Further, administration of ^H-epiA to a normal male resulted in 
only 0.2% conversion to epiA.G whereas the conversion to epiA.S 
was 5.6% (Baulieu, 1963),
The pattern of steroid sulphate excretion for normal males 
by the present report is also in agreement with the earlier findings 
of Jayle (1959) and Baulieu (1963). Both of them found that: 
the 33“hydroxy steroids are exclusively sulphoconjugated, the one 
with equatorial C-3 hydroxyl group (epiA) as well as that with the 
axial (3B, SB-androstane, not found in the urine); the sulphation 
of A (axial, 3a-hydroxyl) is more important than that of E 
(equatorial, 3oi-hydroxyl) ; DBA as regards extent of sulphoconjugation 
falls between epiA and A. However, males do not show the glucuro- 
conjugation predicted by Jayle (1959), which is the reverse of 
sulphoconjugation, that is E>A>DHA>epiA. Thus, although DHA.G was 
by the present report the minor glucuronide conjugate (disregarding 
epiA.G) for males and females, males excreted greater amounts of A 
conjugated to glucuronic acid than they did for E, whereas females 
showed the reverse pattern, which agreed with the pattern predicted 
by Jayle (1959).
The results in Tables 10 & 11 giving the matrix of correlation 
coefficients for individual D.17-OS shows the high degree of inter- 
correlations among, these steroids. This extensive interrelationship 
of D.17-OS would suggest a simple pathway as the major catabolic 
route for the degradation of the D.17-OS precursors DHA.S, DHA, 
androstenedione and testosterone. The simplest pathway in keeping 
with a high degree of intercorrelation would be metabolism through 
a common pathway. Therefore, the old established pathway through
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androstenedione would appear most suitable. However, metabolism 
by this route would be expected to result in a 1/1 ratio for 5a and 
5 3 androstanes derived from androstenedione. The results 
presented here do not show this 1/1 ratio. However, when 
consideration is given to the variety of factors influencing the 
A/E ratio, plus the further metabolism of D,17-OS conjugates, A,G 
alone being excreted without further metabolism, the disparity in 
ratios from 1/1 can be better appreciated, and therefore, metabolism 
of the D.17-OS precursors through androstenedione is more acceptable.
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B. Individual Urinary D.17-OS Sulphates and Glucuronides.
Values in.Male and female Hypertensive Patients.
Urinary D,17-OS sulphate and glucuronide levels and 
serum uric acid levels were estimated in male and female hyper­
tensive patients and compared with the corresponding levels obtained 
in Section V.A.3 for normal males and females.
1. Patients studied.
Thirty-two patients with idiopathic hypertension were 
studied. Idiopathic hypertension was determined by clinical history, 
physical examination and special investigations including infusion 
pyelogram, isotope renogram and aortography where indicated. There 
were 15 males with a mean age of 52 * 9 years (range 30-63) and 17 
females with a mean age of 49 ~ 11 years (range 29-69). The mean 
diastolic and systolic blood pressure for males was 119 - 16 mmllg 
(range 100-150) and 197 ± 30 mmllg (range 150-250) respectively and 
for females 121 - 16 imiHg (range 95-160) and 200 ± 39 mmHg (range 
140-260) respectively. The majority had satisfactory renal function 
as determined by serum creatinine and blood urea apart from 5 males 
with serum creatinine above 1.4 mg/100 ml (mean 1.5 mg/100 ml) and 
one female with a blood urea of 80 mg/100 ml. These patients were 
dealt with separately. No patient had malignant hypertension.
Six patients, all females (mean age 49 * 8 years, range 35-60 
years) had hypertension secondary to renal disease. The underlying
IDD
abnormality was chronic pyelonephritis in 3, renal artery stenosis 
in 2 and polycystic kidneys in one. The mean diastolic blood pressure 
for this group was 118 - 18 mmHg (range 94-140) and the mean systolic 
blood pressure was 193 - 20 mmHg (range 170-220).
Two males and one female had mild diabetes, the others had 
no obvious endocrine disturbances. One male had ischaemic heart 
disease, and one female had peripheral vascular disease. All 
patients were on normal diets and no medication was given for one 
week prior to the study.
2. Analytical techniques.
Collection of blood and urine - Section IV,A5..
Blood urea and serum creatine - Section IV.A.2.a & b.
Serum uric acid - Section IV.A.4.
17-08 & 17-OHCS - Section IV.A.6.a & b.
D.17-OS.S & D.17-OS.G - Section IV.C.2.
All analysis were duplicated.
3. Results,
(a) Male hypertensive patients. The urinary levels of the 
individual D.17-OS for idiopathic hypertensive males are shown in 
Table 14 and are in order of increasing age except for the last five 
sets of results which are the D.17-OS urinary levels for the patients 
with serum creatinines greater than 1.4 mg/100 ml. Compared with 
the values of the other hypertensive patients there is no obvious
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difference shown by these five with renal damage secondary to 
hypertension*
A statistical comparison ‘between the D.17-OS urinary levels 
of idiopathic hypertensive males and normal controls is shown in 
Table 15. The urinary epiA.S and DHA.S levels were significantly 
higher in the control group than in the hypertensive group, with P 
values of 0.056 and 0.067 respectively. A.G urinary levels were 
significantly higher in the control group (P - 0.028) than in the 
hypertensive group. The control group also showed higher values 
for DHA,(S+G) and A.(S+G). Thus in general the control group 
tended to show higher values than the hypertensive group except in 
the case of E.S where the reverse held and in case of E.G and E.(S+G) 
where there were no differences between the two groups. Total 
urinary 17-OS levels were also significantly higher in the control 
group (P = 0.02), this was probably due to an accumulation of the 
less significant differences sho^m by individual D.17-OS levels of 
the control group over the hypertensive group. Total urinary 
17-OHCS were also excreted in moderately greater amounts by the control 
group (P “ <0.1).
i . Serum uric acid - urinary DHA relationship. The relationship 
of a raised S.U.A. and an absence of urinary DHA could not be 
demonstrated. In fact there was no statistical difference between 
the S.U.A. levels of hypertensive patients (5.5 * 0.9 mg/100 ml) 
and normal subjects (5.1 - 1.0 mg/100 ml). Of the 15 hypertensive
t a b l e 15. COMPARISON OF THE INDIVIDUAL D.17-OS
URINARY LEVELS OF IDIOPATHIC HYPERTENSIVE 
MALE PATIENTS AND NORMAL MALE CONTROLS.
1 5 8
NORMOTENSIVE 
MEAN 1 S.D
HYPERTENSIVE 
MEAN ± S.D.
P
VALUE
epiA.S 0.30 ± 0.326 0.16 ± 0.235 0.056
DHA.S 2.75 ± 3.75 1.22 ± 2.171 0.067
E.S 0.23 ± 0.212 0.34 ± 0,401 0.24
A.S 0,82 ± 0.838 . 0.51 ± 0.661 0.12
DHA.G 0,37 ± 0,365 0.30 ± 0.459 0.25
E.G 2,61 ± 1.36 2.74 ± 2.207 1.0
A.G 3,05 ± 1.89 1.91 ± 1.938 0.028
DHA.(S+G) 3.12 ± 4.09 1.52 ± 2.586 0.062
E.(S+G) 2.89 ± 1.36 3.09 ± 2.54 1.0
A. (S+G) 3.87 ± 2.46 2.42 ± 2.559 0.028
17-OS 12.3 ± 5.3 8.8. ± 3.2 0.02
17-OHCS 12.7 ± 3.7 10.5 ± 3,9 <0.1
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patients there were 4 with S.U.A. levels greater than 6.1 mg/100 ml, 
none of whom showed an absence of urinary DHA. In fact, two of 
them had DHA.(S+G) levels of 7.24 and 9.55 mg/day. There was no 
statistical significant correlation between urinary DHA and S.U.A. 
levels. However, urinary E.S, E.G and E.(S+G) showed significant 
correlations with S.U.A. levels, E.S (r = 0.45 P <0.1), E.G (r = 0.51 
P <0.05) and E.(S+G) (r = 0.51 P < 0.05).
ii. Sulphate conjugates. The majority of normotensive subjects 
showed the pattern DHA>A>epi>E for the relative amounts of each 
urinary steroid sulphate excreted. Yet only 2 (12%) of the hyper­
tensive patients showed this pattern, in the other 15 (88%) E.S was 
present in amounts larger than at least one of the 3 other steroid 
sulphates. Figs.10a,b & c, show the E.S/DHA.S, E.S/epiA.S and 
E.S/A.S ratios for hypertensive patients and normal controls and 
statistical comparison of the two groups demonstrated a highly 
significant difference in all three sets of ratios P = 0.0008,
P = 0.0001 & P = 0.0004 respectively. Study of fig.10a indicates 
that, in 82% of the normotensive subjects, the value of DHA.S was 
at least double that of E.S, whereas in the hypertensive patients 
this held for only 29%. In 88% of the hypertensive patients the 
value of E.S was equal to or greater than the respective value for 
epiA.S, while in the normotensive controls this was true only for 
12% (fig. 10b). One normotensive subject, only, had a value for
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E.S>A.S whereas 47% of the hypertensive patients hadialues for 
E,S>A.S (fig, 10c).
iii. Glucuronide conjugates. The urinary excretory pattern of 
steroid glucuronide conjugates for hypertensive patients was 
E>A>DHA whereas in normal controls it was A>E>DHA. The E.G/A.G 
ratios of the hypertensive patients were significantly higher
(P - 0.00004) than the same ratios for the normal controls (fig.11a). 
From fig. 11a it can be seen that 64% of the normal subjects have 
A as their major steroid glucuronide conjugate whereas 87% of the 
hypertensive patients have E. The 5 patients with renal 
impairment secondary to hypertension all showed E to be their 
major urinary steroid glucuronide and one of them, patient 13, was 
the only individual to show the steroid glucuronide excretory 
pattern of E>DHA>A.
iv. Sulphate plus glucuronide conjugates. In 77% of the hyper­
tensive patients the major D,17-OS excreted was E, whereas in the
control group E was the major steroid in only 27%. In the other
\
73%, A(46%) and DHA (27%) were the major D.17-OS excreted. The 
difference between the E.(S+G)/A.(S+G) ratios for the two groups 
was highly significant (P - 0,00002 see fig. 11b). Eighty-two 
percent of the control subjects had a value for A equal to or 
greater than E, whereas in the hypertensive group this was true for 
only 18%.
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Figs 11a & b . Comparison of the ratios of E.G/A,S and E . (S+G)/A.(S+G) 
for idiopathic hypertensive males (H) and normal males (N)
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(b) Female hypertensive patients. The urinary levels of the 
individual D,17-OS for idiopathic and renal hypertensive females 
are shown in Tables 16 & 17. Excluding DHA.S all the.urinary
D.17-OS sulphate levels for female idiopathic hypertensives tended 
to be higher, though not significantly, than the corresponding 
values for normotensive individuals, (Table 18). For the individual
D.17-OS glucuronide levels, the idiopathic hypertensive showed higher 
levels for both E.G and A.G, but lower levels for DHA.G, the differences 
however, were not significant. The results for the excretion of 
individual D.17-OS(S+G) showed the same pattern as the glucuronide 
conjugates, with the levels of A.(S+G) and E.(S+G) higher in the 
hypertensive group P = 0.08 and P = 0.19 respectively, and no 
difference shown for DHA.(S+G) levels.
Comparison of the urinary steroid levels found in renal 
hypertensive patients with normotensive individuals shows no 
significant differences, though the urinary levels of DHA.S, DHA.G 
and DHA.(S+G) tend to be higher in the control group. Table 19 
gives a statistical comparison of urinary D.17-OS levels in renal 
and idiopathic hypertensive patients. Idiopathic hypertensive 
patients tended to have higher D.17-OS urinary levels than renal 
hypertensive patients. Both A.G and A.(S+G) urinary levels were 
significantly higher (P - 0,03 & P = 0.03) in the idiopathic hyper­
tensive group than the renal hypertensive group.
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TABLE 18. COMPARISON OF THE INDIVIDUAL D.17-OS
URINARY LEVELS OF IDIOPATHIC HYPERTENSIVE 
FEMALE PATIENTS AND NORMAL FEMALE CONTROLS.
NORMOTENSIVE 
MEAN ± S.D.(N),
HYPERTENSIVE 
MEAN ± S.D. (H) .
P
VALUE
epiA.S 0.05 ± 0.047 0.11 ± 0.115 0.11
DHA.S 0,45 + 0.990 0.46 ± 0.702 0.58
E.S 0.16 ± 0.150 0.28 ± 0.243 0.12
A.S 0.16 ± 0.149 0.36 ± 0,412 0.17
DHA.G 0.27 ± 0.520 0.15 ± 0.223 0.72
E.G 1.12 ± 0.820 1.63 ± 1.251 0.25
A.G 0.87 ± 0.691 1.31 ± 0.912 0.14
DHA.(S+G) 0.67 1.33 0.61 ± 0,919 0.58
E.(S+G) 1.28 ± 0.912 1.91 ± 1.393 0.19
A.(S+G) 1.03 ± 0.823 1.67 ± 1.138 0.08
17-OS 6.1 ± 3.7 7.1 ± 2.8 0.40
17-OHCS 7.6 ± 3.4 9.6 ± 3.8 <0.20
l b /
TABLE 19. COMPARISON OF THE INDIVIDUAL D.17-QS URINARY 
LEVELS OF IDIOPATHIC AND RENAL HYPERTENSIVE 
FEMALE PATIENTS.
IDIOPATHIC
HYPERTENSIVES
RENAL
HYPERTENSIVES
P
VALUE
MEAN ± S.D. MEAN ± S.D.
epiA.S 0,11 ± 0.115 0.05 ± 0.057 0.20
DHA.S 0.46 ± 0.702 0.24 ± 0.208 0.72
E.S 0.28 ± 0.243 0.17 ± 0.120 0.4
A.S 0.36 ± 0.412 0.19 ± 0.218 0.4
DHA.G 0.15 ± 0.224 0,08 ± 0.085 0.29
E.G 1.63 ± 1.250 0.85 ± 0.450 0.2
A.G 1.31 ± 0.912 0.46 ± 0.233 0.03
DHA,(S+G) 0.61 ± 0.919 0.32 ± 0.231 1
E.(S+G) 1.91 ± 1.390 1.03 + 0.554 0.2
A,(S+G) 1.67 ± 1.137 0.64 ± 0.436 0.03
17-OS 7.1 ± 2.8 4,7 ± 1.7 <0.1
17-OHCS 9.6 + 3.8 6.5 ± 1.6 <0.1
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i. Serum uric acid - urinary DHA relationship. The idiopathic 
hypertensive patients showed marginally higher serum uric acid 
levels (P < 0.25) than the control group. In support of the 
findings of Kolbel’et al (1965a) a 39 year old idiopathic hyper­
tensive patient (Table 16, No.3) with a S.U.A. level of 10.5 mg/100 ml 
had a urinary DHA.(S+G) level of 0,007 mg/24 hr. However, in contrast 
to the findings of Kolbel et al (1965a) two other female hypertensives 
(Table 16, No.7 & 8) with S.U.A. levels of 9.7 and 7.9 mg/100 ml had 
urinary DHA.(S+G) levels of 0.21 and 0.15 mg/24 hr respectively.
No correlation could be found between S.U.A. levels and urinary DHA 
levels or any other urinary D,17-OS for idiopathic or renal hyper­
tensive patients, though urinary A.S levels for normal female subjects 
was positively correlated with S.U.A. levels (r = 0,69 P = 0.02).
ii. Glucuronide conjugates. The major urinary steroid glucuronide 
in the two hypertensive groups and the control group was in all cases 
E.G. The overall pattern of steroid glucuronide excretion by all 3 
groups was E>A>DHA. This pattern held for all the renal hypertensive 
patients, 71% of the idiopathic hypertensive patients and 67% of the 
normal individuals. There was a significant difference (P = 0.074) 
between idiopathic hypertensive patients and normotensive controls 
for the A.G/DHA.G ratio.
iii. Sulphate conjugates. No set pattern of steroid sulphate 
excretion was shown by any of the three groups. The major steroid 
sulphate for normal subjects was DHA.S (40%), for idiopathic hyper-
169
tensive patients A.S (59%) and for renal hypertensive patients
E.S (50%). The only definite feature shown by all the individuals 
of all three groups was the excretion of epiA.S in amounts less 
than that for DHA.S, A.E and E.S.
iv. Sulphate plus glucuronide conjugates. The predominant pattern 
shown by all three groups was E>A>DHA, which is the same as the 
pattern shown for the excretion of steroid glucuronides,
(c) Correlations. Correlation coefficients were calculated 
by computer for any combination of 2 of the 19 variables, collected 
for all the male and femal hypertensive patients. The variables 
were the same as those for the normal subjects. Correlation 
coefficients for the most highly correlated of the 19 variables 
are shown, for idiopathic hypertensive males in Table 20, for 
idiopathic hypertensive females in Table 21 and for renal hyper­
tensive females in Table 22. Correlation coefficients at the 5% 
level and less are underlined.
i. Males. Excluding E.S, the excretion of all other D.17-OS 
conjugates by idiopathic hypertensive males showed statistically 
significant negative correlations with age, especially DHA.G 
where r = -0.68 (P<0.01). These are exactly the same results 
as were obtained for normal male subjects, that is, a generalised 
correlation of the D.17-OS steroids with age, with DHA.G showing 
the highest degree of correlation. The regression equations of • 
urinary D.17-OS sulphate levels on age showed a set pattern when
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they were compared for rormal (N) and hypertensive (H) males. 
epiA.S on age.
N. epiA.S = -0.018 age + 1.12
H. epiA.S “ -0.013 age + 0.86
DHA.S on age.
r =-0.55 P<0.01
r =-0.58 P<0.05
N.
H.
A.S on age, 
N, 
H.
DHA.S = -0.24 age + 13.3
DHA.S = -0,14 age + 8.4
A.S = “0.05 age + 3.0
A.S = -0.04 age + 2.56
r =-0.62 P<0.002
r =-0.64 P<0.01
r =-0.58 P<0.01
r =“0.60 P<0.01
Generalising the pattern shown by these 3 sets of regression 
equations may be illustrated thus:-
Age
At any age between 30-62 for epiA.S, between 30-50 for DHA.S and 
between 30-44 for A.S, the urinary D,17-OS,S levels for normal 
subjects tend to be higher than the respective value for the hyper­
tensive patients, though there is little difference between the two 
groups for individuals older than 50 years.
The opposite pattern h shown by the regression equations of 
urinary D.17-OS glucuronide levels on age, when normal subjects are 
compared with hypertensive patients.
1 72
DHA.G on age.
N. DHA.G = “0.027 age + 1.56
H. DHA.G - “0.031 age + 1.9
E.G on age.
N., E.G. = “0.077 age + 6.07
H. E.G = “0.122 age + 9.09
r = “0.72 P<0.001
r = “0.68 P<0.01
r = “0.56 P<0.01
r = ”0.56 P=0.02
A.G on age.
N.
H.
r = ”0.55 P<0.01
r = ”0.63 P<0.01
A.G ” “0,107 age + 7 . 8
A.G = “0.12 age + 8.2
Generalising the pattern shown by the first 2 sets of regression 
equations may be illustrated thus:-
Age
At any age between 30-85 for DHA.G and between 30-67 for E.G the 
urinary D.17-08.G levels for hypertensive patients tend to be higher 
than the respective values for normal subjects. The regression 
equations for A.G on age are very similar for the two groups, 
suggesting that for this steroid glucuronide both groups behave 
the same.
Comparison of the regression equations of E.S on A.S for 
normal male subjects (N) and hypertensive patients (H),
1 73
N, E.S = 0.20 A.S + 0.07 r == 0,79 P<0.001
H. E.S 0.44 A.S + 0.12 r = 0.73 P<0.001 (fig. 12a)
shows a marked difference in the slope of the lines, A value of
0.2 and 0.44 for normal subjects and hypertensive patients 
respectively indicates that hypertensive patients excrete much 
more E.S relative to A.S than do normal male subjects. If these 
regression lines are compared with those in fig.9a it will be seen 
that the hypertensive males have altered their slope in the direction 
of that for a normal female. The equations for the regression lines 
of E.G and A.G
N. E.G = 0.62 A.G + 0.73 r = 0.86 P <0.001
H. E.G = 0.92 A.G + 0.98 r = 0.81 P<0.001 (fig.12b)
and for E.(S+G) on A.(S+G)
N. E.(S+G) = 0.53 A. (S+G) + 0.81 r = 0.89 P<0.001
H. E.(S+G) = 0.82 A.(S+G) + 1.11 r = 0.82 P<0.001 (fig.12c)
for normal male subjects and hypertensive patients show the same 
pattern as the E.S on A.S. Therefore, it would appear that hyper­
tensive males excrete much more E relative to A than do normal males, 
and that hypertensive males show strong similarities to normal females 
with respects to their excretion of E relative to A (see figs.9a,b & c).
The regression equations of DHA.S on epiA.S
N. DHA.S = 10.60 epiA.S - 0.41 r = 0.92 P<0.001
H. DHA.S = 8.76 epiA.S - 0.23 r = 0.95 P<0.001
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and A.S on epiA.S
N. A.S = 2.49 epiA.S - 0.07 r = 0.97 P<0.001
H. A.S = 2.43 epiA.S - 0.10 r = 0.86 P<0.001
although very highly correlated for both normal males and hyper­
tensive patients, show that there is very little difference in the 
slope of the lines for either sets of equations, in fact, in the 
case of the regression of A.S on epiA.S the two groups have almost 
the same regression equations.
ii. Females. The urinary D.17-OS levels for female idiopathic 
hypertensive patients, like the normal females, showed no 
correlation with age. But, like the normal female subjects, they 
did show a correlation with urine volume (Table 21), though they 
did not reciprocate the correlations between serum creatinine and 
urinary D.17-OS levels shown by normal female subjects.
The regression equations of E.S on ' A.S for normal females 
(N), idiopathic hypertensive females (I.II.) and renal hypertensive 
females (R.H.) are:-
N. E.S = 0.66 A.S + 0.06 r = 0.66 P<0.01
I.E. E.S = 0.41 A.S + 0.13 r = 0.69 P=0.002
R.H. E.S = 0.39 A.S + 0.10 r = 0.71 P<0.25
The regression line for the idiopathic hypertensive females, though 
quite similar to the line for normal female subjects, is very 
interesting in that the slope of the line (0.41) has changed in the 
direction of that for normal males. Thus, the slopes for normal
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males and females are 0.20 and 0.66 respectively and for idiopathic
hypertensive males and females 0.44 and 0.41 respectively. Thus,
the slopes of the regression lines of E.S on A.S for idiopathic 
hypertensive males and femaled would appear to be more or less the 
same, in fact the regression equations for male and female hypertensives 
are almost identical.
female I.H. E.S = 0.41A.S + 0,13
male I.H, E.S ~ 0.44A.S 4 0,12
It might, therefore, be concluded that hypertension results in the two 
very different regression equations of E.S on A.S for normal males and 
females merging into one. The regression equations of E.S on A.S 
for renal hypertensive patients though very similar to the regression 
lines for idiopathic hypertension has very poor statistical validity 
(P<0.25), therefore any conclusions formed relating to it are equivocal.
The regression lines for E.G on A,G for normal female subjects 
and idiopathic hypertensive females are very similar.
N, E.G = 1,05 A.G + 0.22 r = 0,89 P<0.001
. I.H. E.G = 1.23 A.G + 0.02 r = 0.90 P<0.001
R.H. E.G = 1.55 A.G + 0.14 r = 0.79 P<0.1
However, there is no similarity between the regression lines of E.G on 
A.G for male and female hypertensive patients, therefore, unlike E.S on 
A.S hypertension does not induce the different regression lines of E.G 
on A,G for normal males and females to merge into one. The renal
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hypertensive though showing a high correlation coefficient for the 
regression of E.G on A*G still showed poor statistical significance 
(P<0.1), due to the small number of patients studied. Therefore, 
no valid conclusion can be made relating to regression line,
4. Discussion.
(a) Serum uric acid - urinary DHA relationship. If the S.U.A. 
level above which hyperuricaemia is recognised is defined as the mean 
normal + 2 S.D., then in the present report values of 7.1 and 7.0 mg/lOOml 
are obtained for males and females respectively - a less severe criterion 
for defining hyperuricaemia than that imposed by Brçckenridge (1966).
By the present report 12%, 1 male and 3 females, of the idiopathic 
hypertensive patients and 8%, 2 males and 1 female from the normotensive 
control were therebye found to be hyperuricaemic. This is a much lower 
incidence of hyperuricaemia in hypertension than the 27% cited by 
Breckenridge (1966), the 46% by Kinsey et al (1961) or the 50% by 
Itskovitz & Sellers (1963). It is an incidence more in agreement with 
the results of Barlow & Fry (1966), who found, using the same criterion 
as above for defining hyperuricaemia, that 7% from 70 hypertensive 
patients, and 3% from 140 normotensive controls were hyperuricaemic,
Tibblin (1967) found no difference between the S.U.A. levels in 468 
normotensive subjects and 33 severe hypertensive subjects,
Kolbel et al (1965a) gave their normal S.U.A. levels as 3.42 - 0.74 
and 2,52 - 0.57 mg/100 ml for males and females; therefore, values greater 
than 4.86 and 3.64 mg/100 ml for males and females respectively could be
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classed as hyperuricaemic. In 16 hypertensive males and females 
with measurable amounts of urinary DHA Kolbel et al (1965a) reported 
the mean S.U.A. as 4.8 and 3.9 mg/100 ml respectively and for 30 
hypertensive males and females with an absence of urinary DHA the 
reported mean S.U.A, levels were 5.7 and 5.5 mg/100 ml respectively.
Since only 46 hypertensive patients were studied, it may be concluded 
that by the above criterion they were all probably hyperuricaemic, 
indicating selection and, therefore, making comparisons difficult.
Further, the investigators gave no indication of withdrawal of anti­
hypertensive chemotherapeutic drugs, several of which have been shown 
to elevate S.U.A. levels (Laragh, 1958 and Dollery et al, I960).
A variation coefficient of 12.5% for urinary DHA levels was 
.calculated for normal males mean age 52 (range 17 69 years) from
the results of Kolbel et al (1965a). Yet the value found by Keutmann 
& Mason (1967) covering a similar age range and the value by the present 
report covering a narrower range, 29 - 69 years, were 180% and 130% 
respectively. The wide range for urinary DHA levels reported by other 
investigators confirms these large variation coefficients (Feher, 1966, 
Vestergaard, 1962 and Cawley et al, 1967, and others). Kolbel et al (1965a) 
used the method of Sonka, Gregorova, Slabochova & Rath (1963) for estimating 
urinary DHA. It entails hot acid hydrolysis, solvent extraction, paper 
chromatography■and quantitation by comparing unknown spots with standard 
spots, after staining the chromatograms with Zimmerman reagent.
It would appear that the defect, that is the absence of urinary
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DHA , obeys an "all or none" ruling, that is, there does not appear to 
be any gradation in urinary DHA levels with the increase in S.U.A. levels 
This is confirmed by the present report where no correlation between 
urinary DHA and S.U.A, levels could be found in either normal subjects 
or idiopathic hypertensives. Only one idiopathic hypertensive, female 
with a grossly elevated S.U.A. (10.5 mg/100 ml) had an abnormally low 
DHA.(S+G) level. This is possibly significant since almost all the 
hypertensive patients with ah absence of urinary DHA investigated by 
Kolbel et al (1965a) had S.U.A. levels greater than mean normal + 3 S.D.
(b) Urinary D.17-OS levels in hypertension and a proposed theory 
for the explanation of steroid abnormalities in this disease.
Kolbel et al (1964) reported total urinary 17-OS levels in 
normal males and females as 12.8 ± 6,1 and 8.51 ^3.88 mg/24 hr 
respectively and in patients suffering from hypertension they reported 
levels of 6.33 ± 2.2 and 6.38 - 3.12 mg/24 hr for males and females 
respectively. Thus the male hypertensive patients showed a highly
significant drop in 17-OS excretion but the drop was not nearly so 
significant for the female hypertensive patients. By the present 
report hypertensive males tended to have lower 17-OS urinary levels 
than the controls (P = 0.02), whereas the femal hypertensive patients 
showed no difference compared to controls. Earlier reports are also 
equivocal, Bruger et al (1944), Selye (1947) and Wallace et al (1955) 
all reported lower urinary 17-08 levels in hypertension, whereas Hetzel 
& Hine (1952) and Warter et al (I960) found no difference in urinary 
17-OS levels of hypertensive patients when compared with normal controls.
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Of the earlier studies only Waters et al (1960) estimated 
urinary DHA levels. These,,they found to be normal even when the 
hypertensive group was subdivided into those with elevated urinary 
aldosterone levels and those with normal aldosterone levels and the 
DHA levels again compared. However, they often found urinary 17-OS 
and DHA levels to be subnormal in the hypertensive group, but the 
urinary aldosterone/DHA ratios were not significantly different on 
comparing normal controls with hypertensive patients. Their results 
are in disagreement with the very recent report of Nowaczynski, Genest,
& Fragachan (1968). These investigators reported elevated plasma 
aldosterone levels in 11 out of 17 idiopathic hypertensive patients and 
markedly low levels of urinary DHÂ.S in 16 out of 16 idiopathic hyper­
tensive patients. They also estimated urinary DHA.G levels but found 
no difference between hypertensive patients and normal controls. The 
results of the present report would tend to agree with those of Howaczynski 
et al (1968). By the present report urinary DHA.S levels were found to 
be lower in the male hypertensive patients than in the normal controls, 
however, the difference was not highly significant (P = 0.067). Also 
as found by Nowaczynski et al, there was no difference between the 
urinary DHA,G levels for male hypertensive patients and normal controls. 
Finally, as previously mentioned, Kolbel et al (1965a)reported an 
absence of urinary DHA in 65% of the hypertensive patients they studied 
and normal urinary levels in the other 35%, - they further claimed that 
the same hypertensive patients could be classified into the same two 
groups of 65% and 35% by their S.U.A. levels.
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Generalising it would appear that urinary DHA levels tend to be 
depressed in hypertension. Further the present report and that of 
Nowaczynski et al (1968) are in agreement that urinary DHA.G levels of 
idiopathic hypertensive patients are no different from normal controls, 
unfortunately this tends to disagree with the results of Kolbel et al (1965a) 
who reported zero levels for total DHA. However, when it is considered 
that the technique employed by Kolbel et al was incapable of accurately 
distinguishing between zero and very low urinary DHA levels, and that 
relative to DHÂ.S, urinary DHA.G levels are small, by the present report 
DHA.G was only 12% of total urinary DHA for males, then the disparity in 
the results seems less important. The difference between the urinary 
DHA.S levels of Nowaczynski et al (1968), all extremely low, and those 
of the present report, tending to be low, is not so easily explained, 
though the possible cause of this difference will be considered further 
in the next section on the effect of salt intake on urinary D.17-OS 
excretion.
The results of Nowaczynski et al (1968) and those of the present 
report are the only two studies on idiopathic hypertension where DHA 
has been estimated in both the sulphate and glucuronide fraction, therefore 
close comparison of values would be of interest. Unfortunately, the 
report of Nowaczynski et al is at present only available as an abstract. 
Therefore, no details of age and sex are available and for valid 
comparison to be made these two variables are indispensable.
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Thyroid hormones have been found to favour the production of 
A over E and through this decrease of the urinary E/A ratio (Bradlow,
Heilman, Zumoff & Gallagher, 1956, and Heilman et al, 1959a,b). Also 
Heilman et al (1959a,b) studying patients with myxoedema - a disease 
caused by marked hypothyroid function - found them to have elevated 
urinary E/A ratios, as was found by the present report for hypertensive 
males. It is not suggested that the hypertensive males studied were 
suffering from hypothyroidism. Besides any indication of thyroid 
disfunction would have been uncovered in each patient's clinical "work 
up". This aside, it is of interest to note that hypothyroidism is 
closely associated with hypercholesterolaemia and that a similar 
relationship between hypertension and hypercholesterolaemia was reported 
by Thomas (1966). Further, several authors have demonstrated that 
hypertension is more common in myxoedematous patients than in the normal 
population (Thompson, Dickie, Morris & Hilkevitch, 1933 and Fuller, Spittell, 
McConahey & Schirger, 1966). However, there the similarity ends for 
although the urinary E/A ratio is raised in both conditions the urinary 
levels of E and A are much lower in myxoedema, especially A, than in 
hypertension where only the level of A is reduced (see Table 15).
Lombardo et al (1959) found values ranging from 5 - 22 pg/100 ml 
for 11-deoxycortisol from adrenal vein blood of women with breast cancer 
whereas Touchstone et al (1959) estimated ll-deoxycortisol in adrenal 
venous blood of 9 hypertensive males and found values ranging from 2 to 
200 yg/100 ml with a mean of 77 pg/100 ml. If these values of
ito
Touchstone et al (1959), which are contrary to his own theory of a 
gradual diminution of 17a-hydroxylase activity in hypertension, are 
to be accepted then the preferential metabolism of 11-deoxycortisol 
to E might to some extent explain the elevated urinary E/A ratios 
of male hypertensive patients.
It is interesting that the values of the E/A ratio for male hyper­
tensive patients are more comparable with values for normal females
than they are with the values for normal males. Comparison of urinary 
steroid levels for male hypertensive patients and females shows another 
similarity in that normal pregnant females show elevated levels of the 
polar steroid 6g-hydroxycortisol (Burstein, Dorfman & Nadel, 1954), 
the same compound found to be elevated in blood and urine of the idio­
pathic hypertensive patients (Kernel & Motohashi, 1965 and Kernel & 
Takeda, 1967).
Since an elevated E/A ratio is a distinctive feature of male
hypertensive patients, it might be expected that a similar feature
would be displayed by female hypertensive patients, however, this does 
not appear to be the case. The elevated E/A ratio in male hypertensive 
patients is probably a long standing phenomenon since it was present in 
the majority of the patients, irrespective of the duration of the 
hypertension, which ranged from 2 to 10 yars. The change in E/A ratio 
is probably due to changes in relative and absolute amount of D.17-08 
precursors secreted, and to possible changes in the catabolic enzyme 
systems involved in D.17-OS precursors' degradation.
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It was mentioned in Section V.A.A that castration of males 
resulted in elevation of the E/A ratio to values similar to those of 
normal females. Thus in theeunuch DHA.S and DHA were the precursors 
of the elevated E/A ratio. The testes in man has been shown to secrete 
some DHA and much lesser amounts of DHA.S (Chapdelaine, MacDonald, Gurpide, 
Van de Wiele & Lieberman, 1965a,b). If in the eunuch the adrenals 
behave as in normal males then castration will result in the elevation 
of the DHA.S/DHA secretion ratio. Further Baulieu et al (1965) 
demonstrated that in normal male the metabolism of DHA.S produces more 
urinary E.G than A.G, whereas DHA produces equal amounts of urinary E.G 
and A.G. Thus it could be that the secretion ratio plays a major role 
in the control of the urinary E/A ratio, and that alteration of it may 
be involved in the production of elevated E/A ratio in male hypertensive 
patients.
Any theory attempting to explain the abnormal urinary D.17-08 
patterns in hypertension, would have to take into consideration,the 
decreased urinary DHA.S levels which are concomitant with normal urinary 
DHA.G levels; the consistently elevated urinary E/A ratio in male hyper­
tensives and the fact that there is no similar change in the E/A ratio 
in female hypertensive patients. Further if the theory could also 
explain the other abnormal steroid patterns presented in hypertension, 
such as the decreased urinary levels of pregnanediol, pregnanetriol and 
pregn-5-en«53, 17a,' 203-triol; the decreased pregnenolone production 
rates; the increased plasma and urinary levels of 6a and 6g-hydroxycortisol
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sulphate; the elevated 20a and 203“cortisol adrenal tissue levels;
the theory might be coming close to resolving the role played by
steroids in the aetiology of hypertension,
A theory fulfilling the above provisos might be a modification
of that proposed by Cooper et al (1958) to explain the changes in
cortisol/corticosterone production ratios they obtained on incubating
sliced adrenal gland in autologous plasma from a series of patients,
Cooper et al proposed a progressive diminution of "17a-hydroxylase"
activity with increase in the severity of the hypertension. However,
let this theory be simply that in hypertension there is a "17a-hydroxylase"
block and that the block is restricted to the enzyme converting
'
pregnenolone to 17a-hydroxypregnenolone as illustrated below.
Pregnenolone
sulphate
Block
Cholesterol^™™ regneholone j—
-^17a-Hydroxy- DHA.S
pregnenolone sulphate
-t*--17a-Hydr oxy- 
pregnenolone
^ D H A
AndrostenedioneProgesterone 7a—Hydroxy—
progesterone
1
B
t
Cortisol
Pig. 13, A proposed mechanism to explain the steroid 
abnormalities present in hypertension - an enzymatic block,
A block in the conversion of pregnenolone to 17a-hydroxy-
pregnenolone would result in the decreased secretion of DHA, Kolbel et al
(1965a), Nowaczynski et al (1968) and the present report respectively found,
LOO
an absence of urinary DHA in 66% of all the hypertensives studied, very
low urinary DHA.S levels in all the idiopathic hypertensives studied
and a tendency to low urinary DHA.S levels in the majority of idiopathic
hypertensive studied. Accepting the proposed mechanism for explaining
the steroid abnormalities presented in hypertension (fig.13) then low
urinary DHA.S levels probably indicate decreased secretion of DHA and
not decreased secretion of DHA.S. Now DHA.S and DHA are interconvertible
in vivo (Chapdelaine et al, 1965a, and MacDonald et al, 1965) and under
conditions of depressed DHA secretion the DHA.S^^f^DHA equilibrium will
favour DHA formation. This is very necessary if normal DHA blood levels
are to be maintained. However, since DHA blood levels relative to DHA.S
are extremely small (Kirschner et al, 1965 and Plager, 1966) the conversion
e
of more DHA.S to DHA than vie/ verca would not greatly alter the DHA.S 
blood levels. But when this is considered in relation to blood half- 
lives, which for DHA.S is only minutes compared with that of hours for 
DHA (Baulieu et al, 1965 and Wang, Bulbrook, Sneddon & Hamilton, 1967), 
then it is realised that any attempt to maintain normal DHA blood levels 
could result in appreciable conversion of DHA.S to DHA. Therefore, the 
amount of DHA.S normally excreted in hypertension will be diminished 
dependent on the conversion of DHA.S to DHA which is governed by the DHA 
secretion rate, which itself in turn is determined by the extent of the 
block in the conversion of pregnenolone to 17a-hydroxy-pregnenolone.
The differences in the urinary DHA levels found by Waters et al 
(1960), Kolbel et al (1965), Nowaczynski et al (1968) and the present 
report may be explained by a difference in the extent of the enzyme
LO'J
block together with the effect of salt intake on D.17-OS metabolism 
(see Section V.C.) and probably other environmental differences as 
yet not known.
In hypertensive males a block in the conversion of pregnenolone 
to 17a-hydroxypregnenolone, through a decrease in the secretion of DHA, 
would result in an increased DHA.S/DHA secretion ratio, and therefore, 
elevate the urinary E/A ratio. In normal females, there is very little 
DHA secreted (MacDonald etaL, 1965), therefore the presence of a 
"17u-hydroxylase" block in hypertensive females would probably have more 
influence on the androstenedione secretion. The net result of an increase 
in DHA.S/DHA secretion ratio plus a drop in androstenedione would be 
little or no change in the urinary E/A ratio,
Genest et al (1960) and Vermeulen & Van der Straeten (1963) both 
studying urinary steroid levels in hypertension reported a significant 
decrease in the excretion of pregnanetriol, the catabolic product of 
17a-hydroxyprogesterone and to a smaller extent 17a-hydroxy-pregnenolone. 
Further Nowaczynski et al (1964) found the urinary levels of pregn-5-ene36, 
17a, 20B-triol, the unique metabolite of 17a-hydroxy-pregnenolone (Roberts 
et al, 1961), to be significantly lower in idiopathic, renal and malignant 
hypertension when compared to normal subjects. These metabolic 
abnormalities may be explained also by the presence of a "17a-hydroxylase" 
block. A decrease in the conversion of pregnenolone to 17a-hydroxy- 
pregnenolone would presumably result in a decrease in the secretion of
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17a”hydroxypregnenolone, and therefore a decrease in the urinary 
levels of it's unique metabolite pregn-5-en*3B, 17a, 203”triol.
Also since 17a-hydroxypregnenolone is also metabolised in part to 
pregnanetriol, the decrease in secretion of 17a-hydroxypregnenolone 
would contribute to the diminished levels of pregnanetriol found in 
the urine. However, a more complete explanation of the low urinary 
pregnanetriol levels would probably be better understood after 
consideration of pregnenolone production rates in this disease.
Additional support of the theory for a "17a-hydroxylase" block 
would be an explanation of it's function together with some confirmatory 
experimental proof of its existence. Figure 13 indicates that in 
the adrenal gland pregnenolone is the precursor of both D,17-OS and 
glucocorticoids including cortisol. Since it has long been known 
that cortisol is necessary for maintenance of life, a constant source 
of cortisol is, therefore, always necessary, and is presumably *
maintained if necessary at the cost of a decreased production of 
other steroids. Quantitatively there is normally a large production 
of D,17-OS steroids, therefore, by shunting the pregnenolone normally 
going to DHA through progesterone to cortisol by means of a 
"17a-hydroxylase" block, a constant source of cortisol would thus be 
available. Such a mechanism for maintaining cortisol output would
be feasible in the event of circumstances where there was a reduced 
availability of pregnenolone.
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Nowaczynski et al (1968) estimated pregnenolone production 
rates in 11 idiopathic hypertensive patients and 10 normal controls and 
found mean production rates 4.1 and 11.7 mg/24 hr respectively.
Therefore, it would appear that hypertension, is a disease where there 
is a reduced availability of pregnenolone. Regrettably, concomitant 
estimates of cortisol secretion rates were not available. However, 
Vermeuleu & Van der Straeten (1963) estimated cortisol secretion rates 
in hypertensive patients and found them normal. Therefore, the 
function of the proposed "17a-hydroxylase" block in hypertension could 
be to maintain normal blood cortisol levels in presence of reduced 
biosynthetic precursors.
The marked difference between the mean production rates of 
pregnenolone for hypertensive patients and normal controls 11.7 - 4.1 
” 8,6 mg/24 hr would demand a very extensive "17a-hydroxylase" block 
and even with an extensive block the secretion of cortisol might still 
be depressed. However, if the secretion rates, but not the production 
rates, of the glucocorticoid biosynthetic intermediates between 
pregnenolone and cortisol were markedly depressed then a normal cortisol 
output might be maintained. In support of this both Genest et al (1960) 
and Van der Straeten (1963) found decreased urinary levels of preg­
nanetriol the catabolic product of 17a-hydroxyprogesterone a biosynthetic 
intermediate of cortisol. Further, Nowaczynski et al (1964) reported 
decreased urinary levels of pregnanediol in hypertension. Pregnanediol 
is the metabolic product of progesterone which is also a biosynthetic 
intermediate of cortisol.
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Besk et al (1962) demonstrated in dogs with experimental 
hypertension a 50% increase in the formation of 203-hydroxycortisol. 
Touchstone et al (1965) have shown in vitro that the biosynthesis of 
20a and 203 -hydroxycortisol are increased in the adrenal tissue of 
hypertensive patients. Kernel & Motohashi (1965) and Kernel & Takeda 
(1967) found increased urinary and plasma levels of 6a and 63“hydroxy- 
cortisol sulphate and another still more polar steroid sulphate in 
patients with idiopathic hypertension. All these findings might be 
explained by the "17a-hydroxylase" block (fig. 13). Restriction of 
the conversion of pregnenolone to 17a-hydroxypregnenolone would result 
in a decrease in secretion of both DHA and androstenedione. Both 
these steroids are inhibitors of the enzyme G-6-P.D.(Marks & Banks, 1960). 
Therefore, their absence or their reduced level especially at the adrenal 
level could result in a stimulation of available G-6-P.D. The stimulation 
of G-6-P.D. would in turn lead to excessive NADPH production which could 
then potentiate further and possibly excessive steroid hydroxylation as 
has been demonstrated in hypertension.
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C . An Investigation of the Xffect of DHA on Steroid Hydroxylation 
in Human Adrenal Tissue.
1. Analytical techniques.
(a) Source of tissue. - Section IV.B.l.
(b) Preparation of tissue,- Section IV.B.2.
(c) Incubation procedure. - Section IV.B.3. Two incubations
“4were set up, one with 500 yg of DHA (3.8 x 10 M-DHA) and one 
without any DHA, In each case 3 ml of adrenal tissue preparation
plus 1.5 ml of incubation medium were incubated with 100 ymoles
3 '14
of lor H DOC (25 yc/ymole) and 4- C progesterone (21.7 yc/ymole)
at 37° for 1.5 hours.
At the end of the incubation the reactions were stopped by
the addition of 20 ml of acetone and refrigerating at -15°. The
following unlabelled carrier steroids, 500 yg of each, were added
to each of the two flasks, progesterone, DOC, llg-hydroxyprogesterone,
17ci-hydroxyprogesterone and corticosterone.
(d) Extraction of steroids. - Section IV.B,4.
(e) Purification and quantitation. - Section IV.B.5,6 & 7.
(f) Radioactive measurement of steroids and derivatives. - Section IV.B,8
2. Results.
The evidence for the identification of the steroids isolated 
is given in Tables 23 a & b . The results from these two tables are 
summarised in histogram fashion as illustrated in fig. 14.
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F i g .  1 4 .  EFFECT OF DEHYDROEPIAN DROSTERONE ON STEROID
h y d r o x y l a t io n :
m
1 9111
PROGESTERONE & DOC INCUBATED WITH 
HUMAN ADRENAL TISSUE IN  THE PRESENCE
^50 OF DHA CD)
_ 4 0
.30
Ip Hydroxy -  
PROGESTERONEPROGESTERONE
-10
DEOXYCORTICOSTERONE 17a Hydroxy — 
PROGESTERONE
D D
CORTICOSTERONE
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The residual amounts of ^*^C"progesterone are markedly higher 
for the incubation containing DHA compared with the incubation without
DHA, therefore indicating an inhibitory effect by DHA. Similar
3 . 3 .
findings were found for H-DOC where the residual H-DOC was higher
in the test incubation relative to the control,
Twenty-one hydroxylation of progesterone, that is conversion
to DOC, does not appear to be affected by DHA. However, the
conversion of DOC to corticosterone was higher in the control
3 16
incubation for both H-DOC and "C-DOC, therefore, again indicating 
inhibitory action by DHA. The reverse holds for the formation of 
17a-hydroxyprogesterone where DHA would appear to have stimulated 
the 17a-hydroxylation of progesterone.
The formation of llS-hydroxyprogesterone could be detected 
in only trace amounts in the test and control incubations.
3. Discussion,
The results of the present incubations support, within limits,
the results of the in vitro studies of Tsutsui et al (1962). They
demonstrated in rat adrenal tissue that under conditions of excess 
+
NADP , that NADPH formation was reduced by the addition of DHA, In
14the present studies it. was found that the residual amounts of C-
3
progesterone and H-DOC were much lower in the incubation without
14added DHA, This was especially true for C-progesterone where
the ratio of counts remaining as ^^C-progesterone in the incubation 
with DHA to the incubation without DHA was 27/1. From this it was
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concluded that much more progesterone was metabolised in the 
control incubation over that time period than was metabolised 
in the test incubation and therefore presumably, more NADPH 
dependent hydroxylation reactions occurred.
In the present incubations it was expected that DHA 
would influence NADPH dependent hydroxylation steps through inhibition 
of G-6-P.D. Therefore, it would have been expected that all the 
hydroxylative steps utilising NADPH as a coenzyme would have been 
affected equally. This expectation was not realized, for example,
the difference between the ratios of the residual counts of the
. . . . .  14
incubation with DHA to the incubation without DHA for C-progesterone
3
was 27/1 and for H-DOC 1.6/1. This and the other difference 
regarding the extent of hydroxylation in the presence of DHA may 
be better appreciated, though not necessarily resolved, after 
consideration of other regulatory factors influencing steroid 
hydroxylation.
Sharma, Forchielli & Dorfman (1963) demonstrated that DHA,
DHA.S, testosterone and androstenedione will all competitively inhibit
llg-hydroxylation of both DOC and 17a, 21-dihydroxyprogesterone,
and of the 4 steroids androstenedione, the immediate metabolite of
DHA, was the most active inhibitor. Thus the smaller conversion of 
3 14
both H-DOC and C-DOC to corticosterone in the presence of DHA, 
compared with the conversions of H-DOC and C-DOC to corticosterone 
without added DHA could be due to a combination of inhibitory processes, 
that is, inhibition of NADPH production by action of DHA on G-6-P.D.
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plus the inhibition of DOC 113“hydroxylase activity by DHA.
Inspection of fig. 14 shows that the resultant effect of 
DHA on 17a hydroxylation of progesterone is stimulatory rather than 
inhibitory. Therefore, since this is a NADPH dependent hydroxylation, 
there must also be a very strong stimulatory factor in operation to 
overcome the inhibition known to be mediated through suppression of 
G“6“P,D. activity by DHA. Further if this anomalous stimulus of 
17a-hydroxylation of progesterone by DHA were also true for the 17a- 
hydroxylation of pregnenolone it would mean that DHA, to a certain 
extent, stimulates its own biosynthesis. This autocatalytic feature 
of DHA, if valid, may be sho\m to be further augmented, Kowal, 
Forchielli & Dorfman (1964) studying adrenal A^-33“hydroxysteroid 
dehydrogenase demonstrated that DHA, as well as its biological 
oxidation product androstenedione, actively inhibited the conversion 
of pregnenolone to progesterone. Therefore, more substrate is 
available for converâon to 17a-hydroxypregnenolone the precursor of 
DHA, DHA.S was, however, without any inhibitory activity with 
respects to A^-33”hydroxysteroid dehydrogenase (Kowal et al, 1964).
The competitive inhibition of 113“hydroxylase by adrenal 
steroids is of great interest, especially as one of these steroids is 
DHA.S. This inhibitory activity of DHA.S contrasts markedly with the 
complete lack of activity of DHA.S in the inhibition of G-6-P.D or in 
the inhibition of A^-33~hydroxysteroid dehydrogenase (Tsutsui et al, 
1962 and Sharma et al, 1963), The contrast is further
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emphasised when it is realised that as yet nobody appears to have 
demonstrated any other adrenal regulatory function for DHA.S. This 
therefore, allows speculation of a possible permissive role for 
sulphokinase activity in the regulation of steroid biosynthesis.
On the other hand, hydrolysis of DHA.S by steroid sulphatases 
(Burstein & Dorfman, 1963) would probably more effectively check 
steroid biosynthesis, thus emphasising the importance of the 
adrenal DHA J DHA.S equilibrium in the biosynthesis of steroids.
(a) Hypertension. Direct hormonal functions have been
described for adrenal steroids such as cortisol and aldosterone, 
but as yet no direct hormonal function has been described for 
DHA or DHA.S despite the fact that quantitatively their combined 
secretion is the most important steroidal secretion by the adrenal 
gland (Cope & Black, 1958; MacDonald et al, 1965 and Chapdelaine 
et al, 1965a).
It has been suggested by Baulieu et al (1965) that DHA.S 
and DHA may function in the adrenal gland as a "safety valve".
It is suggested that in situations of stress where suddenly 
excessive amounts of cortisol are necessary, that its precursor 
pregnenolone, and possibly pregnenolone sulphate, which are the 
general precursors of corticoids and adrenal D.17-08, be shunted 
towards cortisol production, and vica versa in periods of quiescence 
and after a period of stress when the demand for cortisol has 
subsided, the pregnenolone is shunted in favour of
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adrenal D.17-OS production. However, though proposed by Baulieu 
et al (1965) as a function for the D H A ^  DHA.S system no example 
of this mechanism appears as yet to have been demonstrated.
Reconsideration of the discussion dealing with steroids
in relation to high blood pressure (Section V.B.3) supplies
information relevant to DHA and DHA.S functioning in a "safety
valve" mechanism. However, before reconsideration, let the initially
proposed "safety valve" mechanism which covers temporary stress
changes be extended to cover other stress changes which are of a
more permanent nature, such as hypertension. In the idiopathic
form of this disease it was stated that pregnenolone was produced
in lower amounts by patients as compared with normal individuals
and concomitant with this DHA was excreted in lower amounts ■
(Nowaczynski et al, 1968; Sonka et al, 1964 and present report).
Therefore, this could represent a situation of not temporary, but of
a permanent decrease in the production of corticoidb and D.17-OS
principal precursor and necessitating a permanent shunting of
pregnenolone through the cortisol pathway. An automatic result
of the above shunting would be the stimulation of steroid hydroxylation
through the removal of the normal inhibition of G-6-P.D, 113-hydroxylase 
5 .
and A -33-hydroxysteroid dehydrogenase by DHA, DHA.S and androstenedione.
The results of the present section support the latter points 
regarding the effect of shunting steroid anabolism towards cortisol 
in idiopathic hypertensive disease. If in the present study:
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the control incubation is equated with hypertension with respect 
to effective DHA levels, that is, the control is without DHA and 
the hypertensive disease is associated with low urinary DHA levels 
and by the above "safey valve" theory, hypertension would therefore, 
represent a condition of reduced adrenal DHA production; and the 
test incubation is equated with normal health, that is, the test 
contains DHA as do adrenal of normal individuals. Fig. 14 
illustrates that in the control incubation the amounts of 17a- 
hydroxyprogesterone formed were, relative to the test incubation, 
extremely small, similarly the progesterone value was extremely 
small for control relative to test incubation. These findings are 
in agreement with the studies of Genest et al (1960) and Vermeulen 
& Van der Straeten (1963), who both found while studying hypertensive 
patients decreased urinary levels of pregnanetriol, the catabolic 
product of 17a-hydroxyprogesterone, and are also in agreement with 
the studies of Nowaczynski et al (1964) who found decreased urinary 
levels of pregnanediol, the catabolic product of progesterone, in 
the same disease.
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D . Studies on the Effect of Salt Loading, Salt Restriction and
Saline Infusion on the Excretion of Individual D.17-OS Sulphates
and Glucuronides.
1. Salt loading and salt restriction.
In these studies, subjects were placed on salt diets which
generally took the form of 2 days salt ad libitum, 4 days high salt
and a final 5 days of low salt diet. Twenty-four hour urine volumes
were collected and electrolytes, individual D.17-OS, total 17-08 and
total 17-OHCS estimated. Blood pressure was measured and in some
subjects plasma electrolytes and plasma cortisol were estimated.
Five normal males and one hypertensive female were studied.
Their salt intakes were as below:-
Subjects Ad Libitum 300 meq/day 10 meq/day 
  ---- No. days. .No. days. No. days.
IF 2 9* 6
2M 2 4 5
3M 0 3 7
4M 2 - 4  5
5M 2 4 4
6M 0 25 4
* In subject IF high salt intake followed low salt intake.
Subjects 2M-6M were normal adult males, 2M & 3M were medical students,
4M & 5M were voluntary patients convalescing after ulcer complaints,
and 6M was a member of staff. Subject iF was a mild idiopathic
hypertensive female aged 45 years with an average blood pressure of
160/100 mmHg.
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All were free from disorders known to influence urinary 17-OS 
levels (Section V ,A. 1). All had normal renal function, as determined 
by blood urea and serum creatinine levels, and all, excluding subject IF, 
had normal blood pressure. None of the subjects was taking medication 
of any sort for 1 week prior to the studies.
2. Saline Infusion.
A single infusion study was carried out on a healthy medical 
student. After emptying his bladder the student drank 1 pint of 
water, 2 hours later he again emptied his bladder, and immediately 
after this he received by intravenous infusion 2 pints of saline at the 
rate of 54 ml/minute, that is, 1 hour for the two pints of saline.
Urine was collected at 1 hourly intervals for 4 hours, then for a 
further 2.4 hourly interval.
Urine volumes were measured and urinary electrolytes, 
creatinine and individual D.17-08 were estimated.
3. Analytical Techniques.
Collection of blood and urine
17-08 & 17-OHCS
D.17-08 & D.17-08.G
All analyses were duplicated.
Section IV,A.5.
Section IV.A.I.a & b.
Section IV.A.2 ,a,b,&c.
Section IV.A.6.a & b .
Section IV.C.2.
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4. Results.
(a) Salt loading and salt restriction. The levels of urinary 
electrolytes and excretion of urinary D.17-OS for subject 2M while 
on a varying salt intake are shown in Table 24, and the histogram 
(fig.15) illustrates the changes in the excretion of the individual
D.17-OS sulphates and glucuronides. High salt intake caused definite 
increase in DHA.S with less definite increases for the other steroid 
sulphates and glucuronides. Low salt intake caused a marked 
reduction in steroid sulphate excretion. Comparison of the average 
urinary steroid sulphate levels during high salt intake with amounts 
excreted on day 9, the third day of low salt intake, shows a 93%
drop in DHA.S excretion and a 83,74 and 50% drop in epiA.S, A.S and
E.S respectively. Similarly for the steroid glucuronides, drops of 
85, 36 and 32% for DHA.G, E.G and A.G respectively were observed.
After 5 days on the low salt diet the urinary D.17-OS sulphates were 
still very low, however, the D.17-08 glucuronides E.G and A.G had 
returned to, and even surpassed their highest urinary levels while on 
high s^ s(t diets. It is noteworthy that urine volumes associated with 
these high glucuronide levels were 53% higher than the average of the' 
previous 4 days of low salt diet.
The ratio of E.G/A,G remained fairly constant throughout the 
study, varying from 0,50 to 0,57 with no special trend during the 
different salt intakes. The ratio of E.(S+G)/A,(S+G) was not just 
as constant varying from 0.38 to 0,5, tending to be higher on the low 
salt diet. The variation of E. (S+G)/A,(S+G) was determined to great
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extent by the urinary level of A.S which varied to a greater extent 
than did the other three steroid conjugates involved in this ratio. 
Comparison of day 4 with day 9 illustrates this point:-
E.G/A.G E.(S+G)/A.(S+G) A.S A.G A.G/A.S 
Day 4 0.5 0.38 1.12 2,93 2.32
Day 9 0.5 0.46 0:3 1.98 6.60
The most dramatic changes in relative excretion of steroids was that 
for DHA,(S+G) relative to E.(S+G) and A.(S+G), During all four days 
of the high salt diet DHA.(S+G) was the major urinary D,17-OS whereas 
during the low salt diet A.(S+G) was the major urinary D.17-OS (fig.15). 
Excretion of DHA.(S+G) dropped so low during low salt intake that it 
fell below that of E.(S+G) thus on high salt diet the urinary excretory 
pattern of the combined sulphates and glucuronides was DHA>A>E whereas 
on d^ys 8,9,10 & 11 it was A>E>DHA,
Urine volumes tended to follow the changes in salt intake, that 
is, urine volumes rose during salt loading and dropped to control levels 
during salt restriction. Blood pressure followed the same pattern 
increasing during salt loading aid dropping on low salt diet, but never 
below the blood pressure levels registered while the subject was on 
salt ad libitum.
The levels of the urinary electrolytes and the excretion of 
urinary D,17-OS by subject 3M while on high and low sodium intake are 
shown in Table 25, The results are very similar to those for subject 
2M. There was again a marked decrease in the excretion of D,17-OS
209
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sulphates, on moving from a high to a low salt diet. The lowest 
levels were registered on day 1 of low salt diet. DHA.S levels 
dropped by 93% and epiA.S, A.S and E.S by 93, 84 and 80% respectively, 
and the drop shoim by the steroid glucuronides were 93, 70 and 70% for 
DHA.G, E.G and A.G respectively. After the initial drop in the urinary 
levels of both the steroid glucuronides and sulphates they increased 
gradually on the low salt intake to reach levels close to that of 
respective levels while on high salt intake. Unlike 2M, subject 3M 
did not show marked changes in the E .(S+G)/A.(S+G) ratio on going from 
high to low salt intake, though the ratio was not constant, it varied 
from 0.41 to 0.53. However, the marked change in the relative 
excretion of DHA(S+G) relative to E,(S+G) and A.(S+G) was demonstrated. 
On the high salt diet the pattern of excretion of total D.17-OS 
conjugates was DHA = A>E, which changed to A>E>DHA and remained so for 
the first 4 days of the low salt diet.
The level of the urinary electrolytes and the excretion of
D.17-OS by subject 4M are as sho^m in Table 26, A histogram of the 
urinary D,17-OS sulphate and glucuronide levels while subject 4M was 
on varying salt intake is sho\m in fig, 16, The pattern of excretion 
of urinary steroid conjugates by subject 4M was somewhat different 
from that of subjects 2M & 3M, There was a very marked increase on 
the change from salt ad libitum to high salt intake for DHA.S(113%), 
epiA.S(61%), A.S(48%) and DHA.G(102%), whereas the changes for E.S,
E.G and A.G were negligible. There was a drop on going from high to
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low salt diet, the drop however, was not nearly as great as that 
for subjects 2M & 3M. The D.17-OS urinary levels did decrease 
gradually reaching their lowest on the fourth day of the low salt 
intake, levels lower than those of the control days. However, in 
comparison with the drop in urinary sodium levels, the drops shown by 
the individual were negligible.
The E.. (S+G)/A. (S+G) ratio varied from 0.46 - 0.58 with a 
tendency to higher values during high salt intake. Similarly the
E.G/A.G ratio ranged from 0.57 - 0.8, during high salt intake the 
mean-ratio was 0.7, while over the period of salt ad libitum and low 
salt intake the mean ratio was 0.63. The pattern of excretion of 
total D.17-OS conjugates was for salt ad libitum and low salt intake 
A>DHA>E and for high salt intake DHA>A>E. The blood pressure 
measurements showed no marked changes with variation in salt diet.
Urine volumes were larger during salt loading, and dropped to levels 
slightly lower than the control levels during salt restriction.
Urinary total 17-OHCS were estimated in subjects 2M, 3M & 4M 
(see Tables 24, 25 & 26) with purpose of uncovering any possible stress 
effects which might be induced through extremes of salt intake. Stress 
through release of ACTH causes secretion of urinary D.17-OS precursors 
as well as urinary 17-OHCS precursors. Thus, increases in urinary 
D.17-OS levels could be the result of the stress of varying the salt 
intake, especially salt loading, and not a direct effect of salt on 
D.17-OS metabolism. Table 27 demonstrates the effect of stress on
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TABLE 27. THE URINARY EXCRETION OF TOTAL 17-OHCS, TOTAL 17-OS
AND DHA.S BY 3 MALES BEFORE AND AFTER ADMINISTRATION 
OF SYNTHETIC ACTH (DEPOT SYNÀGTHEN, 50 UNITS)._____
SUBJECT,
DAY
1
DAY
2
*DAY
3
DAY
4
DAY
5
*17-0HCS 14.1 14.9 57.5 23.9 15.3
A17-0S 7.2 8.3 15.8 9.9 7.8
1 17-OHCS
17-OS
1.96 1.8 3.64 2.41 1.96
*DHA. S 0.44 0.35 1.77 0.47 0.14
17-OHCS 11.8 12.9 33.5 21.2 11.3
17-OS 9.9 9.9 15.3 13.2 6.1
2 17-OHCS
17-OS 1.19 1.30 2.19 1.61 1.85
DHA.S 1.34 1.44 3.43 0.84 0.46
17-OHCS 8.5 9.4 27.7 8.5 15.0
17-OS 11.0 11.3 18.1 9.1 15.4
3 17-OHCS
17-08
0,77 0.83 1.53 0.94 0.97
DHA.S 4.44 4.5 8.01 0.86 3.35
* mg/24 hours.
^ Depot synact.hen administered (i.m.) on morning of 
third day.
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the excretion of 17-OHCS, 17-OS and DHA.S in man. The injection (i.m.) 
of depot synacthen into three males resulted in very large increases in 
the urinary levels of 17-OHCS and moderate increases in 17-OS.
Comparison of absolute increases in urinary 17-OHCS and 17-OS together 
with their 17-OHCS/17-OS ratio with the values obtained from subjects 
2M, 3M and 4M (Table 28) would indicate that the changes in urinary
D.17-OS levels were not mediated through stress induced ACTH stimulation 
of the adrenals.
Compared with subjects 2M, 3M & 4M, subjects 5M & 6M did not 
show marked changes in D.17-OS excretion while on different salt intakes. 
The levels of the urinary electrolyte and individual D.17-OS for subjects 
5M & 6M are shown in Tables 29 & 30 respectively. Subject 5M showed a 
small increase for DHA.S(21%), E,G(11%) and A.G(14%) in the mean amount 
of these steroids on going from salt ad libitum to a high salt intake, 
however, the increases were not statistically significant. The marked 
decrease expected in the excretion of the D.17-OS on changing from high 
to low salt diet was not obtained, although in the case of epiA, DHA,
E & A sulphates there were, statistically significant decreases, P = 0.02, 
P = 0.02, P - 0.10 and P = 0.05 and although there were drops in urinary 
individual D.17-OS. glucuronide levels they were not statistically 
significant. Similarly for subject 6M (Table 30 ) the drop in the 
excretion of D.17-OS on going from high to low salt intake was very 
small and only statistically significant in the case of epiA.S(P<0.02), 
DHA.S(P = 0.02), E.S(P = 0.02) and A.G(P<0.02).
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The results of the electrolyte and D.17-OS urinary levels 
for subject IT, an idiopathic * female, are shown in Table 31* There 
were definite decreases in the excretion of all the D.17-OS sulphates 
by subject IF on changing from salt ad libitum to a low salt intake. 
The percentage decrease between the mean DHA.S excreted during salt 
ad libitum and that excreted during low salt intake was 56% and for 
epiA.S, E.S and A.S the decreases were 66, 80 and 70% respectively, 
all were statistically significant decreases. On the other hand, 
the D,17-OS glucuronide levels showed no decreases for the same 
dietary changes. In fact E.G showed an increase of 30%.
The dietary change from low to high salt intake caused no 
difference in the excretion of D. 17-OS glucuronides. However, the 
same dietary change caused statistically significant increases in 
the excretion of all the D.17-OS sulphates at the 0.2% level of 
significance for DHA.S and epiA.S and at the 0.4 and 0.8% level for 
E.S and A.S respectively. Only in the case of DHA.S did the 
urinary levels return to and. surpass those obtained on salt ad 
libitum. The amount of DHA.S excreted on day 14, second day of the 
high salt diet, showed a remarkable increase over the mean urinary 
levels on low salt diet. It increased by 2900%, however, it dropped 
immediately to levels comparable with those of the two control days. 
The remarkably high levels of DHA.S on day 14 were not reciprocated 
by the other D.17-OS.
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(b) Saline infusion study. The effect of saline infusion on 
individual D.17-0S excretion in normal males is shown in Table 32.
The percentages of the sodium load, administered intravenously, and 
excreted over the first four 1 hourly periods were 18.3, 7.7, 14.3 
and 11,0, therefore, the total of the load excreted over the first 
four hours was 51.3%. This is about 15% greater than the proportion 
of an administered saline load normally excreted over a four hour 
period (Rovner, Conn, Knopp, Cohen & Hsueh, 1965). Table 32 and 
fig. 17ademonstrate that all the D.17-OS sulphates are excreted in 
a. pattern very similar to that followed by sodium. All the steroid 
sulphates showed two peak excretion periods as did sodium. The 
first peak shown by all the steroid sulphates occurred at the same 
time as that for sodium ( 0 - 1  hours) and the second peak shown by 
DHA.S, epiA.S and A.S occurred between 3 - 4  hours was after that 
for sodium and E.S ( 2 - 3  hours). Thus the excretion of E.S 
followed that of sodium excretion very closely,
A similar pattern was shown by the D.17-OS glucuronides 
(Table 32 & fig.17b) though in the case of A.G and E.G their second 
peaks were not as sharp as their first peaks, they tended to plateau, 
as did the peak for A.S, over the 2 - 4  hour time intervals (fig. 17^.
The E.G/A..G ratio gradually increased over the 4 one hourly 
periods of salt excretion as follows - 0.82, 0.91, 0.98 and 1,03 and 
dropped slightly oyer the last time interval 4 - 6 . 4  hours to 0.97.
The baseline value and that of the 24 hour urine were 0.87 and 0,9 
respectively.
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5, Discussion.
The results of the present experiments on the effect of 
salt loading and salt restriction on urinary D,17-OS levels indicate 
that in 4 out of 6 subjects, there is a definite relationship between 
salt and D.17-OS metabolism. The marked increase in the excretion 
of certain D.17-OS sulphates and glucuronides by subject 4M on 
changing from salt ad libitum to high salt intake and the very dramatic 
drop in D.17-OS sulphate excretion by subjects 2M & 3M on going from 
high to a low sodium intake, are both very suggestive of either salt 
levels influencing D.17-OS excretion or what is more likely D.17-OS 
levels influencing salt excretion. Obviously if the latter 
relationship holds, then the precursors of the urinary D.17-OS are 
suspect of being the active principle involved in the observed changes 
in salt metabolism. This assumption is made since the urinary D.17-OS 
are all conjugated steroids and conjugated steroids are without as yet 
any known hormonal action.
Since the precursors of urinary D.17-08 are ostensibly
testosterone, androstenedione, DHA.S and DHA, it might be expected
that one or more of these four steroids may be the active principle.
' . . 
However, there is evidence, some definite and some suggestive that
not any of the four steroids is the active principle in question.
Testosterone is automatically eliminated since, if there is a salt-
loading steroid, it would have to be present equally in both sexes,
Tib
and testosterone is not. Besides, it has been known since as early 
as 1938 that testosterone causes salt retention, not excretion (Thorn 
& Engel, 1938). The studies of Lipsett, Coffman & Nixon (1965) would 
appear to rule out DHA and DHA.S as salt losing hormones. They in 
balance studies on sodium, chloride, calcium and nitrogen found that 
continuous infusion of DHA at a rate of 50 mg/day for 5 days had no 
effect on the urinary excretion of sodium, or for that matter on any 
of the other elements studied, in two normal males. Similar studies 
involving the continuous infusion of DHA.S were also negative. It 
is realised that this is not evidence that the reverse holds, that a 
sodium load does not result in a change in DHA and DHA.S secretion.
In fact the results of the present experiments indicate that there is 
an increase in D.17-OS excretion on salt loading, which probably 
indicates an increased secretion of urinary D.17-OS precursors(s). The 
findings of Williamson are suggestive of DHA and androstenedione being 
involved in salt metabolism. Williamson demonstrated in rats that 
DHA and androstenedione administered by subcutaneous injection in 
sesame oil had naturetic properties and that they still possessed the 
naturetic properties when administered to adrenalectomized rats. From 
these findings Williamson concluded that DHA and androstenedione were 
probably physiologic antagonists of aldosterone. Unfortunately the 
naturetic activity of DHA and androstenedione was low, approximately 
80 gm of steroid equivalent to O.lg of aldosterone, too low for
the suggested role of a salt-losing steroid. Thus the evidence of
Ill
Thorn & Engel (1938), Lipsett et al (1965) and Williamson (1966) 
would suggest that neither DHA, testosterone, DHA.S nor androstenedione 
is the active principle.
What then of the present evidence of the effect of salt intake 
on the excretion of D.17-OS sulphates and glucuronides? Biological 
compounds are generally formed by a series of intricate biosynthetic 
steps along a definite pathway, and it is well known that where 
stimulation results in increased secretion of the final compound of 
that pathway concomitant increases are observed in the biosynthetic 
precursors of the compound. ACTH administration results in the 
increased secretion of 17a-hydroxyprogesterone and 17a, 21-dihydroxy- 
progesterone, as well as the increased secretion of cortisol. ACTH 
administration also results in the increased secretion of DHA, DHA*S 
and androstenedione, which do not lie in the main biosynthetic pathway 
to cortisol (Chapdelaine et al, 1965a). Angiotensin besides 
stimulating the increased secretion of aldosterone also stimulates the 
increased secretion of corticosterone an intermediate in the biosynthetic 
pathway to aldosterone. Therefore, it is possible that the changes 
shown by the urinary D.17-OS conjugates are a reflection of the changes 
in some other ’’active" compound in the adrenal "androgen" biosynthetic 
pathways, and the increased or decreased urinary D.17-OS levels are by­
products in the chain of events leading to an increased or decreased 
secretion of an active salt-losing steroid. If the analogies of the 
effect of angiotensin on aldosterone and ACTH on cortisol are applied
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to the hypothetical salt-losing steroid, it would suggest that the 
hypothetical salt-losing steroid comes at the end of a metabolic 
pathway as does aldosterone and cortisol. Therefore, it would 
follow either DHA.S, DHA or androstenedione in the pathway as 
illustrated in fig. 18. However, if the analogy of the effect 
of ACTH on cortisol is further considered, it is realised that this 
is not imperative since ACTH stimulates DHA, androstenedione, and 
DHA.S and these lie on pathways which are branches leading from the 
main biosynthetic pathways to cortisol. Therefore, the hypothetical 
steroid need not necessarily lie at the end of a main pathway as 
depicted in fig. 18, but could be on a branch leading from a main 
pathway. Further since aldosterone is produced in small amounts 
relative to corticosterone, and cortisol in large amounts relative 
to 17a-hydroxyprogesterone, then either pattern could be shown by 
the hypothetical salt-losing steroid, that is it could be secreted in 
either yg or mg amounts.
There is no direct evidence relating salt metabolism with 
that of D,17-OS metabolism, further no studies have been carried out 
with the specific purpose of attemtping to demonstrate such a 
relationship. However, there is indirect' evidence available which would 
suggest that such a relationship does exist. Urinary 17-OS levels in 
congenital adrenal hyperplasia when considered in relation to concomitant 
changes in salt excretion provides such indirect evidence. In this 
disease urinary 17-OS levels are markedly elevated in all patient and
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Fig. 18. Suggested biosynthetic pathway for the 
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steroid (X,X^ or X.S). __________________
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about 33% of these patients display severe salt loss and often the 
salt-loss is accompanied by normal or elevated aldosterone secretion 
rates (Jailer et al, 1959 and Visser & Degenhart, 1967). The other 
67% of the patients have normal salt balances, but often these normal 
salt balances are associated with elevated aldosterone secretion 
rates (Jailer et al, 1959 and Kowarski et al, 1965). Further, in 
this disease the urinary 17-OS levels are decreased to normal levels 
by cortisone therapy, treatment which is known to bring some salt- 
losers into sodium balance and lower the elevated aldosterone 
excretion and secretion rates in non-salt-losers (Wilkins et al, 1950; 
Wilkins, 1965 and Visser & Degenhart, 1967). Also 17-OS are excreted 
in greater amounts after ACTH stimulation, treatment which has been 
shown to aggravate the salt-loss in the salt-losing types and to induce 
salt-loss in the non-salt-losing types of congenital adrenal hyperplasia.
Indirect evidence other than that from congenital adrenal 
hyperplasia which also substantiates the present findings is available.
The elevated urinary levels of free aldosterone (New et al,1966), together 
with the high urinary 17-OS levels found in the new born infant could 
be explained by the existence of a salt-losing steroid. The elevated 
urinary, aldosterone level could be a compensatory mechanism initiated in 
the adrenal adult zone, in order to maintain salt balance, as a result 
of the high production of 17-OS precursors by foetal adrenal zone.
Thus evidence from three different sources, congenital adrenal 
hyperplasia, steroid levels in newborn infants and the present findings
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all implicate 17-OS with salt metabolism and the present report 
restricts the 17-OS involved to the 11-deoxy, 17-OS. However, as 
already pointed out the hypothetical steroid does not appear to be 
any of the known urinary D.17-03 precursors.
■ Several studies have been made in attempt to find a salt- 
losing steroid. Neher et al (1958) isolated 33, 16a-dihydroxy- 
allopregnan-20-one, however Cope & Parry (3.959) found it ineffective 
as a. naturetic hormone on patients with congestive cardiac failure. 
Klein et al (1958) isolated from the urine of infants with salt- 
losing congenital adrenal hyperplasia, a steroid with salt excreting 
properties, and interestingly enough the urinary steroid extracts 
seemed more potent after ACTH stimulation. The steroidtas shown 
to have a polarity somewhere between tetrahydro A and 11-deoxycortisol. 
Rosemberg et al (1960) isolated from the urine of salt-losing patients 
with congenital adrenal hyperplasia a mixture of steroids composed 
mainly of 17a-hydroxypregnenolone which actively antagonised the salt 
retaining properties of DOC, unfortunately the antagonist was thought 
to be an impurity. Regrettably none of the above studies were brought 
to a fruitful conclusion.
If there is such an entity as a salt-losing steroid, it might 
be expected to contribute to the aetiology of idiopathic hypertension. 
Hypertension is recognised as having high incidence in communities 
consuming large quantities of salt (Dahl, 1960), also salt restriction 
has long been known to ameliorate hypertension (Ambard & Beauyard, 1905; 
Allen & Sherrill, 1922 and Volhard, 1931). Therefore, inadequate.
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excretion of salt could be a causative factor in the aetiology 
of hypertension. A decreased production of the hypothetical salt- 
losing steroid might present such a symptom as inadequate salt 
excretion. In Section V.B. an explanation for the various steroid 
abnormalities presented in hypertension was given - an enzymatic 
block in the conversion of pregnenolone to 17a-hydroxypregnenolone.
If as suggested the hypothetical salt-losing steroid may be in the 
biosynthetic pathway leading from 17a-hydroxypregnenolone then its 
secretion would probably be reduced in idiopathic hypertension. 
Therefore, the proposed explanation for the steroidal abnormalities 
presented in hypertension would also have an aetiological basis.
Most of the previous steroids proposed as the hypothetical 
salt-losing steroid were active only in the presence of mineralo- 
corticoids, therefore, they were all probably competitive inhibitors 
of aldosterone. Obviously, if the steroid in question only acts 
through competitive inhibition its potential is limited and its action 
will always be secondary to that of mineralocorticoids. Williamson 
(1966) showed DHA and androstenedione to be physiologic antagonists 
of aldosterone, that is, having naturetic properties independent of 
aldosterone. They are antagonists of aldosterone only in the sense 
that they have the reverse action of aldosterone on salt metabolism. 
Since it is possible that DHA and androstenedione may have biosynthetic 
pathway common to the hypothetical salt-losing steroid, then it may be 
structurally similar to these two D.17-OS and therefore also display 
physiologic antagonism.
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The existence of a salt-losing steroid with physiologically 
antagonism towards aldosterone would be in harmony with the results 
recorded for the saline infusion experiment. In the saline infusion 
experiments it was shown that during the first hour of the excretion 
of the saline load all the D.17-OS showed increased excretion, 
concomitant with that of sodium, suggesting that D.17-OS steroids 
may be involved in the increased excretion of sodium. Acute studies 
performed by other investigators have shown that the changes observed 
in sodium excretion took place before any changes in plasma and 
urinary aldosterone levels were registered (Ross, 1964 and Fraser, 1967). 
Also other studies have shown that there is a two hour delay before the 
effect of aldosterone on sodium excretion by the kidney is observed in 
man. On considering this evidence it might, therefore, be concluded 
that the observed changes in sodium metabolism are initially dependent 
on a steroid other than aldosterone and the evidence is further 
suggestive that the steroid might be à D.17-OS displaying physiologic 
antagonism and, therefore, closely structurally related to DHA and 
androstenedione.
Of the six patients involved in studies concerning the D.17-08 
salt relationship, two, 5M and 6M (see Tables 28 & 29), did rot show 
results which truly indicate such a relationship. This apparent 
disagreement could be explained in terms of a dual control of salt 
metabolism. Aldosterone inducing salt retention and the hypothetical 
steroid inducing salt loss, and a balance between them set up for each 
individual. In the subjects 5M and 6M it is proposed that the
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hypothetical steroid plays a lesser role than it does in the other 
four subjects studied.
Experimental results can often be interpreted in more than 
one way. The existence of a salt-losing steroid is one explanation 
of the results presented here, however, any other possible 
explanations must also be considered.
ACTH has been shown to increase the secretion of DHA, DHA.S 
and androstenedione (Chapdelaine et al, 1965a) and the excretion of 
individual D.17-OS. Stress stimulates the release of ACTH. Gross 
variation in salt intake, especially salt loading, might possibly be 
regarded as stressful. Therefore, increases in urinary D.17-08 
levels could be the result of stress from salt loading and decreases 
due to the removal of the stress by changing to low salt intake.
ACTH administration which may in certain respects be equated to stress, 
results in a far greater increase in'urinary 17-OHCS levels than it does 
in 17-OS levels, such that urinary 17-OHCS/17-OS ratio is approximately 
doubled as compared with normal (Table 27). The results of the present 
report indicate that even though individual urinary IX17-0S levels were 
elevated by high salt intake and lowered by low salt intake, the 
urinary 17-OHCS levels did not show the ^ me variation, and in no case 
did the urinary 17-0HCS/l7^0S ratio double or nearly double (Table 28), 
Therefore, the changes observed in the individual urinary D.17-03 levels 
while on varying salt intake cannot be attributed to stress release of 
ACTH.
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Diet has been shown to greatly influence the excretion of 
individual D,17-OS. Cawley et al (1965) studying a single normal 
male and Hendrikx et al (1965) studying 7 obese females lave both 
shown that starvation and low calorie diets cause a marked 
reduction in the excretion of DHA(S+G), A.(S+G) and E.(S+G) and 
Cawley et al (1965) further demonstrated that.starvation had much 
less effect on the excretion of 11-oxy, 17-OS. Unfortunately 
details of salt intake were not available for either of the two 
studies. However, contrary to these two reports Lopez-S & Krehl (1967) 
demonstrated an increased excretion of DHA.(S+G) by 5 young obese 
females when they were placed on a diet restricted in calories and 
very low in carbohydrate.
Thus it may be possible that in the present report the 
changes observed in D.17-OS excretion by the test subjects while they 
were on varying salt intake were through unnoticed changes in calorific 
intake due to changes in the diet necessary to obtain high and low salt 
intake. This reasoning might explain the marked drop in excretion of 
individual D.17-OS shown by subjects 2M & 3M on going from high to low 
salt intake. This reasoning might also explain subject iF’s marked 
increase in DHA.S excretion on changing from a low to high salt intake, 
if low salt intake is partially equated with low calorie intake and 
high salt intake equated with normal diet. In high salt intake the 
supplementary salt was given in the form of tablets. However, the 
idea of calorific intake changing in accordance with salt intake
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does not explain the very marked increase in DHA excretion shown 
by subject 4M on going from salt ad libitum to high salt intake. 
Further, what of the two patients showing very little change in
D.17-OS excretion while on varying salt intake.
If salt dieting or dieting in general does influence the 
excretion of individual D.17-OS, then reconsideration of the results 
discussed in Section V.B. on hypertension are necessary. In 
the studies carried out by Kolbel et al (1965) the patients were 
placed on low purine, low cholesterol diets prior to their studies, 
this being necessary since besides the estimation of urinary DHA, 
S.U.A. and plasma cholesterol levels were also estimated. In the 
studies of Nowaczynski et al (1968) the patients were placed on salt 
diets prior to the estimation of plasma aldosterone and urinary DHA.S. 
In the present studies on hypertension the patients and control 
subjects remained on their normal hospital diets. Is a hospital 
diet a normal diet for all individuals?
Therefore, the low urinary DHA levels in hypertension 
demonstrated by the three reports could be attributed to changes in 
diet. The markedly low urinary DHA levels found by Kolbel et al, 
and Nowaczynski et al, compared with the moderately low DHA levels 
found by the present report could be attributed to the definite 
dietary measures imposed upon the patients by the two former groups 
and the difference between the individually normal and hospital 
diets in the studies of the latter investigation.
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However, the suggestion that the changes in D.17-OS 
excretion induced by varying salt intake were actually due to changes 
in calorific intake, could be considered from a different aspect, 
namely weight reduction. In starvation and low calorie diets there 
is a weight loss which is always associated with marked elevation of 
sodium excretion and further this sodium excretion is associated with 
increased aldosterone excretion, presumably in attempt to maintain 
sodium balance (Haag, Reidenberg, Shannon & Channick, 1967). 
Therefore, if there is a salt-losing steroid and its excretion is 
mirrored by the excretion of D.17-OS, then a decrease in this might 
be expected in starvation and low calorific diet in an attempt to 
maintain salt balance. Thus the decreased excretion of D,17-OS 
shown in starvation and low calorie diets may be due directly to 
salt loss and indirectly to low calorie intake. -The results of 
Haag et al (1967) interrelate weight loss, salt excretion and 17-OS 
excretion along with calorie intake in form of glucose, and 
demonstrated that during starvation there is weight loss concomitant 
with increased sodium excretion, increased aldosterone excretion and 
decreased 17-OS excretion and that glucose, but not fat consumption 
could stop the weight loss and salt loss, and brought about a plateau 
of the falling 17-OS levels. Thus these findings together with the 
fact that D.17-OS, especially DHA and androstenedione are known to 
have some control over the pentose phosphate pathway through 
inhibition of the rate limiting enzymatic step (G-6-P.D.) suggests 
a tie-up among the metabolisms of salt, D.17-OS and carbohydrates.
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E. Individual Urinary D.17-OS Sulphates and Glucuronides:
Values for Male Patients Suffering from Gout.
Urinary D.17-OS sulphate and glucuronide levels and serum uric 
acid levels were estimated in male patients suffering from gout and 
compared with the corresponding levels obtained in Section V.A.3 for 
normal males.
1. Patients studied.
Seven patients with gout were studied. Gouty arthritis was 
diagnosed on clinical grounds with supporting evidence of hyperuricaemia 
defined as a serum uric acid level greater than 7,0 mg/lOO ml. The mean 
age of the patients was 4 3 - 9  years (range 31 - 57). The duration of the 
gout in the 7 patients varied from 3 months to 10 years. Two of the 
patients with the longer standing gout were also hypothyroid and one of 
them was also a mild diabetic. The % overweight of each patient was 
calculated from the tables of Kerns ley et al (1962), on this basis all the 
patients were overweight with a mean % overweight value of 132.6 * 20.8 
(range 110 - 170). One patient was hypertensive with blood pressure of 
220/130 mmHg, All patients had satisfactory renal function as 
estimated by blood urea (mean 32 * 8 mg/.lOO ml) and serum creatinine 
(mean 0.87 - 0.11 rag/100 ml). All patients were on normal hospital
diets and no medication was given for 1 week prior to the study.
2. Analytical techniques.
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2. Analytical techniques.
Collection of blood and urine - Section IV.A.5.
Blood urea and serum creatinine - Section IV,A.2 a & b.
Serum uric acid - Section IV,A .4,
Plasma cholesterol & -glycerides - Section IV,A.3 a & b.
17-OS & 17-OHCS - Section IV.A.6 a & b.
D,17-OS.S & D,17-OS.G - Section IV.0.2,
All estimations were duplicated.
Urinary D.17-OS,S and D,17-06,G levels were 
estimated in 5 0 ml volumes of urine, not 
25 ml volumes.
3. Results.
The urinary levels of the individual D ,17- 06 for gouty males 
are shown in Table 33.
*
. (a) Sulphate conjugates. The values for the individual urinary
D.17-OS sulphates were extremely low and on statistical comparison with 
the values for the normal controls reported in Section V.A. the values 
proved to be significantly very much lower (Table 34). All the steroid 
sulphate values except E.S. had P values of 0.0002 or less.
The urinary D.17-C6.S levels did not show the same degree of 
variation as the normal controls. Inspection of Table 34 indicates 
that the normal controls had standard deviations greater than or equal 
to the respective mean values, whereas in the case of gouty males the
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TABLE 34. COMPARISON OF D.17-OS URINARY LEVELS AND % 
OVERWEIGHT VALUES FOR MALES SUFFERING FROM GOUT 
WITH NORMAL MALE CONTROLS.
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NORMAL MALES 
MEAN ± S.D.
.GOUTY MALES 
MEAN i S.D.
■ P
VALUE
EpiA,S 0.30 ± 0.326 0.026 ± 0.016 0.0002
DHA.S 2.75 ± • 3.75 0.097 ± 0.035 0.001
E.S 0.23 ± 0.212 0.094 ± 0.079 0.066
A.S 0.82 ± 0.838 0.052 ± 0.039 0.0002
DHA. G 0.37 ± 0.365 0.051 ± 0.099 0.001
E.G 2.61 ± 1.36 1.457 ± 1.095 0.028:
A. G 3.05 ± 1.89 1.696 ± 1.925 0.024
DHA.(S+G) 3.12 ± 4.07 0.148 + 0.109 0.0004
E.(S+G) 2,89 ± 1.36 1.551 ± 1.073 0.032
A.(S+G) 3.87 ± 2.46 1.748 ± 1.910 0.010
17-OS
17-OHCS
12.3 ± 4.3
12.7  ^ 3.7
7.1 ± 1.8
11.6 ± 3.2
0.006
0.62
% O.WT. 116 15 132.6 ± 20.8 0.058
standard deviations were all less than the respective mean values.
E.S was quantitatively the most important D,17-OS.S in 4 (57%) 
of the 7 gouty males, whereas this held for only 1 (4.5%) of the 22 
normal controls. Thus for 4 gouty males the urinary excretion pattern 
.was E>DHA>A>epi (fig. 19), whereas in normal males it was DBA>A>epi>E (fig.5). 
The fact that E.S^ i-as the major D.17-CS.S in 4 patients and never the minor
D.17-OS.S in any of the 7 gouty males is possibly related to the fact that, 
of all the D.17-08.S excreted by the gouty males, E.S levels showed the 
smallest deviation from those of normal controls (Table 34).
The E.S/A.S ratios for gouty males were markedly different from 
that of normal males, this is clearly illusbated by comparison of the gas- 
chromatographic tracings for gouty and normal males (figs. 19 & 5).
Gouty males show E>A whereas normal males show very much the reverse with 
A>E. This is further exemplified by the regression equations of E.S on 
A.S f or :-
Normal males E.S = 0.20 A.S + 0.068 = 0.79 P = 0.001
Gouty males E.S = 1.68 A.S + 0.00 - 0.84 P = 0.02
The value of the slopes of the regression lines indicate that more E.S 
was excreted relative to A.S by the gouty males whereas the reverse holds 
for normal males.
(b) G.lucuronide conjugates. The values for the individual urinary
D.17-OS glucuronides were very low when compared with normal controls, 
although excluding E.G, they were not, relative to normal controls, as
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Fig. 19. Gas chromatographic tracing of the D.17-OS sulphate 
fraction obtained from a gouty male urine. 3% QF-1 column at 
200^. A) Androsterone, E) Aetiocholanolone, DHA) Dehydroepi- 
androsterone, epiA) Epiandrosterone and Preg) Pregnenolone all 
as TMSE derivatives.
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low as the urinary D,17-OS sulphates. Also the urinary glucuronide 
levels unlike the D.17-OS.S levels showed more variation about their 
respective mean values than did the corresponding values for the 
normal controls.
The urinary E.G/A.G ratios showed no definite pattern, 4(57%) 
of the 7 patients showed E.G as their major steroidglucuronide while 
the other 3 showed A.G to be their major steroid glucuronide. Of the 
seven patients, the patient who also suffered from hypertension 
(No.6, Table 33) showed the expected elevated E.G/A.G ratio for a 
hypertensive patient. However, of the 2 gouty males with hypo­
thyroidism (No.2 & 3, Table 33) only patient No, 2 showed an elevated
E.G/A.G ratio with a markedly high value (2.3). Patient No.3 had 
normal E.G/A.G ratio (0.59), but very low urinary levels of both 
A •G and E.G.
(c) Sulphate plus glucuronide conjugates. They showed exactly the 
same pattern as that shown by the urinary D,17-OS glucuronides.
(d) Discriminant function analysis. This was carried out as 
described in Section IV.D.4. For ©ch of the two groups, gouty males
and normal males, values for 14 variable 17-OS, 17-OHCS, epiA.S, DHA.S,
E.S, A.S, DHA.G, E.G, A.G, DHA.(S+G), E.(S+G), A,(S+G), (epiA.+DHA+E+A).S , 
(DHA+E.+A).G were tabulated and statistically compared using a simple 
test of significance (t-test or U-test). The three variables showing 
the most significant differences - epiA.S, A.S and (epiA.+DHA+E+A).S 
were employed in thé discriminant function analysis. Complete 
discrimination between the two groups was obtained.
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Discussion.
Of the 3 previous investigations on the levels of urinary 
17-OS in gout, 2 found decreased levels while the other one found 
normal levels. Wolfson et al (1949) the first to investigate
urinary 17-OS in this disease found very low levels, well below the lower 
limits of their normal controls. In addition to this, two gouty females 
included in the study had urinary 17-OS levels of less than 1 mg/24 hr.
From these results Wolfson et al concluded that the 17-OS deficiency was 
of an adrenal origin and in their opinion the investigation excluded 
hyperuricaemia and arthritides as causitive factors of this deficiency 
since normal 17-OS urinary levels were found in both iion-gouty hyper­
uricaemia and mild rheumatoid arthrites. ' Robinson et al (1949) 
confirmed the findings of Wolfson et al (1949), however, although they 
obtained urinary 17-03 levels that were low, they were still within 
the lower limits of normal.
The more recent studies of Sonka et al (1964) and the present 
report, both confirm the earlier findings of Wolfson et al (1949).
Sonka et al (1964) besides confirming the earlier results demonstrated 
that the low 17-OS urinary levels found in gout were the result of 
total absence from the urine of DHA. They reported zero urinary levels 
of DHA in 26 male gouty patients and a mean DHA level of 2.5 * 0.46 mg/24 hr 
in normal individuals. Unlike Wolfson they associated the high S.U.A. 
levels found in gout with the absence of urinary DHA. The validity of 
this association they based on the following: 26 hyperuricaemia gouty
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patients all showed an absence of urinary DHA; 4 non-gouty arthritic 
patients with uric acid stones had hyperuricaemia concomitant with an 
absence of urinary DHA; 3 non-gouty non-arthritic patients with uric 
acid stones had normal S.U.A- and normal urinary DI%. levels; one gouty 
patient with normal S.UA levels had normal urinary DHA levels. Other 
studies by the same group of investigators on hypertension also 
substantiate the association of hyperuricaemia with an absence of urinary 
DIA (Kolbel et al, 1964 and Kolbel et al, 1965a).
Later studies on urinary DHA levels in gout by Beck et al (1967) 
also demonstrated a urinary DHA deficiency. However, their results 
were not as "clear cut" as those of Sonka et al (1964) . Beck et al (1967) 
found no DH^ in 7 (54%), a trace in 4 (31%) and normal amounts in 2(15%) 
in a study of 13 gouty male patients. Unfortunately they did not report 
S.U.A levels, but it is presumed that all the patients were hyperuricaemic 
since they further reported that 4 arthritic, but normouricaemic patients 
had low urinary DHA levels and that only one such type of patient had 
normal urinary DHA levels. Results which, therefore, do not lend support 
to an association between hyperuricaemia and an absence of urinary DHA.
The present report which provides the only available data on the 
urinary -levels of individual D.17-OS sulphates and glucuronides in this 
disease supports within limits both the findings of Sonka et al (1964) 
and Beck et al (1967), In the present report it was found that the 7 
gouty males studied had very low urinary DHV.(S-fÔ) levels, but in none 
of their urines was it not detectable. As a group the urinary DHA(S-Hl)
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levels were significantly much lower than normal controls (P = 0.0004), 
but a more dramatic difference was demonstrated for urinary DFA .S levels, 
where normal controls had a mean level of 2.75 mg^24 hr, whereas that for 
the gouty group was only 0.097 mg/24 hr.
Despite these highly significant differences the unique feature 
of the gouty males in relation to D,17-OS levels was not just the very 
low levels of DHA, but the fact that all the D.17-C6 sulphates were 
present in extremely small quantities. In fact, utilising the 
variables epiA.S, A.S and (epiA+DîA+E+A) .3 complete discrimination 
between normal individuals and gouty patients was possible.
With minor reservations, that is, the difference between zero 
and very small amounts, the results of the present report agree with 
those of Sonka et al (1964) with respects to urinary DHA. However, 
this is not so when A and E are considered. Sonka et al (1964) found 
normal levels of urinary E.(ShG) in gouty patients whereas by the 
present report both steroids were present in diminished amounts both as 
the sulphate and as the glucuronide conjugates. Thus, obviously the 
values for E.(ShG) and A.(S-fG) were also low, their differences from 
normal were significant at 3% and 1% levels respectively.
What is the meaning of the markedly low urinary D.17-OS levels, 
especially the D.17-CS.S levels, found in gout?
In all 7 cases of gout studied there was very low urinary 
DHA.S levels and in all 7 cases the S.UA levels were elevated. This
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would appear to support Sonka et al (1964) theory of an association 
between hyperuricaemia and an absence or very low urinary DHA levels. 
However, this is invalidated when the hyperuricaemic normotensive 
subjects of Section V.A. and the hyperuricaemic hypertensive patients 
of Section V.B. are considered. In both these sections it was 
demonstrated that there was no obvious association between hyper­
uricaemia and low urinary DHA levels, further there was no correlation 
between S.U.A. levels and urinary DtA levels. Also the results 
in Section V.A. & B . shows that low urinary DHA levels are often 
present in individuals with normal S.U.A. levels, for example, Table 7 
lists the following values for normal males.
DHA.(S-K?) mg/24 hr S.U.A. mg%
Patient 17 0.13 5.3
Patient 18 0.10 5.8
Similarly, Table 14 lists the following values for idiopathic hyper­
tensive males.
DBA . (S+G) mg/24 hr S.UA. mg%
Patient 7 0.11 5.0
Patient 17 0.05 5.4
Thus contrary to the results of Sonka et al (1964) and confirmatory 
with those of Beck et al (1967), hyperuricaemia does not appear to be 
in close association with low urinary DHA levels.
Duration of gout does not appear to influence the urinary
249
D.17“ es.S levels. For example, two of the 7 gouty patients studied 
had suffered from gout for 3 months and 12 years respectively, yet 
both had very low urinary D.17-0S.S levels and of the two the former 
patient had the lower urinary D.17-CS.S levels,
Sonka et al 0964) reported that gouty patients produced 
significantly more urine than normal controls. In Section V.A. 
significant correlations between urine volume and individual D.17-CB 
urinary levels in normal females was demonstrated. Therefore, it 
was decided that closer inspection of this observation was merited.
However, by the present report there was no correlation between
urine volume and the individual D.17-OS urinary levels, nor was there 
any difference between urine volumes of gouty males (157 0 ml) and 
normal males (1467 ml).
Numerous investigators have reported the close association 
between gout and obesity (Getler, Garn & Levine, 1951; Sonka et al, 1964; 
Benedek, 1967 and Barlow, 1968). The present report supports these 
findings, a significant difference being observed between normal and
gouty males for % overweight values ( P ” 0. C58) .
This association is of further interest in that lopez-S & Krehl
(1967) while studying urinary DHA levels in a series of obese individuals 
graded by increasing % overweight from 0 - 160%, demonstrated a decrease 
in urinary DîA levels which were inversly related to an increase in % 
overweight. Also Hendrikx et al (1965) reported significantly lower 
urinary E and A levels, expressed as mg/100 Kg/24 hr, when comparing
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values for obese females with those for normal females. Both studies 
would suggest that urinary D.17-OS studies in obesity may be of importance 
in attempting to explain the abnormally low urinary D.17-0 8 levels found 
in gout; that is, overweight may be the link between gout and low urinary 
D. 17- CS levels .
On the basis of this premise, the 22 normal male controls were 
divided into two groups according to % overweight (Table 35), and the 
values for each of the 10 individual D.17-08 urinary levels of the two 
groups statistically compared. No significant difference between the 
two groups for any of the 10 variables could be demonstrated nor could 
a significant correlation be demonstrated between any of the individual 
D.17-CS urinary levels and % overweight when treated as two groups or 
as one combined group. Further although the 7 gouty males studied 
were all overweight (mean % overweight 32.6 ± 20.8) and they all excreted 
very small quantities of D.17-08, their % overweight values showed no 
significant correlation with the D.17-03 urinary levels.
However, it must be emphasised that in the present study the 
7 gouty males and the overweight normal males involved were not nearly 
as obese as the subjects studied by Lopez-S & Krehl and Hendrikx et al, 
and therefore the influence of overweight on the individual D.17-08 
urinary levels might not be significant except in really obese individuals. 
Consideration of the results of Lopez-S & Krehl shown below will illustrate 
this point.
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DHA mg/24 hr.
No. Patients MEAN ± S.E.M.
18 1,13 ± 0,05
9 1 .08 ± 0,03
7 0,90 ± 0 .0 1
7 0,63 ± 0 ,0 2
6 • 0,75 ± 0 .0 1
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% Overweight 
0 -  20 
20 - 50
50 - 80
80 - 120 
120 - 160
Therefore, although obesity does appear to influence the urinary DHA 
levels it does not affect them as markedly as would be necessary to 
explain the very low urinary DHA levels found in gout.
Recently there has been much interest in the inter-relationships 
of gout and hyperlipidaemia. (Berkowitz, 1966; Hansen, 1966; Benedek, 1967 
and Barlow, 1968). The latter investigator, through comparing the serum 
concentration of various lipids in healthy normals and in patients with 
atherosclerosis obtained criteria for defining hyperlipidaemia. By 
applying these criteria to the serum lipid results obtained for the gouty 
patients he showed that as many as 77% of gouty patients were hyper- 
lipidaemic, yet only 15% at that time showed evidence of atherosclerosis.
Thus, the high incidence of hyperlipidaemia in gout could possibly 
be of importance in the interpretation of the very low D.17-OS.S levels 
found in gout. Of interest in this respect are the studiescf Heilman et 
al (1958a,b) in myxoedema, a condition characterised by hypercholesterolaemia. 
They reported very low urinary levels of E and A together with elevated 
urinary E/A ratios. Further, Heilman et al associated the hypercholestero­
laemia found in this disease with the very low urinary A levels and demonst­
rated that parentally administered A was an effective hypocholesterolaemic 
agent/..
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when administered to normocholesterolaemic patients as well as to 
hypercholesterolaemic patients. This work was subsequently
confirmed by Cohen et al (1961) and Furman & Howard(1962). In
support of this is the evidence that another D.17-OS (DHA) has
been shovm to have a hypocholesterolaemic effect when administered 
orally to rats rendered hypercholesterolaemic by propylthiouracil 
treatment (Ben-David et al, 1967). Finally Kotasek et al (1967) 
demonstrated low urinary DHA levels in women with toxaemia of 
pregnancy,.a condition characterised by elevated phospolipids 
and g-lipoproteins (Boyd, 1935, and Kotasek et al, 1965).
Thus there would appear to be a causal relationship between
plasma lipids and D,17-OS levels particularly for A and DHA, which 
is often manifested as patients with elevated plasma lipids con­
comitant with low urinary D.17-OS levels.
Unfortunately, plasma lipid values for only 4 of the gouty 
patients studied are available. These are presented below, together
with the corresponding D.17-OS urinary levels (mg/24 hr).
^•PLASMA LIPIDS DHA epiA E A
CHOL. GLY. S
G S S G S G
*2 458 384 0,047 0 .0 0 0 0.041 0.175 1.130 0.047 0.490
4 213 288 0,163 0.048 0.014 0.025 1.960 0.023 1.150
5 374 249 0.098 0 .0 0 0 0.029 0.216 1.440 0.133 1.051
6 236 260 0.105 0 .0 0 0 0 .000 0 .0 10 3.540 0 .0 10 5.700
* Refers to numbers given to patients as in Table 33.
$ Normal male plasma lipids - cholesterol (Choi). - 15-250 mg/100 ml
- glycerides (Gly) . - 80-150 mg/100 ml
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All four of the gouty males were hyperglyceridaemic and two of them 
also hypercholesterolaemic, and as demonstrated in the result section 
all 7 have exceptionally low D,17-OS levels and especially low sulphate 
levels. Thus the evidence, though only in 4 cases is 100% in support 
of a relationship between elevated plasma lipid levels and low 
urinary D,17-08.S levels.
On the basis of the above evidence it was decided to compare the 
urinary D.17-OS levels of normolipidaemic individuals with those of 
hyperlipidaemic individuals. In this study which is presented in the 
next section, it was attempted to standardise the other two factors 
which might also be implicated with low urinary D.17-0S levels, namely 
over-weight and elevated S.U.A. levels.
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F, Individual Urinary D.17-OS Sulphates and Glucuronides:
Values for Normolipidaemic and Hyper lipid aeinic Males.
Urinary D.17-OS sulphate and glucuronide levels were estimated 
in normolipidaemic males, and the results compared with those for 
hyperlipidaemic males, Normolipidaemia was defined as plasma glyceride 
levels of less than 15 0 mg/100ml and hyperlipidaemia as plasma glyceride 
levels of greater than 210 mg/100ml.
1, Subj ects s tudied.
Twenty male subjects were studied, 13 normolipidaemic and 7 
hyperlipidaemic. The mean plasma lipid levels for the normolipidaemic 
males were glyceride 126 - 25 mg/lOOml, cholesterol 229 - 38 mg/100ml, 
and phospholipids 234 * 28 mg/ 1,00ml and for the hyperlipidaemic males 
the values were glyceride 327 * 75 mg/lOQnl, cholesterol 316  ^ 78 mg^lCOml, 
phospholipids 317  ^ 52 mg/ 100 ml.
The normolipidaemic group consisted of 9 normal subjects, 3 
idiopathic hypertensive patients and 1 patient recovering from a myocardial 
infarction. The hyperlipidaemic group consisted of 5 patients recovering 
from myocardial infarction and 2 idiopathic hypertensive patient. The 
mean age of the normolipidaemic group was 49-7  years (range 40 - 59) and 
for the hyperlipidaemic group was 48 * 7 years (range 40 - 59). The two 
variables, % overweight and serum uric acid, referred to in the last 
section were:-
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Normolipidaemic. Hyperlipidaemic. 
mean * S.D. mean ± S.D.
S.U.A.mg%. 5.1 ±. 1.0 5.0 ± 0.9
% overweight 13 ± 1 . 3  23 ± 1.1
The attempt to control the weight variable was not successful.
However, when the results of the study of Lopez-S & Krehl (1967)
referred to in the last Section are considered, it is realised that
a difference of 23 - 13 = 10% overweight should have little influence
on the urinary DHA levels.
All the subjects had normal renal function as estimated by 
blood urea and serum creatinine except for one normolipidaemic patient 
with a serum creatinine of 1.5 mg/100 ml. All subjects were on normal 
or hospital diets and none were taking or being given medication of any 
sort for one week prior to the study.
2. Analytical techniques.
' Collection of blood and urine
Blood urea & serum creatinine
Serum uric acid
Plasma cholesterol, phospho­
lipids and glycerides
17-OS & 17-OHCS
D,17-OS.S & D.17-OS.G
Section IV.A.5.
Section IV.A.2 a & b. 
Section IV,A.4.
Section IV.A.3 a,b & c . 
Section IV.A . 6 a & b . 
Section IV.C.2.
All analysis were duplicated.
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3. Results.
The urinary levels of the individual D,17-OS together with 
the plasma lipid levels for normolipidaemic and hyperlipidaemic males 
studied are shown in Tables 36 & 37 respectively. The values are 
listed in order of increasing age of the subjects studied. In both 
cases there is a wide range of values for all the urinary D.17-OS, 
though not nearly as wide as was found for normal males (Section V.A., 
Table 7). This disparity is probably due partly to the fact that 
in both Section V,A and the present Section the excretion of D.17-OS 
correlates negatively with age. Therefore, a difference in the 
ranges of urinary D.17-OS urinary levels would be expected since the 
normolipidaemic and hyperlipidaemic males ages range from 40 - 60 years 
whereas in normal males the ages range from 29 - 69 years.
A statistical comparison between the urinary D.17-OS and the 
plasma lipid levels for normolipidaemic and hyperlipidaemic males is 
shown in Table 38. Although the subjects studied were divided into 
two groups on the basis of their plasma glyceride levels, it is obvious 
that the plasma phospholipid, total plasma lipids (cholesterol + glyceride 
+ phospholipid) and to lesser extent cholesterol show equally large 
statistical differences. However, inspection of the actual values 
in Tables 36 & 37 shows that complete discrimination into two groups 
by a single lipid parameter can only be achieved by employing plasma 
glyceride levels.
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TABLE 38. COMPARISON OF INDIVIDUAL D.17-08 URINARY
AMD PLASMA LIPID LEVELS OF NORMOLIPIDAEMIC 
AND HYPERLIPIDAEMIC MALES.
Normolipidaemic 
Males 
MEAN ± S.D.
Hyperlipidaemic 
Males 
MEAN i S.D
P
VALUE
epiA,S 0.16 ± 0.16 0.06 ± 0 .06 0.052
DHA.S 1.48 i. 1.27 0.56 ± 0.39 0 .1 0
E.S 0,19 ± 0,16 0,09 ± 0,07, 0,074
A.S 0.59 ± 0,48 . 0 ,2 0 ± 0 ,2 2 0 .0 1
DHA.G 0.28 ± 0,26 0.17 + 0.19 0 ,4 8
E.G 2.08 ± 0 .8 6 1.65 ± 1.17 0.42
A.G 2.14 ± 1,36 1.24 ± 0.63 0.08
DHA.(S+G) 1.74 ± 1.50 0.73 ± 0.47 0 .1 2
E.(S+G) 2,26 ± 0,91 1.74 ± 1.23 0.28
A.(S+G) 2.73 ± 1.61 1,44 ± 0.81 0.029
PHOSPHOLIPIDS 234 ± 28 317 ± 52 <0.0005
CHOLESTEROL 229 ± 38 316 + 78 <0 .002
GLYCERIDES 126 ± 25 323 ± 75 <0.0005
TOTAL LIPIDS 589 ± 70 952 ± 162 <0.0005
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(a) Sulphate conjugates. The urinary D.17-OS.S levels for 
normolipidaemic males were all significantly higher than the 
respective values for hyperlipidaemic males, and of these A.S was 
significantly higher at the 1% level. On quantitative comparison 
of the mean urinary D.17-OS,S levels, DHA.S showed the greatest 
difference (1.48 - 0,56 = 0.92 mg/24 hr). However, despite this, 
the difference between the DHA.S levels of the two groups was only 
significant at the 10% level.
In both groups the major steroid sulphate was DHA, In the 
normolipidaemic group this applied to 11 (85%) subjects, in the other 
2 (15%), a normal male and an idiopathic hypertensive male, A was the 
major steroid sulphate. Of the above 11 subjects, 10 showed the 
typical D.17-OS.S urinary excretion pattern for normal males, namely 
DHA>A>epiA>E. In the other group which was predominantly patients 
recovering from myocardial infarctions there was no typical D.17-OS.S 
excretion pattern, the only semi-consistent feature was DHA.S as the 
major steroid sulphate in 6 (86%) of the group.
(b) Glucuronide conjugates. All the D,17-OS.G were excreted in 
greater amounts by the normolipidaemic males but A.G was the only
D.17-OS,G excreted in amounts significantly greater (P - 0.08) than 
that by the hyperlipidaemic group.
In the normolipidaemic group E.G was the major steroid 
glucuronide in 7 (54%) and A.G in the other 6 (46%). Similarly, in 
the hyperlipidaemic group E.G was the major steroid glucuronide in 
4(57%) and A.G in the other 3 (43%),
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(c) Sulphate and glucuronide conjugates. Like the D,17-OS 
glucuronide levels the mean urinary levels of the D ,17“0S,(S+G) were 
higher for the normolipidaemic group, with A.(S+G) showing a significant 
difference between the two groups (P - 0,029), The urinary excretion 
of the D.17-OS,(S+G) like the D.17-OS.G showed no definite pattern in 
either group.
(d) Correlations. Correlation coefficients (Section IV.D,2) were 
calculated by computer for any combination of 2 of the 31 variables 
collected for all the subjects. The variables involved were age; 
serum uric acid; serum creatinine; blood urea; urine volume;
height; surface area; weight; % overweight; systolic blood pressure; 
diastolic blood pressure; mean blood pressure; total 17-OS; total 
17-OHCS; epiA.S; DHA.S; E.S; A.S; DHA.G; E.G; A.G; DHA.(S+G);
E.(S+G); A,(S+G); (epiA. + DHA + E + A),S; (DHA + E + A),G;
(epiA. + DHA + E + A),S+G; plasma phospholipids; plasma cholesterol; 
plasma glycerides and total plasma lipids (phospholipids + cholesterol 
+ glycerides). Correlation coefficients for the most highly correlated 
of the 31 variables are shoim. for normolipidaemic and hyperlipidaemic 
males in Tables 39 & 40 respectively. Correlation coefficients 
significant at the 5% level or less are underlined.
Like the normal males (Section VA, Table 10) the age of the 
normolipidaemic males showed extensive negative correlations with the 
excretion of individual D,17-08 and total 17-OS (Table 39). The 
hyperlipidaemic males showed the same trend, however in no case was 
the correlation statistically significant.
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With respect to the relationships of S.U.A levels - urinary 
D.17-OS levels as seen in gout# and hypertensives. (Sonka et al, 1964 
and Kolbel et al, 1964, 1965a), and % overweight - urinary DHA levels 
as seen in obesity (Lopez-S & Krehl, 1967) the results shown in 
Tables 39 & 40 lend little or no support. Of the normolipidaemic 
and hyperlipidaemic males neither of their DHA levels exhibited a 
correlation with S.U.A levels. However, the hyperlipidaemic group
displayed a negative correlation for E.G versus S.U.A, (r ~ -0.79, 
P<0.05). Similarly for % overweight versus DHA levels, there were 
no significant correlations, although there was a significant 
positive correlation (r = 0.75, P<0.05) between % overweight and 
urinary 17-OS levels for hyperlipidaemic males,
Like the normal males (Table 10) both the normolipidaemic 
and the hyperlipidaemic males showed a marked degree of intercorrelation 
between the individual D.17-OS,
However of greatest interest was the marked and extensive 
negative correlations between plasma glyceride levels and certain 
individual urinary D. 17-OS for hyperlipidaemic individuals. These 
negative correlations were as significant as the positive correlation 
demonstrated for plasma glyceride levels versus plasma phospholipid 
levels, two understandably interdependent variables, since both 
incorporate fatty acid molecules in their respective biosynthesis.
The negative correlation between plasma glyceride levels and urinary
D.17-OS levels held for all the D.17-OS sulphates and glucuronides
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except DHA.S and DHA.G. The highest correlation was for E.G 
versus plasma glyceride (r = -0.83, P = 0.02), this negative 
correlation is appreciated by the mere appraisal of the values 
for the two variables.
Urinary E.G levels. Plasma glyceride levels.
mg/24 hr. mg /10 0 m l . _____
20 371
670 436
1300 358
2130 330
1220 281
2040 275
3850 208
(e) Discriminant function analysis. This was carried out as 
described in Section IV.D.3. For each of the two groups, normo­
lipidaemic and hyperlipidaemic males, values for 14 variable - 17-OS; 
17-OHCS; epiA.S; DHA.S; E.S; ' A.S; DHA.G; E.G; A.G; DHA.(S+G);
E.(S+G); A.(S+G); (epiA +DHA + E + A).S and (DHA + E + G).G. were 
tabulated and statistically compared using a simple test of 
significanct (t - test or U - test). The three variables showing 
the most significant differences epiA.S, A.S and A.(S+G) were employed 
in the discriminant function analysis. Employing these three 
variables it was possible to discriminate between hyperlipidaemic 
and normolipidaemic males, for all but one individual, an 
idiopathic hypertensive in the normolipidaemic group (Patient 10,
Table 36) who fell within the elipsoid surrounding the hyperlipidaemic 
group.
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4. Discussion.
The object of this study was to determine, if the expected 
differences between the urinary D.17-OS levels for hyperlipidaemic 
and normolipidaemic males were real or unreal, that is, to test the 
hypothesis based on the results for gouty males.
A real difference was found. The D,17-OS.S urinary levels 
of the hyperlipidaemic group were much lower than the respective 
levels of the normolipidaemic group, especially in the case of A.S 
where the difference was significant at the 1% level. Similarly 
A.G and A.(S+G) urinary levels showed significant differences at the 
8% and 3% levels respectively.
Comparison of the above differences, with respect to steroids 
involved and level of significance, with those found for gouty males 
relative to normal controls would further test the hypothesis.
Inspection of Table 34 (gouty versus normal males) and Table 38 
(hyperlipidaemic versus normolipidaemic males) shows certain similarities. 
Both test groups show lower D.17-OS,S levels than the respective control 
groups and in both cases epiA.S and A.S show the most significant 
differences. Also in both cases A.G and A.(S+G) in both studies 
showed significant differences. The only disparity is that the gouty 
males showed lower levels of DHA.G and DHA.(S+G) relative to the control 
group whereas this difference was not manifested by the other study.
Though the steroids involved are the same, the levels of 
significance of the differences shown in the two studies is not. The
263
P values in the gout study were much lower, due simply to the fact 
that the urinary D,17-OS levels in the gouty males were much lower 
than those for the hyperlipidaemic males and that the values for 
the normolipidaemic male controls were lower than the respective 
values for the normal controls of the gouty males.
The above consideration of the results of the two studies 
supports the hypothesis of a relationship between low urinary 
D.17-OS levels and elevated plasma lipid levels, but does not 
explain why gouty males have such low^urinary D,17-OS levels, 
markedly lower than the respective values for the hyperlipidaemic 
males, This disparity might be in some way related to the markedly 
elevated S.U.A levels or the obesity normally found in gout, though 
as previously stated this explanation is doubtful since by the 
present report there is no significant correlation between either 
urinary D,17-OS levels and hyperuficaemia or D,17-OS levels and 
obesity. However, a strong negative correlation between plasma 
glyceride levels and urinary D.17-OS levels has been demonstrated 
for hyperlipidaemic males. Thus, by the present report, the plasma 
lipid levels, unlike the levels of the other two variables S.U.A 
and % overweight may be influenced by the excretion rate of certain 
D.17-OS, Plasma glyceride the lipid in question is elevated in 
gout (Berkowitz, 1964, 1966 and Feldman & Wallace, 1964), therefore 
this may be a common variable in gout and hyperlipidaemia, the elevation 
of which may be a direct result of low D.17-OS urinary levels in both 
diseases.
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The normolipidaemic males- did not show any significant 
correlations between plasma lipid levels and D.17-OS urinary levels, 
which is contrary to the Hndings of Sonka, Fassati, Gregorova & Picek
(1968) who found that serum lipid levels (cholesterol, phospholipids, 
^-lipoproteins and free fatty acids) were negatively correlated with 
urinary DHA levels in healthy blood donors. However, they suggested 
that the correlations were more a function of the dependence of DHA 
excretion and serum lipid levels on age than a direct inverse 
relationship between urinary DHA and serum lipid variables. But, 
despite this the authors still advocated a causal relationship 
between DHA and lipid synthesis, and by manipulation of their results 
they presented evidence. They divided the group of healthy blood 
donors (47 men, 47 females) into two groups according to urinary DHA 
level, "DHA excretors" (mean 1.44 mg/24 hr, mean age 34 years) and 
"DHA nonexcretors" (mean 0,08 mg/24 hr, mean age 40 years). The 
serum lipid levels were significantly lower, cholesterol (P<0.005), 
phospholipids (P<0.025) and free fatty acids (P<0.05) in the "DHA 
nonexcretors" compared with the "DHA excretors".
The above procedure utilised by Sonka et al (1968) whereby 
the normal group was divided into two, according to their urinary 
DHA levels, and then differences in plasma lipids sought, is exactly 
the same as that for the present exercise except in reverse, that is, 
division according to plasma lipid levels and then differences in 
urinary D.17-OS levels sought. By both procedures significant 
results were found, both therefore, strongly supporting a relationship
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between plasma lipids and urinary D.17-OS.
The discriminant function analysis presented further support 
of a plasma lipid - urinary D.17-OS relationship in that by employing 
only three variables epiA.S, A.S and A.(S+G) it was possible to 
discriminate between hyperlipidaemic and normolipidaemic males for 
all but one individual, an idiopathic hypertensive patient (patient 1 0, 
Table 36) in the normolipidaemic group, who fell within the elipsoid 
of the hyperlipidaemic group. This patient although normolipidaemic 
had steroid levels more in keeping with the hyperlipidaemic males,
epiA.S DHA.S E.S A.S ,DHA.G E.G A.G 
Patient 10 0.07 0.46 0.18 0.11 0.09 1.75 1.22
Hyperlipidaemic
males (mean) 0.06 0.56 0.09 0.20 0.17 1,65 1.24
Normolipidaemic
males (mean) 0,16 1.48 0.19 0.59 0.28 2.08 2.14
and in addition to this patient 10 had a % overweight value of 34%, 
the highest value in that group and, therefore, more suited to the 
hyperlipidaemic group.
Thus the hypothesis of a plasma lipid - urinary D,17-OS 
relationship seems well founded, but obviously requiring further 
confirmatory evidence. It was, therefore, decided to study urinary 
levels in myocardial infarction, since the majority of the males in 
the hyperlipidaemic group were males recovering after a myocardial 
infarction and since numerous other investigators have demonstrated
271
a high incidence of hyperlipidaemia in myocardial infarction 
(Morrison et al, 1948; Getler & Garn, 1950; Steiner et al, 1952; 
Albrink, Meigs & Man, 1961; Albrink, 1962; Getler, White, Cady & 
Whiter, 1964; Benedek, 1967 and Kuo, 1968),
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G. Individual Urinary D.17-OS Sulphates and Glucuronides:
Values for Male Myocardial Infarct Patients.
Urinary D.17-OS sulphates and glucuronides levels were 
estimated in male patients recovering after a myocardial infarction 
and compared with the corresponding levels in normal males as 
reported in Section V.A.3,
1. Patients studied.
Fifteen male patients all recovering after a myocardial 
infarction were studied. The myocardial infarction was diagnosed 
by clinical examination, electrocardiographic findings and serum 
glutamic - oxaloacetic transaminase levels. The mean age of the
patients was 48 * 6 years (range 42 - 56). The % overweight of
each patient was calculated from the tables of Kemsley et al (1962), 
the mean % overweight value was 114 - 9 (range 100 - 127). None 
of the patients had elevated blood pressure and all had satisfactory 
renal function as estimated by blood urea (32 * 6 mg/100 ml) and
serum creatinine (0.89 * 0.10 mg/100 ml). All patients were on
normal hospital diets and no medication was given for 3 days prior 
to the study.
2. Analytical techniques.
Collection of blood and urine - Section IV.A.5.
Blood urea and serum creatinine - Section IV.A.2 a & b .
Serum uric acid - Section IV.A.4.
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(Analytical techniques continued):
17-OS & 17-OHCS - Section IV.A, 6 a & b.
D.17-OS & D.17-OS,G - Section IV.C.2.
All estimations were duplicated.
3. Results.
The urinary levels of the individual D.17-OS sulphates 
and glucuronides for the 15 male myocardial infarct patients are 
shown in Table 41,
(a) Sulphate conjugates. The urinary levels of the individual 
D,17-OS sulphates for myocardial infarct males, were lower than the 
respective levels found in the normal males controls (Table 42).
With the exception of E.S the steroid sulphate conjugates 
were excreted in significantly lower amounts by the myocardial 
infarct patients and in the case of A.S the difference was significant 
at the 0.03% level,
DHA.S, as in normal males, was quantitatively the most 
important D.17-OS,S in 73% of the myocardial infarct patients. But 
unlike normal males, for whom the typical urinary D,17-OS,S excretory 
was DHA>A>epiA>E, the myocardial infarct patients showed no typical 
pattern other than DHA>A, epiA or E and that in 73% of the patients 
epiA was the minor steroid sulphate excreted. However, despite 
this lack of obvious pattern, the E.S/A.S ratios for the myocardial 
infarct patients were consistently higher (P = 0.0028) than those
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t a b l e 42. COMPARISON OR INDIVIDUAL D.17-OS URINARY
LEVELS FOR MALE MYOCARDIAL INFARCT PATIENTS 
WITH NORMAL MALE CONTROLS.
NORMAL 
MEAN ±
MALES
S.D MEAN ± S.D
P
VALUE
epiA. S 0.30 + 0.326 0,07 ± 0.06 0.091
DHA.S 2.75 ± 3.75 0.56 + 0.51 0 .0 1.
E.S 0.23 ± 0.212 0.17 0.14 0.52
A.S 0.82 ± 0.838 0 .2 2 ± 0 .1 2 0.0003
•DHA.G 0.37 + 0.365 0.18 ± 0.13 0.19
E.G 2.61 ± 1.36 1.78 ± 0.98 0.07
A.G 3.05 ± 1.89 1.31 ± 0.64 0.001
DHA.(S+G) 3.12 ± 4.07 0.75 ± 0.56 0.03
E.(S+G) 2.89 ± 1.36 1.95 ± 1.05 0.07
A.(S+G) 3.87 ± 2.46 1.53 ± 0.69 0,0004
17-OS 12.3 ± 5.3 8.5 ± 3.0 0.03
17-OHCS 12.7 ± 3.7 10,7 ± 2 .8 0.084
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for normal males (fig.20a). Similarly for E.S/epiA.S ratios which 
were also significantly higher at the 0.28% level.
(b) Glucuronide conjugates. The urinary D,17-OS,G levels for the 
myocardial infarct patients were low compared with the normal controls 
(Table 42), and were significantly lower in the case cf A.G and E.G
(P = 0.001 and P = 0.07 respectively).
In the myocardial infarct patients E.G was the major steroid
I
glucuronide in 73% and A.G in the other 27%. Thus the typical 
urinary excretory pattern of the steroid glucuronide conjugates for 
the myocardial infarct patients was E>A>DHA, whereas in normal 
controls it was A>E>DHA. The E.G/A.G ratios of the infarct group 
was significantly higher (P = 0.014) than the same ratios for normal 
controls (fig, 20b).
(c) Sulphate plus glucuronide conjugates. Like the D.17-OS.G 
levels the urinary D .17-OS,(S+G) levels for the myocardial infarct 
patients were low compared with normal controls, in fact, relatively 
they were much lower with A.(S+G) significantly lower at the 0.04% 
level,
E was the major D.17-OS excreted by 66% of the infarct group, 
whereas in the control group it was A (46%) followed by E (27%) and 
DHA (27%). The difference between the urinary E .(S+G)/A.(S+G) 
ratios for the two groups was highly significant (P = 0.002, fig,20c).
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4. Discussion.
There is very little previous work on urinary steroid levels 
in myocardial infarction. Marmorston, Lewis, Bernstein, Sobel, Kuzma, 
Alexander, Magidson & Moore (1957) estimating urinary 17-OS in this 
disease found levels markedly decreased in male patients. Their 
findings were later confirmed and extended by Garrett, Creech, Horning 
& DeBakey (1962), who estimated DHA, E and A in both the sulphate and 
glucuronide fractions in urine from a group of atherosclerotic patients 
which included individuals with myocardial infarcts. Their results 
though of great interest, were unfortunately completely lacking in 
normal control values.
They studied individual urinary D.17-OS levels in 20 athero­
sclerotic patients (8 with myocardial infarcts) prior to surgical 
treatment and in another 20 atherosclerotic patients (5 with myocardial 
infarcts) 6 months to 3 years following surgical treatment. No normal 
subjects were studied. Their results in both groups, that is pre and 
post-operative, were very similar to the results of the present study:-
epiA.S DHA.S E.S A.S DHA. G E.G A.G
Present study N 0.30 2.75 0.23 0.82 0.37 2.61 3.05
M.I 0.06, 0.70 0 .20 0.24 0.18 1.60 , 1.30
Garrett et al A — 0.3 0 .2 0.3 — 2.7 1 .2
N “ Normal. M.I. = Myocardial Infarction. A = Atherosclerosis. 
Not only, are the results of Garrett et al (1962) very similar to those
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of the present study in that the urinary D.17-OS levels are very low 
in both studies but also with respect to the excretion of E.G relative 
to A.G and the excretion of E.S relative to A.S. Garrett et al (1962) 
results indicate that 95% of the atherosclerotic patients studied had 
values for E.G > A.G, this compares favourably with 73% for present 
study and contrasts markedly with 34% for normal males. Similarly for 
urinary E.S/A.S ratios Garrett et al (1962) and present study found 65 
and 66% respectively of patients to have E.S/A.S ratios greater than 
0,5 whereas this held for 18% of the normal males. A unique feature 
emerging from both studies is the fact that in vascular disease 
urinary E.S levels are not depressed.
Some of the above findings in both studies bear a strong 
resemblance to those found in Section V.B.3 for idiopathic hypertensive 
males, where elevated urinary E.S/A.S, E.G/A.G and E .(S+G)/A,(S+G) ratios 
were demonstrated, and in all cases the ratios were significantly higher 
for the hypertensive group than for ûie respective ratios of the normal 
males.
Since the results for lypertensive and myocardial infarct patients 
bear such a close similarity, yet display a marked divergence from 
normal, it might be expected that the proposed explanation for 
abnormalities of steroid metabolism in hypertension holds also for 
myocardial infarction, namely an enzymatic block between pregnenolone 
and 17a-hydroxypregnenolone (fig.13). This proposal of a pregnenolone 
17a-hydroxylase block, if accepted, may very satisfactorily explain the
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abnormal, urinary D-17-OS patterns found in hypertension and 
myocardial infarction, but it does not explain why in one case the 
block manifests itself as elevated blood pressure and in another 
case as a myocardial infarct.
Why the urinary steroidal patterns seen in idiopathic hyper­
tension may be explained on the basis of pregnenolone to 17a-hydroxy- 
pregnenolone block, and why this block might result in elevated blood 
pressure have been discussed in Section V.B.4.
Assuming the block between pregnenolone and 17a-hydroxy- 
pregnenolone explains the urinary steroid patterns shown in myocardial 
infarction, what then is the relationship of D,17-OS to myocardial, 
infarction, A lipid - D.17-OS relationship was the outcome of 
earlier discussions.
From the available evidence there definitely appears to be a 
relationship between urinary D,17-OS levels and plasma lipid levels. 
However, is it a causal relationship, are the plasma lipid levels 
dependent on the in vivo D,17-OS levels and, therefore, indirectly 
on the D,17-08 urinary levels, or is it a coincidental relationship, 
the variables being independent of one another?
There, are numerous studies reporting low urinary D,17-08 
levels in diseases characterised by elevated plasma lipids, Heilman 
et al (1959a,b) reported low urinary levels of E and A concomitant 
with an elevated urinary E/A ratio in myxoedema, Garrett et al (1962) 
reported low urinary D.17-08,8 (DHA and A) and D,17-03.G (A and E) in
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atherosclerosis. Sonka et al (1964) reported zero levels of urinary 
DHA in gout, whereas Beck et al (1967.) reported low levels of
urinary DHA in the same disease and the present report found very low
levels of all the urinary D.17-OS, especially the D,17-OS.S. Kotasek 
et al (1967) reported low urinary DBA levels in toxaemia of pregnancy. 
Sonka & Gregorova (1963) reported zero, and Lopez-S & Krehl (1967) 
low urinary DHA levels in obesity, whereas Hendrikx et al (1965) 
reported low urinary A and E levels. The present studies report low 
urinary D.17-OS.S (epiA, E and A) and low A.G in hyperlipidaemia, 
and very low levels of D.17-OS.S (epiA, DHA and A) and low levels of
A.G and E.G in myocardial infarction. Therefore, this supplies the
evidence necessary to justify the conclusion that there is a definite 
relationship between urinary D.17-OS levels and plasma lipid levels, 
though not necessarily proof of a causal relationship.
There is evidence suggesting a causal relationship between
D.17-OS levels and plasma lipid levels, but it is not nearly as 
conclusive as the evidence simply demonstrating a relationship between 
the two variables. While studying the control of plasma lipid levels, 
Heilman et al (1959a,b), Cohen et al (1961) and Furman & Howard (1962) 
all demonstrated the hypocholesterolaemic effect of parentally 
administered A, and Cohen et al (1961) further demonstrated a 
depression of plasma triglyceride concomitant with the depression of 
plasma cholesterol. Kotasek et al (1967) reported a negative
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correlation between urinary DHA and serum g-lipoprotein levels as 
studied in normal females, pregnant females and toxaemia of pregnancy. 
Sonka et al (1968) reported negative correlations between urinary DHA 
levels and plasma, lipid levels, though the authors suggested the 
correlations might have been more a dependence of DHA and plasma lipids 
on age rather than on each other. The present report describes a 
negative correlation between each of several urinary D.17-OS and plasma 
glyceride levels and the correlations could not be attributed to a 
mutual dependence of the variables on age. Experiments on rats by 
Ben-David et al (1967) and Kahn (1966) describe the hypocholesterolaemic 
effects induced by administration of DHA and A respectively.
Therefore, from the aforegoing evidence, the proposal of a 
relationship and possibly a causal one between D.17-OS and plasma 
lipids seems fairly reasonable, but what of the mechanism by which the 
two variables are interrelated, and why are the plasma lipids elevated 
in the afore-mentioned diseases?
Expressions such as "the thyromimetic effect" of A have been 
bandied about, but the expression merely equates the hypocholesterol­
aemic effect of thyroxine■and A and gives no indication of mode of 
action of A, merely.of the end result. Orally administered A was 
shotm to be inactive in the depression of plasma cholesterol without 
the vehicle clofibrate (Oliver, 1963 and Heilman et al, 1963).
However, studies on the mode of action of clofibrate indicated that 
it acted by potentiating the effect of endogenous hormones particularly 
thyroxine and A. This evidence though favouring the hypocholesterdaemic
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properties of A does not give eay insight into its node of action,
The explanation proposed by Kotasek et al (1967) to interpret 
the elevated plasma lipid levels in toxaemia of- pregnancy is of 
relevance here. They suggested that the removal of the inhibitory 
effect of DBA on G-6-P.D activity would result in increased BADPB 
production and, therefore, ultimately in increased lipid biosynthesis 
in circumstances of low in vivo DHA levels.
The above explanation with modifications suggested by the results 
of other studies, could possibly form the basis of a working hypothesis 
for the mechanism of action of D.17-OS in control of lipid biosynthesis.
Marks & Banks (I960) demonstrated the inhibition of G-6-P.D by 
not only DHA, but also by E,A and epiA, In fact, epiA showed greater 
inhibition than DHA, but unfortunately later experiments untilising 
the inhibitory effect of D.17-08 appear to be restricted to DHA.
G-6-P.D activity has been shown to decrease in liver during 
starvation and increase to a peak activity several times the level of 
non-starved controls 72 hours after refeeding with a high glucose diet, 
(Potter & Ono, 1961; McDonald & Johnson, 1965, and Johnson, Mos'er & 
Sassoon, 1966). Following the demonstration of the inhibitory effect 
of DHA on the G-6-P.D activity in vitro by Marks & Banks (I960),
Willmer & Foster (1965) showed that the injection of DHA into rats 
sharply limited the increase in G.6 .P.D activity that occurs on 
starvation and refeeding. There is good circumstantial evidence 
from inhibitory studies to suggest that the increased enzyme activity
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represents de novo synthesis of new enzyme (Potter & Ono, 1961 and 
Tepperman & Tepperman, 1963), It is not yet certain whe^er the 
decreased shunt enzyme (G-6-P.D) activity seen in the steroid- 
treated rats is due to repression or due to inhibition or both.
However, preliminary observations by Tepperman, De La Garza &
Tepperman (1968) suggest that the decreased enzyme activity probably 
represents decreased enzyme synthesis.
Therefore, it is possible that there could be present in 
the liver a dual inhibitory control over G-6-P.D activity which 
would result in decreased NADPH production in circumstances of high 
in vivo DHA levels and, therefore, probably in circumstances of high 
D,17-OS in vivo levels. The dual control limiting NADPH production 
would be a short term control, by D,17-08 enzyme inhibition and a 
longterm control, by D,17-03 enzyme repression.
The liver has been shown to be intimately involved in lipid 
synthesis: fatty acids (Tietz & Popjak, 1955); cholesterol (Bloch,
Borek & Eittenberg, 1964; Little & Bloch, 1950); glycerides (Weiss 
& Kennedy, 1956) and phospholipids (Kennedy, 1961). All of these * 
lipids require NADPH for their biosynthesis, therefore their production 
would be regulated by any mechanism regulating NADPH production, namely
D.17-08 in vivo levels. Under normal conditions there is no storage 
of lipids by the liver, thus the plasma will be the next immediate 
site of liver synthesised lipids. Therefore, plasma lipids would
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to some extent come under the control of NADPH levels in the liver.
The liver is the major site of DHA, DHA.S androstenedione 
and testosterone metabolism. There they are metabolised to the 
D,17-08, DHA, epiA, A and E (fig. 1). Steroid hormones are active 
only as free steroids and not as their steroid conjugates. Since 
the liver is the site of the*%atbolism of D.17-08 precursors, it 
is most likely that the highest concentration of free D.17-08 in 
the body will be found in the liver cells. Therefore, any 
regulation by D.17-08 over G-6-P.D activity by either or both 
inhibition and repression will be manifested to the greatest degree 
in the liver. The end result of this would be regulation of lipid 
synthesis, therefore of plasma lipid levels.
Thus in conditions characterised by elevated plasma lipids 
and low D.17-08 levels it is suggested that the removal of inhibitory 
effects of D.17-08 on G-6-P.D activity would result in increased 
liver NADPH production and, therefore, ultimately in increased lipid 
biosynthesis.
2bb
VI. S U M M A R Y
1. A method is described for determining the ll-deoxy-17-
oxosteroids (D.17-08), dehydroepiandrosterone (DHA), aetiocholanolone 
(E), androsterone (A) and epiandrosterone (epiA) in the sulphate (S) 
and glucuronide (G) fractions of urine. Internal standards
pregnenolone and pregnenolone sulphate were added to separate 
aliquots of urine and the steroid conpgates isolated and cleaved 
separately. The steroid extracts were purified by alumina column 
chromatography, then the steroids were separated and quantitated by 
gas-liquid chromatography as their trimethylsilyl either derivatives.
Absolute and relative recoveries for the. method were
satisfactory. The method was specific and reproducible and
. #
sufficiently sensitive to determine 0 .1 pgm or steroid/2#' ml of urine.
2. Thirty-seven normal males (22) and females (15) were
studied. Their urinary steroid levels (mg/24 hr) were:-
Males Females P
Mean * S.D. Mean - S.D. value
epiA.S 0.30 ± 0,33 0.05 ± 0.05 0.0008
DHA.S 2.75 ± 3.75 0.45 ± 0.99 0.0008
E.S 0.23 ± 0.21 0.16 ± 0,15 0.2
A.S 0.82 ± 0.84 0.16 ± 0.15 0.00006
DHA.G 0.37 i 0.36 0,27 ± 0.52 0.044
E.G 2.61 ± 1.36 1,12 ± 0.82 0,0008
A.G 3.05 ± 1.89 0.87 ± 0.69 0.00002
The above values for males compare favourably with those
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for other investigators whereas those for the females are low.
The study revealed hitherto unrecognised correlations between 
individual urinary D.17-OS. Therefore, understandably, the 
urinary excretion of steroid conjugates showed definite patterns:- 
males - DHA.S>A.S>epiA.S>E«S
- A,G>E.G>DHA.G 
females - E.G>A.G>DHA.G
The E.S/A.S, E.G/A.G and E. (S+G)/A. (S-i-G) ratios were significantly 
higher for females. Possible reasons for the above differences 
were discussed.
3. Thirty-two hypertensive males (15) and females (17) were
studied. The hypertensive males excreted significantly less 
epiA.S (P - 0.056), DHA.S (P = 0.067) and A.G (P = 0.028), than 
normal controls. They also showed significantly higher ratios 
for epiA.S/A.S (P = 0.0008), DHA.S/E.S (P = 0.0001), A.S/E.S 
(P = 0.0004), E.G/A.G (P = 0.00004).
As with normal males the individual D.17-OS were highly 
intercorrelated, but no set pattern for steroid sulphate excretion 
arose, that for glucuronide conjugates was E.G>A.G>DHA.G.
The urinary steroid levels for the hypertensive females 
showed no significant differences compared with normal controls.
On the basis of the present results together with those 
for previous investigations a theory to explain the abnormal urinary
D.17-OS patterns in hypertension is presented. The theory also
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attempts to accomraodate the other steroid abnormalities presented 
in hypertension.
4. Incubation studies on the effect of DHA on steroid
hydroxylation in human adrenal tissue demonstrated an inhibitory 
action by DHA. ^^C-progesterone and ^H-DOC were metabolised to 
a much lesser extent by incubations containing DHA than those 
without. The results supported the increased sterid hydroxy­
lation found in hypertension.
5. Studies on the effect of varying salt intake on the
excretion of D,17-OS conjugates were carried out. The results 
of 4 of the 6 subjects demonstrated a relationship between salt 
and D,17-OS metabolism. One subject showed a marked increase 
in D.17-OS excretion after increasing his salt intake and in 2 
other subjects there was a very dramatic drop in.D,17-OS sulphate 
excretion on decreasing their salt intake. The hypertensive 
female showed significant decreases in the excretion of D.17-OS 
sulphates after decreasing her salt intake and significant increases 
after increasing her salt intake.
Intravenous saline infusion resulted in increased salt 
excretion concomitant with increased excretion of D.17-OS.
These results were interpreted in terms of a "salt-losing" 
steroid and its possible role in hypertensive disease.
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6 . Seven gouty males were studies. Their urinary D.17-OS 
sulphate levels were remarkably low relative to normal controls 
(epiA.S P = 0.0002, DHA.S P = 0.001, E.S P = 0.066, A.S P = 0.0002). 
The glucuronide levels were also low (DHA.G P ” O.OOl, E.G P = 0.028, 
A.G P = 0.024). Complete discrimination from normals was obtained 
using the variables epiA.S, A.S and total sulphates.
A common factor between the low D.17-OS Levels found in 
gout and in other diseases was sought. Hyperuricaemia, obesity and 
hyperlipidaemia,all characteristics of gout, were considered and 
hyperlipidaemia favoured.
7. Thirteen normolipidaemic and 7 hyperlipidaemia males were 
studied. The urinary D.17-OS sulphate levels were significantly 
lower for the hyperlipidaemic group (epiA.S P = 0.05, DHA.S P = 0.1,
E.S = 0.07, A.S P = 0.08), Of the glucuronide conjugates only
A.G was significantly lower (P = 0.08). But for 1 normolipidaemic 
individual, complete discrimination between the two groups was 
achieved, using the variables epiA.S, A.S and A.(S+G). For the 
hyperlipidaemic group there was significant negative correlation 
between plasma glyceride levels and certain urinary D.17-OS levels.
The results were considered as evidence for a D.17-0S- 
hyperlipidaemic relationship. As confirmatory evidence of this 
relationship a study of D.17-OS levels in myocardial infarction 
was carried out, since this is a disease characterised by a high 
incidence of hyperlipidaemia.
2 9 0
8 * Fifteen male myocardial infarct patients were studied.
Their urinary D,17-OS sulphate levels were remarkably low relative 
to normal controls (epiA.S P = 0.001, DHA.S P - 0.01, E.S P = 0.52,
A.S P = 0.003). Their glucuronide levels were also low (DHA.G 
P “ 0.19, E.G P = 0.07, A.G P = 0.001) and the urinary excretion 
pattern of their glucuronides was E>A>DHA. They also showed 
significantly higher ratios for E.S/A.S (P - 0.002), E.G/A.G (P = 0.014) 
and E.(S+G)/A.(S+G) (P = 0.002).
The results supported a D .17-OS-hyperlipidaemic relationship.
A theory based on the inhibitory action of D.17-OS on glucose-6- 
phosphate dehydrogenase is proposed to explain the relationship.
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